Rheumatology & Haematology — MCQs

Q: A 52-year-old woman presents with progressive dysphagia and weight loss. She has tight skin on her hands and face. ANA shows nucleolar pattern. What is the most concerning systemic complication?

Pulmonary hypertension. ***Pulmonary hypertension*** - This patient's presentation with **dysphagia**, **tight skin on hands and face**, and **nucleolar ANA pattern** strongly suggests systemic sclerosis, particularly the limited cutaneous form. - **Pulmonary hypertension** is a common and severe life-threatening complication of systemic sclerosis, especially in the limited cutaneous subtype, requiring vigilant screening and management. *Renal crisis* - **Scleroderma renal crisis** is a severe complication, but it is more frequently associated with **diffuse cutaneous systemic sclerosis** and anti-RNA polymerase III antibodies. - It presents with **malignant hypertension** and rapidly progressive renal failure, which is not suggested as the primary concern here. *Cardiac arrhythmias* - While **cardiac involvement** like myocardial fibrosis and pericarditis can occur in systemic sclerosis, **cardiac arrhythmias** are typically not the most concerning life-threatening systemic complication. - They are less common as a primary life-threatening event compared to **pulmonary hypertension**. *Digital ulceration* - **Digital ulceration** is a common localized vascular manifestation of systemic sclerosis due to **Raynaud's phenomenon** and small vessel disease. - Though it can cause pain, infection, and significant morbidity, it is not considered the most concerning **systemic life-threatening complication**. *Arthritis* - **Arthritis** or arthralgia can occur in systemic sclerosis, often affecting small joints and typically **non-erosive**. - While it contributes to discomfort, it is not considered a major **life-threatening systemic complication** compared to visceral organ involvement like pulmonary hypertension.

Q: A 42-year-old woman presents with fatigue, muscle aches, and widespread pain. She has multiple tender points but normal inflammatory markers. Sleep is poor. What is the most appropriate initial treatment?

Pregabalin. ***Pregabalin*** - **Pregabalin** is a **gabapentinoid** drug that modulates voltage-gated calcium channels, decreasing the release of excitatory neurotransmitters involved in central pain sensitization characteristic of **fibromyalgia**. - It is one of the FDA-approved medications (along with duloxetine and milnacipran) specifically recommended for managing the **widespread pain** and associated symptoms like **poor sleep** in fibromyalgia. *NSAIDs* - Non-steroidal anti-inflammatory drugs (NSAIDs) target inflammatory pain, which is generally absent in **fibromyalgia** as evidenced by **normal inflammatory markers**. - NSAIDs are usually **ineffective** in treating the centralized pain and hyperalgesia seen in this condition, making them a poor choice for monotherapy. *Prednisolone* - **Prednisolone** is a powerful corticosteroid used for conditions driven by **inflammation** (e.g., active arthritis or vasculitis). - The patient has normal inflammatory markers and a clinical presentation consistent with a non-inflammatory central pain syndrome, making steroids **inappropriate** and potentially harmful. *Methotrexate* - **Methotrexate** is a **Disease-Modifying Anti-Rheumatic Drug (DMARD)** indicated for managing autoimmune inflammatory diseases like **Rheumatoid Arthritis** or **Psoriatic Arthritis**. - Since the patient does not show evidence of an inflammatory or autoimmune joint disease, this immunosuppressant drug treatment is **not warranted**. *Physiotherapy alone* - While non-pharmacological therapies like **aerobic exercise** and **Cognitive Behavioral Therapy (CBT)** are essential long-term components, they are often insufficient alone to manage severe initial symptoms, particularly **poor sleep** and disabling pain. - Initial treatment typically requires a combination of pharmacological agents (like **Pregabalin**) combined with supportive non-pharmacological management for optimal symptom control.

Q: A 48-year-old man presents with progressive muscle weakness affecting proximal muscles. CK is elevated at 3200 U/L. Muscle biopsy shows inflammatory infiltrates. What is the cancer screening recommendation?

No screening needed. ***No screening needed***- The clinical presentation of **progressive proximal muscle weakness**, elevated **CK**, and **inflammatory infiltrates** on muscle biopsy is consistent with **polymyositis**.- Unlike **dermatomyositis**, which has a strong association with occult malignancies, **polymyositis** is generally not associated with an increased risk of cancer, therefore **routine cancer screening** is not indicated. *Chest X-ray only*- A **chest X-ray** is a limited screening tool and would be insufficient to detect a wide range of potential malignancies associated with paraneoplastic syndromes.- It would miss cancers in other vital organs, making it an inadequate approach if malignancy were suspected. *CT chest/abdomen/pelvis*- This extensive imaging is typically recommended for patients with **dermatomyositis** due to its strong association with various occult malignancies.- In the absence of dermatomyositis-specific features (e.g., characteristic skin rashes) or other malignancy risk factors, such broad screening is not indicated for **polymyositis**. *Colonoscopy only*- While gastrointestinal malignancies can be associated with paraneoplastic syndromes, performing **colonoscopy** alone is insufficient for comprehensive cancer screening.- This approach would overlook other common cancer sites linked to inflammatory myopathies, such as lung, breast, or ovarian cancers. *PSA testing only*- **PSA testing** is specific for prostate cancer screening and would be part of a more comprehensive workup, not the sole screening measure for malignancy.- Focusing solely on prostate cancer would miss other potential malignancies that might be associated with paraneoplastic syndromes in other forms of inflammatory myopathies.

Q: A 38-year-old woman presents with fatigue, joint pain, and photosensitive rash. ANA is positive 1:640, anti-dsDNA is positive, and complement levels are low. Urinalysis shows proteinuria and RBC casts. What is the most appropriate initial treatment?

High-dose prednisolone. ***High-dose prednisolone***- This patient presents with features of **severe active Systemic Lupus Erythematosus (SLE)**, confirmed by high-titer ANA, positive anti-dsDNA, low complement, and active **Lupus Nephritis** (proteinuria, RBC casts).- **High-dose glucocorticoids** (e.g., prednisolone or methylprednisolone pulses) are the cornerstone initial treatment to rapidly induce remission and prevent irreversible damage in severe, active organ-threatening SLE.*NSAIDs*- **NSAIDs** are reserved for mild disease manifestations, typically musculoskeletal symptoms such as arthralgia or non-erosive arthritis, without major organ involvement.- They are generally avoided in active severe **Lupus Nephritis** as they carry a risk of exacerbating renal impairment or non-steroidal induced nephropathy.*Hydroxychloroquine*- **Hydroxychloroquine** is foundational maintenance therapy for almost all SLE patients, reducing flares, preventing damage accrual, and improving survival.- It acts slowly and is **insufficient as monotherapy** to control acute, severe, organ-threatening disease activity like active nephritis, which requires immediate, potent immunosuppression.*Methotrexate*- **Methotrexate** is typically considered for non-organ-threatening manifestations of SLE, such as refractory arthritis or treatment-resistant rash, when hydroxychloroquine fails.- It is not the most appropriate initial agent for acute, severe flares with major organ involvement requiring immediate, high-level immunosuppression.*Rituximab*- **Rituximab** (a B-cell depleting therapy) is a biologic agent usually reserved for SLE that is refractory (non-responsive) to standard induction therapies.- It is not generally recommended as the **first-line initial treatment** for a newly diagnosed major organ flare before high-dose corticosteroids and standard immunosuppressants have been utilized.

Q: A 35-year-old woman presents with recurrent miscarriages and thrombosis. She has positive lupus anticoagulant and anticardiolipin antibodies. What is the mechanism of thrombosis?

Endothelial dysfunction. ***Endothelial dysfunction***- This is the primary mechanism in **Antiphospholipid Syndrome (APS)**, where **antiphospholipid antibodies (aPL)** bind to complexes involving plasma proteins, particularly **$eta_2$-glycoprotein I**, on the endothelial surface.- This binding activates and injures the endothelium, leading to the expression of pro-coagulant factors and adhesive molecules, resulting in a systemic shift toward **thrombosis**.*Platelet activation*- While aPL antibodies do cause platelet activation and aggregation, this effect is often considered downstream or secondary to the primary interaction the antibodies have with **endothelial cells** and plasma proteins.- aPL antibodies binding to platelets via **$eta_2$-glycoprotein I** enhances the production of thromboxane A2 and promotes thrombus stabilization.*Protein C deficiency*- This is typically an inherited disorder causing decreased levels or function of the key anticoagulant Protein C, a mechanism distinct from **autoimmunity**.- Although aPL antibodies can sometimes interfere with Protein C and S function indirectly, the underlying mechanism generating the thrombotic state remains **endothelial activation**.*Factor V Leiden mutation*- This is the most common inherited thrombophilia, leading to resistance to activated **Protein C** degradation of Factor Va and VIIIa.- This inherited defect is separate from the acquired, autoimmune mechanism responsible for thrombosis in **Antiphospholipid Syndrome**.*Hyperhomocysteinemia*- Elevated **homocysteine** levels create a prothrombotic state primarily via direct cytotoxicity and oxidative stress to the **vascular endothelium**.- This condition is an independent risk factor for thrombosis and is not the pathognomonic mechanism of acquired thrombophilia defined by **lupus anticoagulant** and **anticardiolipin antibodies**.

Q: A 61-year-old man presents with progressive weakness in his hands and difficulty swallowing. EMG shows myopathic changes. Muscle biopsy shows rimmed vacuoles and eosinophilic inclusions. What is the most likely diagnosis?

Inclusion body myositis. ***Inclusion body myositis*** - The combination of **progressive distal weakness** (hands) and **dysphagia**, particularly in an older man, is highly characteristic. - Definitive diagnosis relies on muscle biopsy findings of **rimmed vacuoles** and **eosinophilic inclusions**, as well as **myopathic changes** on EMG. *Polymyositis* - Typically presents with **proximal muscle weakness**, affecting hips and shoulders, rather than predominant distal hand weakness or prominent dysphagia. - Muscle biopsy shows **endomysial inflammatory infiltrates** but lacks the characteristic rimmed vacuoles or inclusions seen in IBM. *Dermatomyositis* - Shares **proximal muscle weakness** with polymyositis but is uniquely identified by specific **cutaneous manifestations** like heliotrope rash and Gottron's papules, which are not mentioned. - Muscle biopsy shows **perifascicular atrophy** and perimysial inflammation, differing from IBM's distinctive pathology. *Myasthenia gravis* - A **neuromuscular junction disorder** causing fluctuating weakness that worsens with activity, often affecting ocular, bulbar, and limb muscles. - EMG would show a **decremental response** on repetitive nerve stimulation, not primary myopathic changes, and muscle biopsy would be normal. *Muscular dystrophy* - A broad category of **genetic muscle diseases** that cause progressive weakness and myopathic changes, but the specific biopsy findings of rimmed vacuoles and eosinophilic inclusions are not typical. - Different types of muscular dystrophy have distinct genetic causes and biopsy findings (e.g., dystrophin absence in Duchenne) that do not match the features presented.

Q: A 52-year-old woman presents with progressive dysphagia and weight loss. She has tight skin on her face and hands. ANA shows nucleolar pattern. What is the most concerning complication to screen for?

Pulmonary hypertension. ***Pulmonary hypertension*** - This patient's presentation (tight skin on face/hands, dysphagia, nucleolar ANA pattern) strongly suggests **Systemic Sclerosis (SSc)**, likely the limited cutaneous form. - **Pulmonary arterial hypertension (PAH)** is a leading cause of mortality in SSc, particularly associated with the nucleolar ANA pattern (often linked to anti-U3 RNP/fibrillarin antibodies), requiring regular screening with **echocardiograms**. *Renal crisis* - **Scleroderma Renal Crisis (SRC)** involves acute onset of **malignant hypertension** and rapid kidney failure. - SRC is more commonly associated with **diffuse cutaneous SSc** and **Anti-RNA Polymerase III antibodies**, rather than the nucleolar ANA pattern. *Cardiac involvement* - Direct **cardiac involvement** (e.g., myocarditis, pericarditis, conduction defects) can occur in SSc. - While serious, **pulmonary hypertension** is statistically the most common and acutely life-threatening cardiopulmonary complication in SSc patients, making it the priority for routine screening. *Esophageal stricture* - **Dysphagia** and weight loss are highly suggestive of **esophageal dysmotility**, a nearly universal finding in SSc. - While **esophageal strictures** can occur from chronic reflux in SSc, they are a local complication, not the most concerning *systemic* or *life-threatening* complication requiring primary screening compared to PAH. *Digital ulceration* - **Digital ulcerations** are caused by severe **Raynaud's phenomenon** and microvascular ischemia, leading to pain and potential tissue loss. - Though causing significant morbidity, digital ulcerations are a peripheral manifestation and not the most acutely life-threatening *systemic* complication requiring broad mortality screening compared to **pulmonary hypertension**.

Rheumatology & Haematology UK Medical PG Practice Questions and MCQs

Question 1: A 52-year-old woman presents with progressive dysphagia and weight loss. She has tight skin on her hands and face. ANA shows nucleolar pattern. What is the most concerning systemic complication?

A. Renal crisis
B. Pulmonary hypertension (Correct Answer)
C. Cardiac arrhythmias
D. Digital ulceration
E. Arthritis

Explanation: ***Pulmonary hypertension*** - This patient's presentation with **dysphagia**, **tight skin on hands and face**, and **nucleolar ANA pattern** strongly suggests systemic sclerosis, particularly the limited cutaneous form. - **Pulmonary hypertension** is a common and severe life-threatening complication of systemic sclerosis, especially in the limited cutaneous subtype, requiring vigilant screening and management. *Renal crisis* - **Scleroderma renal crisis** is a severe complication, but it is more frequently associated with **diffuse cutaneous systemic sclerosis** and anti-RNA polymerase III antibodies. - It presents with **malignant hypertension** and rapidly progressive renal failure, which is not suggested as the primary concern here. *Cardiac arrhythmias* - While **cardiac involvement** like myocardial fibrosis and pericarditis can occur in systemic sclerosis, **cardiac arrhythmias** are typically not the most concerning life-threatening systemic complication. - They are less common as a primary life-threatening event compared to **pulmonary hypertension**. *Digital ulceration* - **Digital ulceration** is a common localized vascular manifestation of systemic sclerosis due to **Raynaud's phenomenon** and small vessel disease. - Though it can cause pain, infection, and significant morbidity, it is not considered the most concerning **systemic life-threatening complication**. *Arthritis* - **Arthritis** or arthralgia can occur in systemic sclerosis, often affecting small joints and typically **non-erosive**. - While it contributes to discomfort, it is not considered a major **life-threatening systemic complication** compared to visceral organ involvement like pulmonary hypertension.

Question 2: A 42-year-old woman presents with fatigue, muscle aches, and widespread pain. She has multiple tender points but normal inflammatory markers. Sleep is poor. What is the most appropriate initial treatment?

A. NSAIDs
B. Prednisolone
C. Pregabalin (Correct Answer)
D. Methotrexate
E. Physiotherapy alone

Explanation: ***Pregabalin*** - **Pregabalin** is a **gabapentinoid** drug that modulates voltage-gated calcium channels, decreasing the release of excitatory neurotransmitters involved in central pain sensitization characteristic of **fibromyalgia**. - It is one of the FDA-approved medications (along with duloxetine and milnacipran) specifically recommended for managing the **widespread pain** and associated symptoms like **poor sleep** in fibromyalgia. *NSAIDs* - Non-steroidal anti-inflammatory drugs (NSAIDs) target inflammatory pain, which is generally absent in **fibromyalgia** as evidenced by **normal inflammatory markers**. - NSAIDs are usually **ineffective** in treating the centralized pain and hyperalgesia seen in this condition, making them a poor choice for monotherapy. *Prednisolone* - **Prednisolone** is a powerful corticosteroid used for conditions driven by **inflammation** (e.g., active arthritis or vasculitis). - The patient has normal inflammatory markers and a clinical presentation consistent with a non-inflammatory central pain syndrome, making steroids **inappropriate** and potentially harmful. *Methotrexate* - **Methotrexate** is a **Disease-Modifying Anti-Rheumatic Drug (DMARD)** indicated for managing autoimmune inflammatory diseases like **Rheumatoid Arthritis** or **Psoriatic Arthritis**. - Since the patient does not show evidence of an inflammatory or autoimmune joint disease, this immunosuppressant drug treatment is **not warranted**. *Physiotherapy alone* - While non-pharmacological therapies like **aerobic exercise** and **Cognitive Behavioral Therapy (CBT)** are essential long-term components, they are often insufficient alone to manage severe initial symptoms, particularly **poor sleep** and disabling pain. - Initial treatment typically requires a combination of pharmacological agents (like **Pregabalin**) combined with supportive non-pharmacological management for optimal symptom control.

Question 3: A 52-year-old man presents with progressive dysphagia and weight loss. He has tight skin on his hands and Raynaud's phenomenon. What is the most likely esophageal abnormality?

A. Esophageal carcinoma
B. Achalasia
C. Esophageal dysmotility (Correct Answer)
D. Peptic stricture
E. Eosinophilic esophagitis

Explanation: ***Esophageal dysmotility***- The combination of **tight skin (scleroderma)** and **Raynaud's phenomenon** is characteristic of **Systemic Sclerosis**, which causes atrophy and fibrosis of smooth muscle in the distal two-thirds of the esophagus.- This loss of smooth muscle function leads to decreased peristalsis (dysmotility) and, crucially, incompetence of the **lower esophageal sphincter (LES)**, causing severe GERD and the resulting dysphagia.*Esophageal carcinoma*- While progressive **dysphagia** and **weight loss** are concerns for malignancy, the patient's systemic features (**tight skin**, **Raynaud's**) strongly suggest a connective tissue disorder as the etiology.- Carcinoma often occurs in the context of significant risk factors (e.g., smoking, alcohol, HPV) and typically does not present with the classic dermatologic or peripheral vascular signs of Scleroderma.*Achalasia*- Achalasia involves impaired relaxation of the **LES** and aperistalsis, but it is a primary esophageal motility disorder and lacks the systemic features (Raynaud's, sclerodactyly) seen in this patient.- Dysphagia in achalasia tends to be prominent for both **liquids and solids** from the start, often without significant GERD symptoms.*Peptic stricture*- A **peptic stricture** is a *consequence* of chronic acid exposure resulting from the incompetent LES caused by Scleroderma-related esophageal dysmotility.- While a stricture may eventually explain the severe dysphagia, the primary diagnostic link between the systemic symptoms and the esophageal pathology is the **underlying smooth muscle failure** (dysmotility).*Eosinophilic esophagitis*- This condition is typically associated with **atopic disorders** (allergies, asthma) and presents histologically with excessive **eosinophil infiltration**.- It typically causes dysphagia, often for solids, and sometimes **food impaction**, but it is not linked to generalized fibrosis or vascular changes like those causing tight skin and Raynaud's phenomenon.

Question 4: A 46-year-old woman presents with fatigue, muscle weakness, and purple discoloration around her eyes. She has Gottron's papules over her knuckles. CK is 3800 U/L. What is the most important investigation?

A. EMG
B. Muscle biopsy
C. CT chest/abdomen/pelvis (Correct Answer)
D. Myositis antibodies
E. Echocardiogram

Explanation: ***CT chest/abdomen/pelvis*** - The most important investigation in a patient with new-onset **dermatomyositis**, especially in a middle-aged or older individual, is a thorough screening for **underlying malignancy**. - Approximately 15-30% of patients with dermatomyositis have an associated cancer, making **malignancy screening** crucial for prognosis and management. *EMG* - While an **EMG** can show **myopathic changes** (e.g., fibrillation potentials, small-amplitude polyphasic motor unit potentials) consistent with inflammatory myopathy, it primarily confirms muscle involvement. - Confirming muscle involvement is important diagnostically, but ruling out an **associated malignancy** takes precedence given its significant impact on patient survival. *Muscle biopsy* - A **muscle biopsy** is often considered the gold standard for diagnosing inflammatory myopathies, showing characteristic **perifascicular atrophy** and inflammation in dermatomyositis. - However, while confirming the diagnosis, the immediate priority in this clinical picture is to identify or exclude a potentially life-threatening **underlying malignancy**. *Myositis antibodies* - **Myositis-specific antibodies** (e.g., anti-Jo-1, anti-MDA5, anti-TIF1γ) are useful for classifying inflammatory myopathies, predicting disease course, and assessing specific associations (e.g., malignancy risk with anti-TIF1γ). - While helpful diagnostically and for risk stratification, these antibodies do not directly screen for an **underlying malignancy**; imaging is required for that purpose. *Echocardiogram* - An **echocardiogram** assesses cardiac function and can detect myocardial involvement, which can occur in inflammatory myopathies (e.g., myocarditis, heart failure). - While cardiac complications can arise, they are not the *most important initial investigation* when the clinical picture strongly suggests **dermatomyositis** with its significant risk of an **underlying malignancy**.

Question 5: A 48-year-old man presents with progressive muscle weakness affecting proximal muscles. CK is elevated at 3200 U/L. Muscle biopsy shows inflammatory infiltrates. What is the cancer screening recommendation?

A. No screening needed (Correct Answer)
B. Chest X-ray only
C. CT chest/abdomen/pelvis
D. Colonoscopy only
E. PSA testing only

Explanation: ***No screening needed***- The clinical presentation of **progressive proximal muscle weakness**, elevated **CK**, and **inflammatory infiltrates** on muscle biopsy is consistent with **polymyositis**.- Unlike **dermatomyositis**, which has a strong association with occult malignancies, **polymyositis** is generally not associated with an increased risk of cancer, therefore **routine cancer screening** is not indicated. *Chest X-ray only*- A **chest X-ray** is a limited screening tool and would be insufficient to detect a wide range of potential malignancies associated with paraneoplastic syndromes.- It would miss cancers in other vital organs, making it an inadequate approach if malignancy were suspected. *CT chest/abdomen/pelvis*- This extensive imaging is typically recommended for patients with **dermatomyositis** due to its strong association with various occult malignancies.- In the absence of dermatomyositis-specific features (e.g., characteristic skin rashes) or other malignancy risk factors, such broad screening is not indicated for **polymyositis**. *Colonoscopy only*- While gastrointestinal malignancies can be associated with paraneoplastic syndromes, performing **colonoscopy** alone is insufficient for comprehensive cancer screening.- This approach would overlook other common cancer sites linked to inflammatory myopathies, such as lung, breast, or ovarian cancers. *PSA testing only*- **PSA testing** is specific for prostate cancer screening and would be part of a more comprehensive workup, not the sole screening measure for malignancy.- Focusing solely on prostate cancer would miss other potential malignancies that might be associated with paraneoplastic syndromes in other forms of inflammatory myopathies.

Question 6: A 41-year-old woman presents with recurrent miscarriages and arterial thrombosis. She has positive lupus anticoagulant and anticardiolipin antibodies. What is the most appropriate long-term treatment?

A. Aspirin alone
B. Warfarin (INR 2-3) (Correct Answer)
C. Clopidogrel
D. LMWH
E. No treatment

Explanation: ***Warfarin (INR 2-3)***- For patients with **Antiphospholipid Syndrome (APS)** who have experienced a confirmed thrombotic event (arterial or venous), **vitamin K antagonists** like **Warfarin** are the mainstay of long-term secondary prevention.- Given the history of **arterial thrombosis**, a target **International Normalized Ratio (INR)** of 2.0 to 3.0 is typically recommended, as this range effectively reduces the risk of recurrent thrombotic events in APS.*Aspirin alone*- Aspirin is generally reserved for primary prophylaxis in high-risk, asymptomatic carriers of antiphospholipid antibodies or often used as **adjuvant therapy**, but it is insufficient as monotherapy following a definite **arterial thrombotic event** in APS.- The risk of recurrence after thrombosis in APS is high, necessitating **full anticoagulation**, which **Aspirin** (an antiplatelet agent) cannot provide effectively.*Clopidogrel*- Clopidogrel is an antiplatelet agent often used for high-risk cardiovascular conditions but is not the standard first-line agent for the prevention of recurrent **thrombosis** associated with APS, which requires potent **anticoagulation**.- Like aspirin, **antiplatelet therapy** alone does not adequately address the highly procoagulant nature of circulating **lupus anticoagulant** and other antiphospholipid antibodies following a thrombotic episode.*LMWH*- **Low Molecular Weight Heparin (LMWH)** is the preferred treatment for APS patients during **pregnancy** (for fetal and maternal health) or during acute thrombotic events.- While effective, LMWH is impractical for **lifelong secondary prevention** outside of pregnancy due to the requirement for daily subcutaneous injections.*No treatment*- This patient has classic features of **definite Antiphospholipid Syndrome (APS)**, including required laboratory criteria and clinical thrombotic events (arterial thrombosis and pregnancy morbidity).- Untreated patients with a history of **APS-related thrombosis** face a very high risk of **recurrent life-threatening events**, making therapy mandatory.

Question 7: A 38-year-old woman presents with fatigue, joint pain, and photosensitive rash. ANA is positive 1:640, anti-dsDNA is positive, and complement levels are low. Urinalysis shows proteinuria and RBC casts. What is the most appropriate initial treatment?

A. NSAIDs
B. Hydroxychloroquine
C. High-dose prednisolone (Correct Answer)
D. Methotrexate
E. Rituximab

Explanation: ***High-dose prednisolone***- This patient presents with features of **severe active Systemic Lupus Erythematosus (SLE)**, confirmed by high-titer ANA, positive anti-dsDNA, low complement, and active **Lupus Nephritis** (proteinuria, RBC casts).- **High-dose glucocorticoids** (e.g., prednisolone or methylprednisolone pulses) are the cornerstone initial treatment to rapidly induce remission and prevent irreversible damage in severe, active organ-threatening SLE.*NSAIDs*- **NSAIDs** are reserved for mild disease manifestations, typically musculoskeletal symptoms such as arthralgia or non-erosive arthritis, without major organ involvement.- They are generally avoided in active severe **Lupus Nephritis** as they carry a risk of exacerbating renal impairment or non-steroidal induced nephropathy.*Hydroxychloroquine*- **Hydroxychloroquine** is foundational maintenance therapy for almost all SLE patients, reducing flares, preventing damage accrual, and improving survival.- It acts slowly and is **insufficient as monotherapy** to control acute, severe, organ-threatening disease activity like active nephritis, which requires immediate, potent immunosuppression.*Methotrexate*- **Methotrexate** is typically considered for non-organ-threatening manifestations of SLE, such as refractory arthritis or treatment-resistant rash, when hydroxychloroquine fails.- It is not the most appropriate initial agent for acute, severe flares with major organ involvement requiring immediate, high-level immunosuppression.*Rituximab*- **Rituximab** (a B-cell depleting therapy) is a biologic agent usually reserved for SLE that is refractory (non-responsive) to standard induction therapies.- It is not generally recommended as the **first-line initial treatment** for a newly diagnosed major organ flare before high-dose corticosteroids and standard immunosuppressants have been utilized.

Question 8: A 35-year-old woman presents with recurrent miscarriages and thrombosis. She has positive lupus anticoagulant and anticardiolipin antibodies. What is the mechanism of thrombosis?

A. Platelet activation
B. Endothelial dysfunction (Correct Answer)
C. Protein C deficiency
D. Factor V Leiden mutation
E. Hyperhomocysteinemia

Explanation: ***Endothelial dysfunction***- This is the primary mechanism in **Antiphospholipid Syndrome (APS)**, where **antiphospholipid antibodies (aPL)** bind to complexes involving plasma proteins, particularly **$eta_2$-glycoprotein I**, on the endothelial surface.- This binding activates and injures the endothelium, leading to the expression of pro-coagulant factors and adhesive molecules, resulting in a systemic shift toward **thrombosis**.*Platelet activation*- While aPL antibodies do cause platelet activation and aggregation, this effect is often considered downstream or secondary to the primary interaction the antibodies have with **endothelial cells** and plasma proteins.- aPL antibodies binding to platelets via **$eta_2$-glycoprotein I** enhances the production of thromboxane A2 and promotes thrombus stabilization.*Protein C deficiency*- This is typically an inherited disorder causing decreased levels or function of the key anticoagulant Protein C, a mechanism distinct from **autoimmunity**.- Although aPL antibodies can sometimes interfere with Protein C and S function indirectly, the underlying mechanism generating the thrombotic state remains **endothelial activation**.*Factor V Leiden mutation*- This is the most common inherited thrombophilia, leading to resistance to activated **Protein C** degradation of Factor Va and VIIIa.- This inherited defect is separate from the acquired, autoimmune mechanism responsible for thrombosis in **Antiphospholipid Syndrome**.*Hyperhomocysteinemia*- Elevated **homocysteine** levels create a prothrombotic state primarily via direct cytotoxicity and oxidative stress to the **vascular endothelium**.- This condition is an independent risk factor for thrombosis and is not the pathognomonic mechanism of acquired thrombophilia defined by **lupus anticoagulant** and **anticardiolipin antibodies**.

Question 9: A 61-year-old man presents with progressive weakness in his hands and difficulty swallowing. EMG shows myopathic changes. Muscle biopsy shows rimmed vacuoles and eosinophilic inclusions. What is the most likely diagnosis?

A. Polymyositis
B. Dermatomyositis
C. Inclusion body myositis (Correct Answer)
D. Myasthenia gravis
E. Muscular dystrophy

Explanation: ***Inclusion body myositis*** - The combination of **progressive distal weakness** (hands) and **dysphagia**, particularly in an older man, is highly characteristic. - Definitive diagnosis relies on muscle biopsy findings of **rimmed vacuoles** and **eosinophilic inclusions**, as well as **myopathic changes** on EMG. *Polymyositis* - Typically presents with **proximal muscle weakness**, affecting hips and shoulders, rather than predominant distal hand weakness or prominent dysphagia. - Muscle biopsy shows **endomysial inflammatory infiltrates** but lacks the characteristic rimmed vacuoles or inclusions seen in IBM. *Dermatomyositis* - Shares **proximal muscle weakness** with polymyositis but is uniquely identified by specific **cutaneous manifestations** like heliotrope rash and Gottron's papules, which are not mentioned. - Muscle biopsy shows **perifascicular atrophy** and perimysial inflammation, differing from IBM's distinctive pathology. *Myasthenia gravis* - A **neuromuscular junction disorder** causing fluctuating weakness that worsens with activity, often affecting ocular, bulbar, and limb muscles. - EMG would show a **decremental response** on repetitive nerve stimulation, not primary myopathic changes, and muscle biopsy would be normal. *Muscular dystrophy* - A broad category of **genetic muscle diseases** that cause progressive weakness and myopathic changes, but the specific biopsy findings of rimmed vacuoles and eosinophilic inclusions are not typical. - Different types of muscular dystrophy have distinct genetic causes and biopsy findings (e.g., dystrophin absence in Duchenne) that do not match the features presented.

Question 10: A 52-year-old woman presents with progressive dysphagia and weight loss. She has tight skin on her face and hands. ANA shows nucleolar pattern. What is the most concerning complication to screen for?

A. Renal crisis
B. Pulmonary hypertension (Correct Answer)
C. Cardiac involvement
D. Esophageal stricture
E. Digital ulceration

Explanation: ***Pulmonary hypertension*** - This patient's presentation (tight skin on face/hands, dysphagia, nucleolar ANA pattern) strongly suggests **Systemic Sclerosis (SSc)**, likely the limited cutaneous form. - **Pulmonary arterial hypertension (PAH)** is a leading cause of mortality in SSc, particularly associated with the nucleolar ANA pattern (often linked to anti-U3 RNP/fibrillarin antibodies), requiring regular screening with **echocardiograms**. *Renal crisis* - **Scleroderma Renal Crisis (SRC)** involves acute onset of **malignant hypertension** and rapid kidney failure. - SRC is more commonly associated with **diffuse cutaneous SSc** and **Anti-RNA Polymerase III antibodies**, rather than the nucleolar ANA pattern. *Cardiac involvement* - Direct **cardiac involvement** (e.g., myocarditis, pericarditis, conduction defects) can occur in SSc. - While serious, **pulmonary hypertension** is statistically the most common and acutely life-threatening cardiopulmonary complication in SSc patients, making it the priority for routine screening. *Esophageal stricture* - **Dysphagia** and weight loss are highly suggestive of **esophageal dysmotility**, a nearly universal finding in SSc. - While **esophageal strictures** can occur from chronic reflux in SSc, they are a local complication, not the most concerning *systemic* or *life-threatening* complication requiring primary screening compared to PAH. *Digital ulceration* - **Digital ulcerations** are caused by severe **Raynaud's phenomenon** and microvascular ischemia, leading to pain and potential tissue loss. - Though causing significant morbidity, digital ulcerations are a peripheral manifestation and not the most acutely life-threatening *systemic* complication requiring broad mortality screening compared to **pulmonary hypertension**.

Question 11: A 41-year-old woman presents with recurrent episodes of severe abdominal pain and confusion. During attacks, her urine turns dark red. She has a family history of similar symptoms. What is the most appropriate acute treatment?

A. High-carbohydrate diet
B. Hemin therapy
C. Avoid precipitating drugs
D. IV fluids and analgesia
E. All of the above (Correct Answer)

Explanation: ***All of the above*** - The clinical presentation (severe abdominal pain, confusion, dark urine, and family history) is highly suggestive of an acute **porphyria attack**, such as **Acute Intermittent Porphyria (AIP)**. - Acute management requires a multifaceted approach, encompassing **hemin therapy**, **high-carbohydrate diet**, **avoidance of precipitating drugs**, and **supportive care** with IV fluids and analgesia. *High-carbohydrate diet* - Administering a high-dose **glucose (dextrose)** intravenously is crucial as a high carbohydrate load represses the activity of **$\delta$-aminolevulinic acid (ALA) synthase**, thereby reducing the production of neurotoxic porphyrin precursors. - This therapy is often initiated promptly for all acute attacks, especially mild ones, and while awaiting the preparation or administration of **hemin therapy**. *Hemin therapy* - **Hemin (or hematin)** is considered the most specific and definitive treatment for a severe acute attack, as it directly suppresses hepatic **$\delta$-aminolevulinic acid (ALA) synthase** through negative feedback. - Early initiation of intravenous hemin significantly shortens the duration of the attack and helps prevent or mitigate **neurological damage**. *Avoid precipitating drugs* - Many medications (e.g., barbiturates, sulfa drugs, some antiepileptics) are potent **inducers of cytochrome P450 enzymes**, which in turn accelerate the production of porphyrin precursors, worsening the attack. - Rapidly identifying and discontinuing all porphyrinogenic agents is mandatory to halt the exacerbation and reduce the accumulation of neurotoxic intermediaries like **ALA** and **porphobilinogen**. *IV fluids and analgesia* - Severe abdominal pain, often disproportionate to physical findings, is a hallmark of acute porphyria and necessitates potent **opioid analgesics** (e.g., morphine) for effective pain management. - Patients are frequently volume-depleted, requiring **IV fluid resuscitation**, and may also need correction of **electrolyte derangements**, such as **hyponatremia** and **hypomagnesemia**, often associated with SIADH.

Question 12: A 44-year-old woman presents with fatigue, joint pain, and a butterfly rash across her cheeks. ANA is positive 1:640. Anti-dsDNA is positive. Complement C3 and C4 are low. What is the most likely diagnosis?

A. Drug-induced lupus
B. Systemic lupus erythematosus (Correct Answer)
C. Sjögren's syndrome
D. Mixed connective tissue disease
E. Systemic sclerosis

Explanation: ***Systemic lupus erythematosus*** - The classic triad of **fatigue**, **joint pain**, and a **butterfly rash** (malar rash) strongly indicates SLE. - The laboratory findings, including a high titer **ANA** (1:640), highly specific **anti-dsDNA antibodies**, and **low complement C3 and C4**, are diagnostic for SLE and suggest active disease. *Drug-induced lupus* - While it can present with similar symptoms, drug-induced lupus is most commonly associated with **anti-histone antibodies** and typically lacks the presence of **anti-dsDNA antibodies** or significant complement consumption. - Symptoms usually resolve upon discontinuation of the causative medication, and severe organ involvement like glomerulonephritis is rare. *Sjögren's syndrome* - The hallmark features of Sjögren's syndrome are **sicca symptoms** (dry eyes and mouth) and gland involvement, not a malar rash. - Although ANA can be positive, specific antibodies are typically **anti-Ro/SSA** and **anti-La/SSB**, without the characteristic anti-dsDNA or profound hypocomplementemia seen here. *Mixed connective tissue disease* - This condition is primarily characterized by very high titers of **anti-U1-ribonucleoprotein (anti-U1-RNP)** antibodies, with features overlapping from SLE, systemic sclerosis, and polymyositis. - However, the presence of significant **anti-dsDNA antibodies** and **hypocomplementemia** are not the defining serological features, differentiating it from this case. *Systemic sclerosis* - The defining feature of systemic sclerosis is **skin thickening** and fibrosis, often accompanied by features like Raynaud phenomenon and internal organ fibrosis. - The associated autoantibodies are typically **anti-Scl-70 (topoisomerase I)** or **anti-centromere antibodies**, which are distinct from the anti-dsDNA and low complements presented.

Question 13: A 32-year-old woman presents with recurrent miscarriages and livedo reticularis. Blood tests show thrombocytopenia and prolonged APTT. What is the most likely diagnosis?

A. Systemic lupus erythematosus
B. Antiphospholipid syndrome (Correct Answer)
C. Thrombotic thrombocytopenic purpura
D. Factor V Leiden
E. Protein S deficiency

Explanation: ***Antiphospholipid syndrome***

Question 14: A 28-year-old man presents with fever, weight loss, and night sweats over 2 months. Chest X-ray shows mediastinal lymphadenopathy. Lymph node biopsy shows Reed-Sternberg cells. What is the most likely diagnosis?

A. Non-Hodgkin's lymphoma
B. Hodgkin's lymphoma (Correct Answer)
C. Sarcoidosis
D. Tuberculosis
E. Lung cancer

Explanation: ***Hodgkin's lymphoma*** - The presentation with unexplained **fever**, **weight loss**, and **night sweats** over months indicates **B symptoms**, which are highly characteristic of Hodgkin's lymphoma (HL). - The definitive diagnosis of HL is confirmed by the presence of **Reed-Sternberg cells** on lymph node biopsy, which are large, binucleated cells considered the pathological hallmark. *Non-Hodgkin's lymphoma* - While Non-Hodgkin's lymphoma (NHL) can also cause B symptoms and lymphadenopathy, it is histologically differentiated from HL by the **absence of Reed-Sternberg cells**. - NHL generally has a more diverse presentation, often involves **extranodal sites**, and spreads in a less predictable, non-contiguous fashion compared to HL. *Sarcoidosis* - Sarcoidosis is characterized by **non-caseating granulomas** on biopsy and often presents with bilateral hilar lymphadenopathy. - Although it can cause constitutional symptoms, the prominent and persistent **B symptoms** combined with Reed-Sternberg cells rule out sarcoidosis. *Tuberculosis* - Lymph node biopsy in tuberculosis typically reveals **caseating granulomas** with central necrosis and may show acid-fast bacilli (AFB). - The presence of **Reed-Sternberg cells** is specific to HL and is not found in tuberculosis, making this diagnosis incorrect. *Lung cancer* - Lung cancer usually affects older individuals, often with a history of smoking, and its diagnosis is based on specific cancerous cell types like **adenocarcinoma** or **squamous cell carcinoma**. - The patient's young age and the specific finding of **Reed-Sternberg cells** on lymph node biopsy make lung cancer an unlikely diagnosis.

Question 15: A 38-year-old woman presents with fatigue and palpitations. Blood tests show Hb 6.8 g/dL, MCV 68 fL, ferritin 5 µg/L. She has heavy menstrual periods. What is the most appropriate initial treatment?

A. Blood transfusion
B. Oral iron (Correct Answer)
C. IV iron
D. Gynecological referral
E. Endoscopy

Explanation: ***Oral iron*** - Oral iron supplementation is the **first-line** and preferred treatment for iron deficiency anemia in stable patients due to its effectiveness, safety, and low cost.- The laboratory findings (Hb 6.8 g/dL, MCV 68 fL, ferritin 5 µg/L) confirm severe **microcytic anemia** due to iron deficiency, which replacement therapy directly targets.*Blood transfusion* - Transfusion is generally reserved for patients with severe symptomatic anemia causing **hemodynamic instability** or those who fail to respond rapidly to iron therapy.- Though Hb is low (6.8 g/dL), stable patients with chronic IDA typically respond adequately and safely to iron supplementation alone.*IV iron* - Intravenous iron is typically reserved for cases of **oral iron intolerance**, documented **malabsorption**, or in specific conditions necessitating rapid correction (e.g., late pregnancy, CKD).- Unless there is a clinical reason preventing oral intake or absorption, it is not the initial standard treatment for uncomplicated IDA.*Gynecological referral* - While essential to manage the underlying cause (**heavy menstrual bleeding** or HMB), addressing the etiology is secondary to initiating treatment for the severe nutritional deficiency.- HMB is the likely cause of the iron depletion, and the referral should follow the initiation of IDA treatment.*Endoscopy* - GI investigation (endoscopy/colonoscopy) is the standard workup for IDA in men, or in postmenopausal women, where GI bleeding is the most likely source.- In a premenopausal woman with heavy menstrual periods, the cause is adequately explained by gynecological loss, making GI workup unnecessary as the initial step.

Question 16: A 48-year-old woman presents with progressive muscle weakness and skin rash over her knuckles. CK is elevated. She's concerned about cancer risk. What percentage have associated malignancy?

A. <5%
B. 10-15%
C. 20-30% (Correct Answer)
D. 40-50%
E. >60%

Explanation: ***20-30%***- The risk of **internal malignancy** in adult patients with **dermatomyositis (DM)** is estimated to be around 15% to 30%, warranting age-appropriate cancer screening.- DM is considered a classic **paraneoplastic syndrome**, often preceding or occurring concurrently with various cancers like ovarian, lung, pancreatic, or gastric cancer.*<5%*- This range significantly **underestimates** the actual malignancy risk associated with adult-onset dermatomyositis.- This percentage is closer to the risk observed in **juvenile dermatomyositis**, which has a much lower association with cancer.*10-15%*- While this range represents a significant risk, it is often cited as the *minimum* risk and **does not capture** the higher prevalence found in specialized studies, particularly in older patients.- This may be closer to the risk for **polymyositis**, which generally has a weaker association with malignancy than dermatomyositis.*40-50%*- This range is considered **too high** for the overall prevalence of associated malignancy in DM.- Although the risk is elevated, the **majority** of adult dermatomyositis cases are not solely paraneoplastic syndrome related.*>60%*- This is a **highly exaggerated** estimate; the majority of patients diagnosed with dermatomyositis **do not** have an underlying malignancy.- A percentage this high would suggest that cancer is almost an **obligate finding**, which is clinically inaccurate.

Question 17: A 65-year-old man presents with sudden onset severe headache and jaw claudication. ESR is 95 mm/hr. What is the most appropriate immediate treatment?

A. Paracetamol
B. Sumatriptan
C. High-dose prednisolone (Correct Answer)
D. Methotrexate
E. Anti-TNF therapy

Explanation: ***High-dose prednisolone***- The clinical presentation (age, severe headache, jaw claudication, and significantly elevated **ESR**) is highly suggestive of **Giant Cell Arteritis (GCA)**, which is a medical emergency.- Immediate high-dose systemic **glucocorticoids** are essential to rapidly suppress the vasculitis and prevent the most feared complication: irreversible **vision loss** (due to ophthalmic artery occlusion).*Paracetamol*- This is a simple analgesic and will not treat the underlying severe systemic **inflammatory vasculitis** characteristic of GCA.- It lacks the necessary rapid and potent **immunosuppressive** effects required to prevent permanent ischemic damage to the vessel and end-organs.*Sumatriptan*- This medication is used for acute treatment of **migraine** or cluster headaches, conditions distinct from GCA.- It is ineffective against headaches caused by **arterial inflammation** and delaying steroid initiation puts the patient at high risk of blindness.*Methotrexate*- This is a slow-acting **disease-modifying antirheumatic drug (DMARD)** often used as a steroid-sparing agent in chronic rheumatologic conditions.- Its onset of action is far too slow to be considered the immediate intervention required to halt acute, sight-threatening **vasculitis**.*Anti-TNF therapy*- Biological agents such as anti-TNF are reserved for specific chronic inflammatory conditions and are not the appropriate **induction therapy** for acute GCA.- They do not provide the immediate, rapid anti-inflammatory effect needed to urgently protect the ophthalmic arteries from **ischemia**.

Question 18: A 42-year-old woman presents with fatigue, muscle aches, and morning stiffness lasting >1 hour. Multiple tender points are present. Blood tests are normal. What is the most likely diagnosis?

A. Rheumatoid arthritis
B. Systemic lupus erythematosus
C. Fibromyalgia (Correct Answer)
D. Polymyalgia rheumatica
E. Hypothyroidism

Explanation: ***Fibromyalgia***- The combination of **chronic widespread pain** (muscle aches), persistent **morning stiffness** lasting >1 hour, and the presence of **multiple tender points** is the classic diagnostic triad for fibromyalgia.- Crucially, **normal blood tests** are a hallmark of fibromyalgia, differentiating it from inflammatory conditions or those with specific lab abnormalities.*Rheumatoid arthritis*- **Rheumatoid arthritis** typically presents with objective inflammatory **synovitis** (swollen joints), usually affecting small joints of the hands and feet, which is not mentioned here.- It is associated with elevated inflammatory markers (**ESR** and **CRP**) and specific autoantibodies (**RF** or anti-CCP), which are absent given the normal blood tests.*Systemic lupus erythematosus*- **Systemic lupus erythematosus (SLE)** is a multisystem autoimmune disorder causing diverse organ involvement, often indicated by abnormal lab findings such as positive **ANA** or specific autoantibodies (e.g., anti-dsDNA).- While SLE causes fatigue and myalgia, the absence of specific organ involvement and the presence of **normal blood tests** make it highly unlikely.*Polymyalgia rheumatica*- **Polymyalgia rheumatica (PMR)** typically affects individuals over 50 years of age and causes pain and stiffness predominantly in the **shoulder and hip girdles** (proximal muscles).- It is an inflammatory condition characterized by **markedly elevated ESR** and **CRP**, contradicting the report of normal blood tests.*Hypothyroidism*- **Hypothyroidism** can cause fatigue and generalized myalgia, but it is diagnosed by abnormal **TSH** and T4 levels, which would invalidate the statement of normal blood tests.- Hypothyroidism does not typically present with the specific constellation of **multiple tender points** used in the diagnostic criteria for fibromyalgia.

Question 19: A 37-year-old man presents with recurrent nosebleeds and easy bruising. Platelet count is 25,000/μL. Bone marrow shows abundant megakaryocytes. What is the most likely diagnosis?

A. Aplastic anemia
B. Acute leukemia
C. Immune thrombocytopenic purpura (Correct Answer)
D. Thrombotic thrombocytopenic purpura
E. Hypersplenism

Explanation: ***Immune thrombocytopenic purpura*** - Characterized by **autoantibody-mediated destruction** of platelets, leading to severe **thrombocytopenia** (25,000/μL) and bleeding symptoms like nosebleeds and bruising. - The bone marrow compensates for peripheral destruction by robust platelet production, evidenced by **abundant megakaryocytes**. *Aplastic anemia* - This condition involves failure of hematopoietic stem cells, resulting in a **hypocellular bone marrow** and pancytopenia. - The diagnosis is excluded by the presence of **abundant megakaryocytes**, as aplastic anemia causes hypocellularity across all cell lines. *Acute leukemia* - Thrombocytopenia in leukemia results from impaired production due to bone marrow replacement by leukemic **blasts**. - The bone marrow would typically show few, if any, normal megakaryocytes, which contradicts the observation of abundant megakaryocytes. *Thrombotic thrombocytopenic purpura* - TTP is characterized by the formation of microvascular thrombi, leading to platelet consumption and requires associated features like **microangiopathic hemolytic anemia** (schistocytes) and neurological symptoms. - While it causes thrombocytopenia, the presentation lacks the key non-hemorrhagic systemic features associated with TTP. *Hypersplenism* - This typically causes mild to moderate thrombocytopenia due to sequestration or pooling of platelets within an enlarged spleen, rarely causing counts as low as 25,000/μL. - It is usually associated with **splenomegaly** and portal hypertension, underlying conditions not described in this patient.

Question 20: A 61-year-old woman presents with fatigue and weight loss. Blood tests show Hb 8.5 g/dL, MCV 105 fL. Blood film shows hypersegmented neutrophils. What is the most likely cause?

A. Iron deficiency
B. Vitamin B12 deficiency (Correct Answer)
C. Folate deficiency
D. Chronic disease
E. Thalassemia

Explanation: ***Vitamin B12 deficiency***- The patient presents with **macrocytic anemia** (Hb 8.5 g/dL, MCV 105 fL), and the hallmark finding of **hypersegmented neutrophils** on the blood film confirms **megaloblastic anemia**.- Vitamin B12 (cobalamin) is crucial for **DNA synthesis**, and its deficiency impairs cell division in hematopoietic precursors, leading to the formation of large, immature cells (megaloblasts) and characteristic hypersegmented neutrophils.*Iron deficiency*- This condition typically results in **microcytic hypochromic anemia** (low MCV), reflecting insufficient hemoglobin synthesis.- Iron deficiency would show decreased MCV, and peripheral smear abnormalities like **microcytes** and **pencil cells**, not macrocytosis.*Folate deficiency*- This condition also causes **megaloblastic anemia** (macrocytosis, hypersegmented neutrophils) because folate is also necessary for **DNA synthesis**.- While blood film findings are identical to B12 deficiency (macrocytosis + hypersegmented neutrophils), B12 deficiency is often tested first as it also carries the risk of **irreversible neurological damage**.*Chronic disease*- Anemia of chronic disease (ACD) is typically **normocytic, normochromic** (normal MCV) or occasionally microcytic.- ACD involves iron sequestration and cytokine-mediated suppression of erythropoiesis, but it does **not** cause the characteristic **hypersegmented neutrophils** seen here.*Thalassemia*- Thalassemia is a genetic disorder of globin chain synthesis that causes severe **microcytic anemia** (very low MCV) due to imbalanced chain production.- The red cells are typically small and pale, and the smear often shows **target cells** and **basophilic stippling**, not macrocytosis.

Question 21: A 52-year-old woman presents with progressive dysphagia and weight loss. She has tight skin on her hands and Raynaud's phenomenon. ANA shows nucleolar pattern. What is the most likely diagnosis?

A. Systemic lupus erythematosus
B. Sjögren's syndrome
C. Systemic sclerosis (Correct Answer)
D. Dermatomyositis
E. Mixed connective tissue disease

Explanation: ***Systemic sclerosis*** - The patient's presentation with **progressive dysphagia**, **weight loss**, **tight skin on hands** (sclerodactyly), and **Raynaud's phenomenon** are classic features of systemic sclerosis. - A **nucleolar ANA pattern** is highly characteristic of systemic sclerosis, particularly in diffuse cutaneous systemic sclerosis, often associated with **anti-topoisomerase I (Scl-70)** or **anti-RNA polymerase III antibodies**. *Systemic lupus erythematosus* - While Raynaud's phenomenon can occur, SLE is typically characterized by **malar rash**, **arthritis**, serositis, renal disease, and hematologic abnormalities, not prominent skin tightening or severe dysphagia as primary features. - ANA in SLE typically shows **homogeneous** or **speckled patterns** and is associated with **anti-dsDNA** or **anti-Sm antibodies**, not a nucleolar pattern. *Sjögren's syndrome* - This condition primarily presents with **sicca symptoms** (dry eyes, dry mouth) due to exocrine gland dysfunction. Tight skin and severe dysphagia are not primary manifestations. - ANA is often speckled, associated with **anti-Ro (SS-A)** and **anti-La (SS-B)** antibodies, not typically a nucleolar pattern. *Dermatomyositis* - Dermatomyositis is characterized by **proximal muscle weakness** and specific skin findings like **Gottron papules** and a **heliotrope rash**. While dysphagia can occur from muscle involvement, tight skin is not a typical feature. - Laboratory findings usually include elevated **muscle enzymes** (CK, aldolase) and specific antibodies like **anti-Jo-1**, rather than a nucleolar ANA pattern. *Mixed connective tissue disease* - MCTD is defined by overlapping features of SLE, systemic sclerosis, and polymyositis/dermatomyositis, often including Raynaud's and swollen hands. - The hallmark laboratory finding is very high titers of **anti-U1-RNP antibodies**, whereas the prominent tight skin, severe dysphagia, and a distinct nucleolar ANA pattern strongly favor systemic sclerosis in this case.

Question 22: A 55-year-old woman presents with bone pain and elevated calcium. Protein electrophoresis shows an IgG paraprotein. Bone marrow shows >30% plasma cells. What is the most likely diagnosis?

A. Multiple myeloma (Correct Answer)
B. Monoclonal gammopathy of uncertain significance
C. Smoldering myeloma
D. Waldenstrom's macroglobulinemia
E. Plasmacytoma

Explanation: ***Multiple myeloma***- The presence of **bone pain**, **hypercalcemia**, an **IgG paraprotein**, and **bone marrow plasmacytosis (>30%)** fulfills the diagnostic criteria for active multiple myeloma, specifically the **CRAB features**.- Active multiple myeloma is diagnosed when there is evidence of clonal plasma cells (≥10% in marrow or plasmacytoma) along with **myeloma-defining events (MDEs)**, such as the observed CRAB features (hypercalcemia and bone lesions).*Monoclonal gammopathy of uncertain significance*- MGUS is characterized by the **absence of symptoms** and **CRAB features**, with bone marrow plasma cells typically **<10%** and M-protein **<3 g/dL**.- This patient's **symptomatic bone pain**, **hypercalcemia**, and **>30% plasma cells** rule out MGUS.*Smoldering myeloma*- Smoldering multiple myeloma (SMM) involves a higher tumor burden (marrow plasma cells 10–60% or M-protein ≥3 g/dL) but, crucially, **lacks any CRAB features** or other MDEs.- The patient's presentation with **hypercalcemia** and **bone pain** indicates active disease, thus ruling out SMM.*Waldenstrom's macroglobulinemia*- Waldenstrom's macroglobulinemia (WM) is primarily associated with an **IgM paraprotein** and lymphoplasmacytic lymphoma in the bone marrow, often leading to hyperviscosity syndrome.- The patient has an **IgG paraprotein** and classic lytic bone disease leading to hypercalcemia, which are characteristic of multiple myeloma, not WM.*Plasmacytoma*- A plasmacytoma is a **localized tumor** of plasma cells, which can be solitary bone plasmacytoma or extramedullary. It typically does not involve diffuse bone marrow plasmacytosis (>30%) or systemic CRAB features.- The extensive bone marrow involvement and systemic complications like **hypercalcemia** and diffuse **bone pain** indicate systemic multiple myeloma rather than a solitary plasmacytoma.

Question 23: A 46-year-old woman presents with fatigue, muscle weakness, and purple discoloration around her eyes. She has difficulty swallowing. CK is 4000 U/L. What is the most important additional investigation?

A. EMG
B. Muscle biopsy
C. CT chest/abdomen/pelvis (Correct Answer)
D. ANA
E. Thyroid function

Explanation: ***CT chest/abdomen/pelvis*** - The patient's presentation with fatigue, muscle weakness, difficulty swallowing, elevated CK, and especially the **purple discoloration around her eyes (heliotrope rash)** is highly suggestive of **Dermatomyositis (DM)**. - DM has a strong association with **occult malignancy** (paraneoplastic syndrome), making **CT chest/abdomen/pelvis** the most important initial investigation to screen for underlying cancers (e.g., ovarian, lung, breast, gastrointestinal). *EMG* - **Electromyography (EMG)** can help confirm the myopathic process and differentiate it from neuropathic causes by showing characteristic electrical findings. - While diagnostically useful, the immediate priority in a patient with suspected dermatomyositis is to screen for potentially life-threatening **underlying malignancy**. *Muscle biopsy* - A **muscle biopsy** is the definitive diagnostic procedure for dermatomyositis, showing characteristic features like **perifascicular atrophy** and perivascular inflammation. - Although confirmatory, addressing the potential for an associated malignancy takes precedence, as the prognosis and management are significantly impacted by its presence. *ANA* - **Antinuclear antibodies (ANA)** can be positive in many connective tissue diseases, including dermatomyositis, but are not specific to the condition. - Given the classic clinical picture, serological confirmation is less critical than the urgent need to identify a potentially co-existing **malignancy**. *Thyroid function* - **Thyroid function tests** are important to exclude **hypothyroid myopathy**, which can cause muscle weakness and elevated CK levels. - However, the presence of the pathognomonic **heliotrope rash** and the markedly elevated CK (4000 U/L) makes dermatomyositis the most likely diagnosis, prioritizing malignancy screening over other potential causes of myopathy.

Question 24: A 51-year-old woman presents with bone pain and elevated alkaline phosphatase. X-rays show mixed lytic and sclerotic lesions. Bone scan shows increased uptake. What is the most likely diagnosis?

A. Osteoporosis
B. Paget's disease (Correct Answer)
C. Metastatic bone disease
D. Multiple myeloma
E. Osteomalacia

Explanation: ***Paget's disease*** - The combination of **bone pain**, significantly **elevated alkaline phosphatase**, **mixed lytic and sclerotic lesions** on X-ray, and **increased uptake on bone scan** are classic findings for Paget's disease of bone. - This condition is characterized by a focal disorder of bone remodeling, involving phases of excessive bone resorption followed by disorganized and rapid bone formation. *Osteoporosis* - **Osteoporosis** primarily presents with **fragility fractures** due to reduced bone mineral density and typically does not cause a markedly elevated alkaline phosphatase or mixed lytic/sclerotic lesions on X-ray. - Bone scans in osteoporosis usually show **decreased uptake**, reflecting low bone turnover, in contrast to the increased uptake seen in this patient. *Metastatic bone disease* - While metastatic bone disease can cause bone pain and lytic or sclerotic lesions, the presentation would often involve a known primary malignancy, and the specific combination of markedly **elevated alkaline phosphatase** with mixed lytic-sclerotic lesions strongly favors Paget's. - Metastatic lesions often present as purely lytic or purely sclerotic, and while mixed patterns exist, the described picture is highly suggestive of Paget's in the absence of a primary cancer. *Multiple myeloma* - Multiple myeloma is characterized by **punched-out lytic lesions** without a sclerotic component, due to osteoclast activation, and is associated with a monoclonal paraprotein. - **Alkaline phosphatase** levels are typically **normal** in multiple myeloma unless there are associated pathological fractures or other complications like liver involvement. *Osteomalacia* - **Osteomalacia** is caused by defective bone mineralization, leading to soft bones, diffuse bone pain, and muscle weakness, and typically presents with X-rays showing **radiolucency** and **pseudofractures (Looser's zones)**. - Although **alkaline phosphatase** can be elevated in osteomalacia, the characteristic mixed lytic and sclerotic lesions described are not consistent with this diagnosis.

Question 25: A 28-year-old woman presents with recurrent miscarriages and a history of DVT. Blood tests show prolonged APTT not correcting with mixing studies. What is the most likely diagnosis?

A. Factor V Leiden
B. Antiphospholipid syndrome (Correct Answer)
C. Protein C deficiency
D. Von Willebrand disease
E. Hemophilia carrier

Explanation: ***Antiphospholipid syndrome*** - This syndrome is characterized by **thrombosis** (DVT) and **pregnancy morbidity** (recurrent miscarriages), driven by **antiphospholipid antibodies**. - The presence of a prolonged **APTT** that does not correct upon mixing with normal plasma is a key laboratory finding, suggesting an inhibitor like the **lupus anticoagulant**, which is part of the diagnostic criteria. *Factor V Leiden* - This is a common inherited cause of **venous thrombosis** (DVT) but is not typically associated with recurrent **miscarriages**. - Lab testing would show **normal coagulation times** (APTT/PT) but a failure to inactivate **Factor Va** by activated **Protein C**. *Protein C deficiency* - This condition also primarily causes an increased risk of **venous thrombosis** due to impaired natural anticoagulant function. - It is not a common cause of recurrent **miscarriages**, and routine lab tests would show **normal APTT/PT** but low levels of **Protein C**. *Von Willebrand disease* - This is a common **bleeding disorder**, not a thrombotic disorder, characterized by defective or deficient **von Willebrand factor**. - Patients typically present with **mucocutaneous bleeding**, and while APTT can be mildly prolonged, the clinical picture is of hypocoagulability, not hypercoagulability. *Hemophilia carrier* - Carriers of **Hemophilia A** or **B** are usually asymptomatic or have mild bleeding tendencies, as they are **bleeding disorders**, not thrombotic disorders. - They would typically have moderately low levels of **Factor VIII** or **Factor IX**, which might prolong **APTT**, but they do not present with DVT or recurrent miscarriages.

Question 26: A 41-year-old woman presents with fatigue, joint pain, and a malar rash. Blood tests show ANA 1:320, anti-dsDNA positive, low C3 and C4. Urinalysis shows proteinuria and hematuria. What is the most likely diagnosis?

A. Drug-induced lupus
B. Systemic lupus erythematosus (Correct Answer)
C. Mixed connective tissue disease
D. Sjögren's syndrome
E. Systemic sclerosis

Explanation: ***Systemic lupus erythematosus***- The presence of the characteristic **malar rash**, polyarthritis (joint pain), elevated **ANA** (1:320), and highly specific **anti-dsDNA** antibodies are key diagnostic criteria for SLE.- Low serum complement levels (**C3 and C4**) along with evidence of severe renal involvement (**proteinuria** and **hematuria**) strongly indicate active disease, specifically **lupus nephritis**.*Drug-induced lupus*- While positive ANA is common, **anti-dsDNA** antibodies and persistent **hypocomplementemia** (low C3/C4) are rare in drug-induced lupus.- This condition typically lacks major organ complications, such as the severe **renal disease** (nephritis) observed in this patient, and is often associated with **anti-histone antibodies**.*Mixed connective tissue disease*- The serologic hallmark is a very high titer of **anti-U1 RNP** antibodies, which is not present, contrasting with the highly specific **anti-dsDNA** seen here.- Although it shares some symptoms with SLE, severe **renal disease** (lupus nephritis) and prominent **hypocomplementemia** are not defining features of MCTD.*Sjögren's syndrome*- This syndrome primarily presents with **sicca symptoms** (dry eyes and dry mouth) and fatigue; the main autoantibodies are **anti-Ro (SSA)** and **anti-La (SSB)**.- While it can cause renal tubulointerstitial disease, the combination of **malar rash**, positive **anti-dsDNA**, and evidence of glomerulonephritis points away from Sjögren's.*Systemic sclerosis*- The defining feature is progressive **skin thickening** and fibrosis, typically associated with **anti-centromere** or **anti-Scl-70** antibodies.- The absence of prominent skin changes and the presence of **malar rash** and highly specific SLE serology make this diagnosis unlikely.

Question 27: A 42-year-old man presents with progressive muscle weakness affecting shoulders and hips. CK is 2500 U/L. Muscle biopsy shows inflammatory infiltrates without skin involvement. What is the most appropriate treatment?

A. Physiotherapy alone
B. High-dose prednisolone (Correct Answer)
C. Methotrexate
D. Azathioprine
E. Immunoglobulin

Explanation: ***High-dose prednisolone*** - This presentation (proximal muscle weakness, high **CK**, and inflammatory infiltrates on muscle biopsy without skin involvement) points toward **Polymyositis** (an Idiopathic Inflammatory Myopathy). - **High-dose corticosteroids** (like prednisolone) are the mainstay and initial first-line treatment for active Polymyositis due to their potent immunosuppressive and anti-inflammatory effects.*Physiotherapy alone* - While physical therapy is a critical component of management to prevent **atrophy** and maintain joint mobility, it is only a supportive measure. - It does not address the underlying **autoimmune inflammation** destroying the muscle fibers, making it insufficient as monotherapy.*Methotrexate* - Methotrexate is a **disease-modifying antirheumatic drug (DMARD)** often used as a steroid-sparing agent or for maintenance therapy in myositis. - It is generally not used as the initial primary induction therapy for severe, active myositis due to its slower onset of action compared to high-dose steroids.*Azathioprine* - Azathioprine is another common **immunosuppressive agent** used in IIMs, typically functioning as a steroid-sparing agent for long-term control or relapse prevention. - Similar to methotrexate, it is usually reserved for patients with refractory disease or those who require dose reduction of the initial high-dose corticosteroids.*Immunoglobulin* - **Intravenous Immunoglobulin (IVIg)** is a treatment option usually reserved for severe, refractory cases of myositis (not responding to steroids/DMARDs) or for specific subgroups like patients with dysphagia or in crisis. - It is not considered the standard initial **first-line therapy** for uncomplicated, newly diagnosed polymyositis.

Question 28: A 28-year-old woman presents with recurrent oral ulcers, genital ulcers, and arthritis. She has a positive pathergy test. What is the most likely diagnosis?

A. Systemic lupus erythematosus
B. Crohn's disease
C. Behçet's disease (Correct Answer)
D. Herpes simplex infection
E. Aphthous stomatitis

Explanation: ***Behçet's disease***- The constellation of **recurrent oral ulcers**, **genital ulcers**, and **arthritis** is the classic presentation of this systemic vasculitis.- A **positive pathergy test**, indicating nonspecific cutaneous hyperreactivity, is highly specific (though not highly sensitive) for Behçet's disease.*Systemic lupus erythematosus*- While SLE can cause oral ulcers, they are usually **painless** and less commonly recurrent, and SLE is classically defined by features like **malar rash** and serositis.- **Genital ulcers** and a specific **positive pathergy test** are not typical features used to diagnose or differentiate SLE.*Crohn's disease*- Crohn's disease is primarily a form of **Inflammatory Bowel Disease (IBD)**; while it can cause oral lesions and peripheral arthritis, severe, recurrent **genital ulcers** are uncommon.- A **positive pathergy test** is a characteristic feature of Behçet's disease and is not typically associated with Crohn's disease.*Herpes simplex infection*- HSV causes painful, recurring **vesicular lesions** that evolve into ulcers in the oral and genital areas but typically does not cause a systemic, persistent **arthritis**.- HSV infection is diagnosed by viral tests (e.g., PCR) and does not result in a **positive pathergy test**.*Aphthous stomatitis*- This common condition only causes **recurrent oral ulcers** (canker sores) and is considered a localized mucosal disorder.- It does not cause associated features like **genital ulcers**, systemic **arthritis**, or the inflammatory skin hyperreactivity seen with a **positive pathergy test**.

Question 29: A 70-year-old woman presents with severe headache and jaw claudication. She also complains of visual disturbances. ESR is 95 mm/hr. What is the most appropriate immediate treatment?

A. Paracetamol
B. Sumatriptan
C. High-dose prednisolone (Correct Answer)
D. Methotrexate
E. Anti-TNF therapy

Explanation: ***High-dose prednisolone*** - The clinical presentation (severe headache, jaw claudication, visual disturbances, and very high ESR in an elderly patient) is highly suggestive of **Giant Cell Arteritis (GCA)**. - **High-dose corticosteroids** are the immediate and most crucial treatment to prevent **irreversible vision loss**, a devastating complication of GCA. *Paracetamol* - Paracetamol (acetaminophen) is a basic **analgesic** that offers symptomatic pain relief but has no significant **anti-inflammatory** properties. - It would not address the underlying **vasculitis** or prevent the progression to **blindness**, which is the critical concern in GCA. *Sumatriptan* - Sumatriptan is a **triptan** specifically indicated for the acute treatment of **migraine headaches** and cluster headaches. - The headache in GCA is caused by **arterial inflammation**, not migraine, making sumatriptan ineffective and inappropriate for this condition. *Methotrexate* - Methotrexate is a **disease-modifying anti-rheumatic drug (DMARD)** that may be used as a **steroid-sparing agent** or for long-term management in GCA, often in combination with corticosteroids. - However, its **slow onset of action** (weeks to months) makes it unsuitable for the immediate, acute treatment necessary to prevent vision loss in new-onset GCA. *Anti-TNF therapy* - **Anti-TNF agents** are generally not effective in GCA and are not a standard part of its treatment regimen. - While other biologics like **Tocilizumab** (an IL-6 inhibitor) might be considered for refractory cases or steroid sparing, they are not the immediate treatment for acute sight preservation.

Question 30: A 55-year-old woman presents with severe bone pain, particularly in her back and ribs. X-rays show multiple lytic lesions throughout the skeleton. Blood tests show elevated calcitonin, low albumin, and raised ESR. What investigation would be most helpful?

A. Bone marrow biopsy
B. Serum protein electrophoresis (Correct Answer)
C. Bone scan
D. Parathyroid hormone
E. Vitamin D levels

Explanation: ***Serum protein electrophoresis*** - The combination of **severe bone pain**, **multiple lytic lesions** on X-ray, and a **raised ESR** strongly suggests **multiple myeloma**. Serum protein electrophoresis (SPEP) is the most helpful initial investigation to detect and quantify the **monoclonal protein (M-protein)**, which is the hallmark of this condition. - The presence of an **M-spike** on SPEP is crucial for the diagnosis of multiple myeloma, as it indicates the proliferation of a single clone of plasma cells. *Bone marrow biopsy* - While a **bone marrow biopsy** is essential for confirming multiple myeloma by identifying an increased percentage of **plasma cells**, it is typically performed after initial screening tests like SPEP suggest a monoclonal gammopathy. - It is an invasive procedure and not usually the *first* or *most helpful* initial investigation when SPEP can quickly indicate the likely diagnosis. *Bone scan* - **Technetium-99m bone scans** are often *not sensitive* for the purely lytic lesions characteristic of multiple myeloma, as these lesions primarily involve **osteoclastic destruction** without significant osteoblastic reaction. - Although helpful for detecting metastatic disease from other solid tumors, **plain X-rays** (already performed in this case) or more advanced imaging like **PET/CT** or **MRI** are superior for evaluating myeloma bone disease. *Parathyroid hormone* - This test is used to evaluate **parathyroid function** and causes of **hypercalcemia**. While multiple myeloma can cause hypercalcemia, it is typically **PTH-independent hypercalcemia** due to increased bone resorption by myeloma cells. - Elevated PTH would suggest **primary hyperparathyroidism**, which is less likely given the widespread lytic lesions and high ESR. It's not the primary diagnostic test for this presentation. *Vitamin D levels* - **Vitamin D levels** are important for bone health, but their measurement is not the *most helpful* initial investigation for a patient presenting with severe bone pain, **multiple lytic lesions**, and a high ESR, which point towards a plasma cell dyscrasia or metastatic bone disease. - While vitamin D deficiency can contribute to bone pain, it does not explain the characteristic lytic lesions or significantly elevated ESR seen in this clinical picture.

Question 31: A 25-year-old woman presents with fatigue, pallor, and spoon-shaped nails (koilonychia). Blood tests show Hb 7.5 g/dL, MCV 65 fL, ferritin 8 µg/L. What is the most likely cause?

A. Vitamin B12 deficiency
B. Iron deficiency anemia (Correct Answer)
C. Thalassemia
D. Chronic disease
E. Folate deficiency

Explanation: ***Iron deficiency anemia*** - This diagnosis is strongly supported by the **microcytic** anemia (MCV 65 fL) and the severely depleted iron stores indicated by the very low **ferritin** level of 8 µg/L. - **Koilonychia** (spoon-shaped nails) is a classic clinical sign of chronic and severe **iron deficiency** that accompanies the symptoms of fatigue and pallor. *Vitamin B12 deficiency* - Vitamin B12 deficiency causes a **megaloblastic, macrocytic** anemia (high MCV), which contradicts the microcytic presentation (MCV 65 fL) seen in this patient. - Ferritin levels would typically be normal or high, and a key distinguishing feature is the potential presence of **neurological symptoms**. *Thalassemia* - Thalassemia causes microcytic anemia, but it is characterized by **normal or elevated ferritin** levels, indicating adequate iron stores, unlike the severely low ferritin observed here. - It is diagnosed by specific findings on **hemoglobin electrophoresis**, reflecting genetic defects in globin chain synthesis. *Chronic disease* - Anemia of chronic disease typically presents as mild to moderate anemia that is often **normocytic** or mildly microcytic. - A defining lab feature is normal or **elevated ferritin** (as ferritin is an acute phase reactant), signifying sequestration of iron stores rather than true depletion. *Folate deficiency* - Folate deficiency presents similarly to Vitamin B12 deficiency, causing a **megaloblastic, macrocytic** anemia (high MCV), which does not match the patient's presentation. - Serum ferritin levels in folate deficiency are usually normal, and it is confirmed by measuring the **red cell folate** level.

Question 32: A 50-year-old woman presents with fatigue, muscle weakness, and purple discoloration around her eyes (heliotrope rash). She also has difficulty rising from chairs and climbing stairs. CK is elevated at 3000 U/L. What is the most likely diagnosis?

A. Polymyositis
B. Dermatomyositis (Correct Answer)
C. Inclusion body myositis
D. Polymyalgia rheumatica
E. Hypothyroidism

Explanation: ***Dermatomyositis*** - The presence of the **heliotrope rash** (periorbital violaceous discoloration) and **proximal muscle weakness** (difficulty rising/climbing stairs) is pathognomonic, distinguishing it from other inflammatory myopathies. - This condition involves both skin and muscle inflammation, resulting in classic findings like the rash, elevated **Creatine Kinase (CK)**, and often an increased risk of underlying malignancy. *Polymyositis* - Shares features of **proximal muscle weakness** and elevated CK but **lacks the characteristic violaceous skin rash** (heliotrope rash or Gottron's papules) seen in this patient. - It is primarily a muscle disease characterized by lymphocytic invasion of the **endomysium** on muscle biopsy. *Inclusion body myositis* - While it presents with muscle weakness, it typically affects the **distal muscles** (forearm flexors and quadriceps) asymmetrically and often affects older individuals. - CK elevation is usually mild (often less than 10 times the upper limit of normal), unlike the significant elevation (3000 U/L) seen here. *Polymyalgia rheumatica* - Presents mainly with pain and severe stiffness (girdle pain) in the shoulder and pelvic areas, but **true objective muscle weakness is absent**. - **CK levels are normal**, and the diagnosis relies on elevated inflammatory markers like ESR and CRP, and the absence of skin changes. *Hypothyroidism* - Can cause myopathy with fatigue and mild proximal weakness, and CK may be mildly elevated, but it does **not cause the specific heliotrope rash**. - Diagnosis is confirmed by abnormal thyroid function tests (low **Free T4** and usually high **TSH**), which is not suggested by the clinical presentation or severity of the CK elevation.

Question 33: A 45-year-old woman presents with fatigue, joint pain, and a butterfly rash across her cheeks and nose. Blood tests show positive ANA and anti-dsDNA antibodies. Complement levels (C3, C4) are low. What is the most likely diagnosis?

A. Systemic sclerosis
B. Sjögren's syndrome
C. Systemic lupus erythematosus (Correct Answer)
D. Dermatomyositis
E. Mixed connective tissue disease

Explanation: ***Systemic lupus erythematosus*** - The presence of fatigue, joint pain, and a characteristic **butterfly (malar) rash** across the cheeks and nose is a hallmark clinical presentation of Systemic Lupus Erythematosus (SLE). - The laboratory findings of **positive ANA**, highly specific **anti-dsDNA antibodies**, and **low complement levels (C3, C4)** due to immune complex consumption are definitive for the diagnosis of active SLE. *Systemic sclerosis* - This condition is characterized by **skin thickening (scleroderma)**, Raynaud's phenomenon, and often leads to fibrosis of internal organs like the lungs and gastrointestinal tract. - Typical autoantibodies include **anti-Scl-70** or **anti-centromere antibodies**, and it does not typically present with a malar rash or anti-dsDNA antibodies. *Sjögren's syndrome* - The primary clinical manifestations involve **sicca symptoms** (dry eyes and dry mouth) resulting from immune-mediated damage to exocrine glands. - It is often associated with **anti-Ro (SSA)** and **anti-La (SSB)** antibodies, and lacks the prominent malar rash and anti-dsDNA antibodies seen in this case. *Dermatomyositis* - This autoimmune disease presents with characteristic **proximal muscle weakness** and distinctive cutaneous findings such as **Gottron papules** (over joints) and a **heliotrope rash** (periorbital edema with a violaceous discoloration). - Diagnosis usually involves elevated muscle enzymes like **creatine kinase (CK)** and specific antibodies such as anti-Mi-2 or anti-Jo-1, not anti-dsDNA. *Mixed connective tissue disease* - Defined by overlapping features of several connective tissue diseases (e.g., SLE, systemic sclerosis, polymyositis) along with a high titer of **anti-U1-RNP antibodies**. - While some features may overlap with SLE, the combination of a classic malar rash and high-titer **anti-dsDNA antibodies** with low complements points more specifically to SLE rather than MCTD as the primary diagnosis.

Question 34: A 60-year-old woman presents with bone pain and fatigue. Blood tests show calcium 2.9 mmol/L, phosphate 0.6 mmol/L, ALP 200 U/L. X-rays show osteopenia and Looser zones. What is the most likely diagnosis?

A. Osteoporosis
B. Osteomalacia (Correct Answer)
C. Paget's disease
D. Multiple myeloma
E. Metastatic bone disease

Explanation: ***Osteomalacia*** - The presence of **Looser zones** (pseudofractures) on X-ray, which represent unmineralized osteoid, is pathognomonic for **osteomalacia** (or rickets in children). - The biochemical constellation of **high ALP** (indicating increased osteoblast activity/turnover) and **hypophosphatemia** (due to reduced renal phosphate reabsorption, often driven by secondary hyperparathyroidism) strongly supports a bone mineralization defect. *Osteoporosis* - This condition is characterized by a reduction in bone quantity but normal bone mineralization; hence, **Looser zones** are not seen. - Lab values (calcium, phosphate, **ALP**) are typically within the normal range, unlike the high ALP and abnormal calcium/phosphate seen here. *Paget's disease* - Paget's disease causes focal abnormal bone remodeling, leading to disorganization (mosaic pattern) and thickening of the affected bones, but not **Looser zones**. - It is typically characterized by a very markedly elevated **ALP**, but calcium and phosphate levels usually remain normal. *Multiple myeloma* - This plasma cell malignancy typically causes **punched-out lytic bone lesions** rather than diffuse osteopenia and pseudofractures, alongside systemic symptoms like anemia. - While hypercalcemia is frequent, ALP is usually normal (unless pathological fracture occurs), and the combination of low phosphate and high ALP is atypical. *Metastatic bone disease* - Malignant cells metastasize to the bone, causing either lytic or blastic lesions, but these structural lesions do not include the specific unmineralized zones known as **Looser zones**. - The combination of **hypophosphatemia** and high ALP points more specifically toward a metabolic bone disorder rather than generalized cancer spread.

Question 35: A 60-year-old woman presents with bone pain, particularly in her back and hips. X-rays show multiple lytic lesions in the spine and pelvis. Serum calcium is elevated, and she has a normocytic anemia. What investigation would be most helpful?

A. Bone marrow biopsy
B. Serum protein electrophoresis (Correct Answer)
C. PSA level
D. Mammography
E. Thyroid function tests

Explanation: ***Serum protein electrophoresis*** - The patient's presentation with **bone pain**, **multiple lytic lesions**, **elevated serum calcium**, and **normocytic anemia** is highly suggestive of **Multiple Myeloma**. - **Serum protein electrophoresis (SPEP)** is the most helpful initial investigation as it detects and quantifies the **monoclonal immunoglobulin (M-protein or M-spike)**, which is a hallmark of this plasma cell dyscrasia.*Bone marrow biopsy* - While a **bone marrow biopsy** is crucial for confirming the diagnosis of Multiple Myeloma by identifying clonal plasma cells, it is usually performed *after* an M-protein has been detected via SPEP or immunofixation. - It provides definitive histological evidence but is more invasive and not the primary screening investigation indicated by the clinical picture.*PSA level* - **Prostate-Specific Antigen (PSA)** is a tumor marker primarily used for screening and monitoring **prostate cancer** in men, which is typically associated with **osteoblastic** (sclerotic) bone lesions rather than lytic lesions. - This patient is a woman, making a PSA level irrelevant to her diagnostic workup.*Mammography* - **Mammography** is a diagnostic imaging tool for **breast cancer**. Although breast cancer can metastasize to bone and cause lytic lesions, the combined clinical findings of significant **hypercalcemia** and **normocytic anemia** strongly point to a hematological malignancy like Multiple Myeloma. - It would not directly explain the systemic laboratory abnormalities characteristic of Multiple Myeloma.*Thyroid function tests* - **Thyroid function tests** are used to diagnose thyroid disorders, which do not typically manifest with **multiple lytic bone lesions**, severe **hypercalcemia**, and **normocytic anemia** simultaneously. - While hyperthyroidism can contribute to bone loss, it would not cause the specific lytic lesions or the monoclonal gammopathy associated with this presentation.

Question 36: A 25-year-old man presents with recurrent mouth ulcers, genital ulcers, and erythema nodosum on his shins. He also complains of joint pain and eye irritation. What is the most likely diagnosis?

A. Herpes simplex infection
B. Behçet's disease (Correct Answer)
C. Crohn's disease
D. Aphthous stomatitis
E. Systemic lupus erythematosus

Explanation: ***Behçet's disease*** - The constellation of recurrent **oral ulcers**, **genital ulcers**, and **ocular lesions** (eye irritation) along with **erythema nodosum** and **joint pain** is highly characteristic of Behçet's disease, a systemic vasculitis. - This multisystem inflammatory condition primarily affects small and large vessels and often presents with these mucocutaneous, ocular, and musculoskeletal symptoms. *Herpes simplex infection* - While **herpes simplex** causes recurrent oral and genital ulcers, these are typically **vesicular** before ulceration and are not typically associated with systemic manifestations like **erythema nodosum**, widespread **arthralgia**, or the severe **ocular inflammation** seen in Behçet's. - It is a localized viral infection and does not explain the broad systemic inflammatory presentation described. *Crohn's disease* - **Crohn's disease**, an inflammatory bowel disease, can cause oral aphthous ulcers and perianal lesions, but **genital ulcers** as described here (distinct from perianal) and **erythema nodosum** are not core diagnostic features. - The primary symptoms of Crohn's involve chronic **gastrointestinal inflammation**, which is not the predominant clinical picture in this patient. *Aphthous stomatitis* - **Aphthous stomatitis** explains only the **recurrent mouth ulcers**. - It does not account for the other significant symptoms, including **genital ulcers**, **erythema nodosum**, **joint pain**, and **eye irritation**, which indicate a systemic disorder. *Systemic lupus erythematosus* - **Systemic lupus erythematosus (SLE)** can cause oral ulcers and joint pain (**arthralgia/arthritis**), but **genital ulcers** and **erythema nodosum** are not typical primary diagnostic criteria or common presentations of SLE. - While SLE is a systemic autoimmune disease, the specific combination of symptoms points more strongly towards Behçet's disease.

Question 37: A 40-year-old woman presents with fatigue, muscle aches, and morning stiffness lasting over 1 hour. She has tender points at multiple sites including neck, shoulders, and hips. Blood tests including ESR and CRP are normal. What is the most likely diagnosis?

A. Rheumatoid arthritis
B. Systemic lupus erythematosus
C. Fibromyalgia (Correct Answer)
D. Polymyalgia rheumatica
E. Hypothyroidism

Explanation: ***Fibromyalgia***- This diagnosis is strongly suggested by the combination of chronic, widespread pain, fatigue, prolonged **morning stiffness** (>1 hour), and the presence of multiple definitive **tender points**.- Crucially, fibromyalgia is a non-inflammatory centralized pain disorder, evidenced by the **normal ESR and CRP** results, ruling out most inflammatory arthropathies.*Rheumatoid arthritis*- RA typically presents with objective **synovitis** (joint swelling) and limited use of specific joints, particularly small joints of the hands and feet, which is not described here.- Active RA is an inflammatory disease and would typically show **elevated ESR and CRP**, making it an unlikely diagnosis with normal laboratory findings.*Systemic lupus erythematosus*- SLE is a multi-system autoimmune disorder that often involves specific organ manifestations (e.g., rash, hematologic issues, nephritis) and would usually present with abnormal immunologic markers (e.g., positive **ANA** or anti-dsDNA).- Like RA, active SLE often causes **elevated inflammatory markers (ESR and CRP)**, conflicting with the patient's normal blood test results.*Polymyalgia rheumatica*- PMR causes severe aching and stiffness primarily restricted to the **shoulder and hip girdles** (proximal symptoms), not widespread body tenderness.- A hallmark feature of PMR is a **dramatically elevated ESR and CRP**, which is absent in this case.*Hypothyroidism*- While hypothyroidism can cause fatigue and **myalgia**, it would not typically cause the specific pattern of widespread **tender points** required for a fibromyalgia diagnosis.- Diagnosis relies on abnormal **TSH and free T4** levels; pain and stiffness are less prominent features than in inflammatory or primary pain disorders like fibromyalgia.

Question 38: A 50-year-old woman presents with progressive muscle weakness, particularly affecting her shoulders and hips. She has difficulty rising from chairs and climbing stairs. Her CK is elevated at 2000 U/L. EMG shows myopathic changes. What is the most likely diagnosis?

A. Polymyalgia rheumatica
B. Polymyositis (Correct Answer)
C. Myasthenia gravis
D. Motor neuron disease
E. Hypothyroidism

Explanation: ***Polymyositis***- The patient's presentation with progressive, symmetric **proximal muscle weakness** affecting shoulders and hips, leading to difficulty rising from chairs and climbing stairs, is a classic feature of polymyositis.- A significantly elevated **CK (2000 U/L)** indicates substantial muscle damage, and **myopathic changes** on EMG confirm a primary muscle disorder, all consistent with polymyositis.*Polymyalgia rheumatica*- Polymyalgia rheumatica (PMR) primarily presents with severe muscle **pain and stiffness**, especially in the shoulders and hips, but not objective **muscle weakness**.- In PMR, **CK levels are typically normal**, which contrasts with the markedly elevated CK found in this patient.*Myasthenia gravis*- Myasthenia gravis (MG) causes **fluctuating muscle weakness** and **fatigability** that worsens with activity and improves with rest, often starting with ocular or bulbar symptoms.- **CK levels are normal** in MG, and EMG demonstrates a **decremental response** to repetitive nerve stimulation, indicating a defect at the neuromuscular junction, not muscle inflammation.*Motor neuron disease*- Motor neuron disease (MND) involves signs of both upper and/or lower **motor neuron damage**, such as spasticity, fasciculations, and muscle atrophy, but no sensory deficits.- EMG in MND shows **neurogenic changes** (denervation and reinnervation), and **CK levels are usually normal** or only mildly elevated, not significantly high.*Hypothyroidism*- Hypothyroid myopathy can cause muscle stiffness, cramps, and sometimes **mild-to-moderate proximal weakness**, with **CK levels usually mildly to moderately elevated**.- A CK of 2000 U/L is very high for uncomplicated hypothyroid myopathy, and the primary diagnosis would require abnormal **thyroid function tests**, which are not mentioned.

Question 39: A 35-year-old man presents with acute onset severe pain and swelling in his right great toe. The joint is red, hot, and extremely tender. His serum uric acid is 450 μmol/L (normal 200-430). What is the most appropriate acute treatment?

A. Allopurinol
B. Colchicine
C. Ibuprofen (Correct Answer)
D. Prednisolone
E. Paracetamol

Explanation: ***Ibuprofen*** - **Non-steroidal anti-inflammatory drugs (NSAIDs)** like ibuprofen are the **first-line treatment** for acute gout flares, rapidly reducing severe pain and inflammation due to **uric acid crystal deposition**. - They act by inhibiting **cyclooxygenase (COX) enzymes**, thereby blocking prostaglandin synthesis, which is crucial for managing the intense inflammatory response characteristic of **podagra**. *Allopurinol* - **Allopurinol** is a **xanthine oxidase inhibitor** primarily used for **long-term prophylaxis** to lower serum uric acid levels, not for acute management of a flare. - Initiating allopurinol during an acute attack is generally **contraindicated** as it can mobilize uric acid stores, potentially prolonging or worsening the attack. *Colchicine* - **Colchicine** is an effective anti-inflammatory agent for acute gout, but it's typically a **second-line** option or preferred if started very early (ideally within 12-24 hours of onset). - Its use is often limited by a narrow therapeutic window and dose-dependent **gastrointestinal side effects** such as diarrhea and nausea. *Prednisolone* - **Prednisolone** (corticosteroids) is highly effective for acute gout but is generally reserved for patients who cannot tolerate NSAIDs or colchicine, or those with severe, polyarticular attacks. - Systemic steroids are considered **second- or third-line options**, particularly when NSAIDs are contraindicated (e.g., severe renal failure, heart failure, active peptic ulcer disease). *Paracetamol* - **Paracetamol (Acetaminophen)** is a simple analgesic and antipyretic that **lacks significant anti-inflammatory properties**. - It is insufficient for controlling the intense **chemical inflammation** and severe pain characteristic of an acute gout flare, making it an inappropriate primary treatment.

Question 40: A 35-year-old woman presents with recurrent miscarriages (3 in the past 2 years) and a history of deep vein thrombosis. Blood tests show prolonged APTT that doesn't correct with mixing studies. What is the most likely diagnosis?

A. Factor V Leiden mutation
B. Protein C deficiency
C. Antiphospholipid syndrome (Correct Answer)
D. Prothrombin gene mutation
E. Antithrombin deficiency

Explanation: ***Antiphospholipid syndrome***- The combination of **recurrent miscarriages** and a history of **deep vein thrombosis (DVT)** is a hallmark clinical presentation of Antiphospholipid Syndrome (APS).- The finding of a **prolonged APTT** that fails to correct with a normal plasma mixing study is highly suggestive of **lupus anticoagulant (LA)**, a key diagnostic criterion for APS.*Factor V Leiden mutation*- This condition causes **resistance to activated protein C**, primarily increasing the risk of **venous thrombosis**.- Routine coagulation tests like **aPTT** are typically **normal** in individuals with this mutation.*Protein C deficiency*- This disorder primarily increases the risk of **venous thrombosis** but is less frequently associated with recurrent fetal loss compared to APS.- Coagulation screening tests (**PT** and **aPTT**) are generally **normal** in individuals with this deficiency.*Prothrombin gene mutation*- This mutation (G20210A) results in increased levels of **prothrombin (Factor II)** and primarily causes an increased risk of **venous thrombosis**.- Standard coagulation assays (**PT** and **aPTT**) typically remain **normal** in affected individuals.*Antithrombin deficiency*- This deficiency causes a severe, high-risk state for **venous thrombosis** (DVT/PE).- Although it causes hypercoagulability, it is not strongly associated with the specific combination of thrombosis and **recurrent miscarriages** defining APS, and baseline aPTT is usually normal.

Question 41: A 50-year-old woman presents with a 6-month history of dry eyes and dry mouth. She also complains of joint pain in her hands and fatigue. Blood tests show positive anti-Ro and anti-La antibodies. What is the most likely diagnosis?

A. Systemic lupus erythematosus
B. Sjögren's syndrome (Correct Answer)
C. Rheumatoid arthritis
D. Systemic sclerosis
E. Polymyalgia rheumatica

Explanation: ***Sjögren's syndrome*** - The classic triad of **dry eyes (xerophthalmia)**, **dry mouth (xerostomia)**, and **arthralgia** is highly characteristic of Sjögren's syndrome. - The presence of **positive anti-Ro (SSA)** and **anti-La (SSB) antibodies** further confirms the diagnosis, as these are specific markers for Sjögren's. *Systemic lupus erythematosus* - While anti-Ro/La antibodies can be positive in a subset of SLE patients, the primary presentation in SLE typically includes **malar rash**, **photosensitivity**, **serositis**, or **renal involvement**, which are not the dominant features here. - SLE is a multisystem autoimmune disease with a broader spectrum of manifestations beyond isolated sicca symptoms and joint pain. *Rheumatoid arthritis* - Rheumatoid arthritis primarily presents with **inflammatory synovitis** affecting small joints, characterized by morning stiffness and swelling, often symmetric. - While secondary Sjögren's can occur in RA, the primary complaint of prominent dry eyes and dry mouth with positive anti-Ro/La antibodies makes Sjögren's the more direct diagnosis. *Systemic sclerosis* - Systemic sclerosis is characterized by **skin thickening (scleroderma)**, **Raynaud's phenomenon**, and potential **internal organ fibrosis** (e.g., lungs, GI tract). - Although some patients may experience sicca symptoms, the hallmark skin changes and specific autoantibodies (anti-Scl-70, anti-centromere) are typically present, which are not described. *Polymyalgia rheumatica* - Polymyalgia rheumatica is characterized by **bilateral pain and stiffness** in the **shoulders and hip girdle**, often worse in the morning, typically in older adults. - It does not involve prominent sicca symptoms or specific hand joint pain, and anti-Ro/La antibodies are not associated with this condition.

Question 42: A 45-year-old man presents with a 2-month history of weight loss, night sweats, and painless lymph node enlargement in his neck. Lymph node biopsy shows Reed-Sternberg cells. What is the most likely diagnosis?

A. Non-Hodgkin's lymphoma
B. Hodgkin's lymphoma (Correct Answer)
C. Chronic lymphocytic leukemia
D. Infectious mononucleosis
E. Metastatic carcinoma

Explanation: ***Hodgkin's lymphoma*** - The presence of **Reed-Sternberg cells** (large, often binucleated cells with prominent nucleoli) in the lymph node biopsy is pathognomonic for Hodgkin's lymphoma (HL). - The constitutional symptoms of **weight loss** and **night sweats**, known as **B symptoms**, are classic presenting features highly suggestive of HL in a patient with painless lymphadenopathy. *Non-Hodgkin's lymphoma* - This group of malignancies is very heterogeneous but is *not* defined by the presence of **Reed-Sternberg cells**, which are unique to HL. - NHL typically arises from B or T lymphocytes, often presents later in life, and frequently involves extranodal sites without this specific cellular hallmark. *Chronic lymphocytic leukemia* - CLL is characterized by the proliferation of small, mature, **CD5+/CD23+ B-cells** and typically involves striking peripheral blood lymphocytosis. - The lymph node architecture in CLL would be effaced by these small lymphocytes, not by large, atypical cells like **Reed-Sternberg cells**. *Infectious mononucleosis* - This is an acute, self-limiting infection, usually caused by **Epstein-Barr virus (EBV)**, and would typically not cause chronic **B symptoms** lasting 2 months. - While *Reed-Sternberg-like cells* can sometimes be observed in reactive conditions, true **Reed-Sternberg cells** along with B symptoms point definitively to malignancy. *Metastatic carcinoma* - The biopsy showing **Reed-Sternberg cells**, which are lymphoid in origin, rules out metastatic carcinoma. - Metastatic carcinoma would show nests of **epithelial cells** (usually positive for **cytokeratin**) without features of a primary hematolymphoid malignancy.

Question 43: A 44-year-old woman presents with fatigue, joint pain, and a malar rash. Blood tests show ANA 1:640 (homogeneous pattern), anti-dsDNA positive, low C3 and C4. Urinalysis shows proteinuria and hematuria. What is the most likely diagnosis?

A. Drug-induced lupus
B. Systemic lupus erythematosus (Correct Answer)
C. Mixed connective tissue disease
D. Sjögren's syndrome
E. Dermatomyositis

Explanation: ***Systemic lupus erythematosus***- The combination of **malar rash**, fatigue, joint pain, high titer **ANA** (homogeneous pattern), and the presence of **anti-dsDNA antibodies** is highly specific and diagnostic for **Systemic Lupus Erythematosus (SLE)**.- The findings of **low C3 and C4** indicate active disease with **complement consumption**, which, along with **proteinuria and hematuria**, strongly suggests the presence of active **lupus nephritis**.*Drug-induced lupus*- This condition is typically characterized by the presence of **anti-histone antibodies**, rather than high titers of anti-dsDNA antibodies.- Drug-induced lupus is usually milder and rarely involves key major organs like the kidneys, making severe **nephritis** with proteinuria and hematuria unlikely.*Mixed connective tissue disease*- MCTD is defined by very high titers of **anti-U1-RNP antibodies** and an overlap of features, but high **anti-dsDNA** and severe nephritis are less characteristic.- While overlap can occur, the prominent **anti-dsDNA positivity** and severe **lupus nephritis** of this magnitude are far more indicative of pure SLE than MCTD.*Sjögren's syndrome*- The primary presentation of Sjögren's involves **sicca symptoms** (dry eyes and mouth) and is associated with antinuclear antibodies like **anti-Ro/SSA** and **anti-La/SSB**.- While patients can have arthralgias, the presence of **malar rash**, high **anti-dsDNA**, and severe **nephritis** makes Sjögren's syndrome a less likely primary diagnosis.*Dermatomyositis*- The central features of dermatomyositis are **proximal muscle weakness**, elevated muscle enzymes, and diagnostic skin signs such as the **Heliotrope rash** and **Gottron's papules**.- Severe renal involvement (glomerulonephritis) and high titers of **anti-dsDNA** are not typical findings associated with this primary myopathy, and a malar rash is distinct from typical dermatomyositis rashes.

Question 44: A 29-year-old woman presents with fatigue, pallor, and spoon-shaped nails (koilonychia). Blood tests show Hb 7.5 g/dL. MCV 65 fL, ferritin 8 µg/L. What is the most likely cause?

A. Vitamin B12 deficiency
B. Iron deficiency anemia (Correct Answer)
C. Thalassemia
D. Chronic disease
E. Folate deficiency

Explanation: ***Iron deficiency anemia*** - The triad of **microcytic anemia** (MCV 65 fL), extremely low **ferritin** (8 µg/L, indicating absolute iron deficiency), and clinical findings like **fatigue** and **pallor** is pathognomonic for absolute iron deficiency. - **Koilonychia** (spoon-shaped nails) is a classic, though uncommon, physical sign highly specific to severe or chronic iron deficiency anemia. *Vitamin B12 deficiency* - Vitamin B12 deficiency causes **macrocytic anemia** (high MCV), not the microcytic anemia (MCV 65 fL) observed in this patient. - This deficiency is often associated with **neurological symptoms** (e.g., paresthesias) and typically results in normal or elevated ferritin levels. *Thalassemia* - Thalassemia causes **microcytic anemia** but is characterized by a normal or high **ferritin** level (as iron stores are adequate but utilization is impaired). - Diagnosis relies on the demonstration of abnormal hemoglobin chains via **hemoglobin electrophoresis**, not depleted iron stores. *Chronic disease* - Anemia of chronic disease (ACD) typically presents as **normocytic** or mildly microcytic anemia, but the hallmark is **elevated ferritin** (reflecting sequestered iron) and low transferrin saturation. - The severely low **ferritin** (8 µg/L) strongly contradicts the pathophysiology of ACD, where iron stores are adequate but inaccessible. *Folate deficiency* - Similar to B12 deficiency, folate deficiency causes **macrocytic anemia** (high MCV), which does not match the patient's presentation of MCV 65 fL. - This condition is often associated with poor diet or malabsorption and is primarily distinguished by significantly reduced serum folate levels.

Question 45: A 65-year-old woman presents with severe bone pain, particularly in her back and ribs. X-rays show multiple lytic lesions throughout the skeleton. Blood tests show elevated calcium and raised ESR. What investigation would be most helpful?

A. Bone marrow biopsy
B. Serum protein electrophoresis (Correct Answer)
C. Bone scan
D. Parathyroid hormone
E. Vitamin D levels

Explanation: ***Serum protein electrophoresis***- This test is crucial for detecting and quantifying the **monoclonal protein (M-spike)**, which is the defining laboratory feature of **Multiple Myeloma**.- The clinical presentation—severe bone pain, **multiple lytic lesions**, hypercalcemia, and high ESR—is highly suggestive of a plasma cell malignancy, making SPEP the most helpful initial diagnostic investigation.*Bone marrow biopsy*- While essential for confirming the diagnosis by quantifying **clonal plasma cells**, it is typically performed after the presence of a **monoclonal gammopathy** is established via SPEP/UPEP.- This is an **invasive procedure** and is confirmatory, whereas SPEP is the initial test to identify the hallmark biochemical abnormality.*Bone scan*- Standard **technetium bone scans** are often **negative or misleading** in **Multiple Myeloma** because the lytic lesions lack the osteoblastic phase (new bone formation) needed for tracer uptake.- Plain X-rays, whole-body low-dose CT, or PET scans are superior imaging modalities for assessing the bone destruction (**lytic lesions**) associated with MM.*Parathyroid hormone*- Measuring **PTH** is the standard test to evaluate primary hyperparathyroidism, which is a key differential cause of hypercalcemia.- However, PTH would typically be suppressed in malignancy-associated hypercalcemia, and this test does not explain the concurrent findings of widespread **lytic lesions** and a **raised ESR**.*Vitamin D levels*- While important for general bone health, **Vitamin D levels** are not the primary investigative tool for aggressively destructive bone disease coupled with systemic symptoms like high ESR.- Assessing Vitamin D is more relevant for conditions like osteomalacia or nutritional deficiencies, not a suspected systemic bone malignancy like MM.

Question 46: A 51-year-old man presents with progressive muscle weakness affecting his shoulders and hips. He has difficulty rising from chairs and climbing stairs. CK is 2000 U/L. EMG shows myopathic changes. What is the most likely diagnosis?

A. Polymyalgia rheumatica
B. Polymyositis (Correct Answer)
C. Myasthenia gravis
D. Motor neuron disease
E. Hypothyroidism

Explanation: ***Polymyositis***- The presentation of **progressive, symmetrical proximal muscle weakness** (shoulders and hips, difficulty rising/climbing stairs) is highly typical for inflammatory myopathies like polymyositis. - The markedly elevated **Creatine Kinase (CK) of 2000 U/L** and confirmation of **myopathic changes** on EMG strongly confirm primary muscle tissue damage, characteristic of polymyositis.*Polymyalgia rheumatica*- This condition primarily causes **morning stiffness** and **pain** in the proximal muscles (shoulders and hips), but patients typically exhibit *minimal* or *no* true muscle weakness.- **CK levels** are usually normal in polymyalgia rheumatica, unlike the massive elevation seen here.*Myasthenia gravis*- Characterized by **fluctuating, fatigable weakness** that is often worse at the end of the day or after exercise, commonly affecting **ocular** and **bulbar muscles**.- Muscle enzyme levels such as **CK** are typically **normal**, distinguishing it from an inflammatory myositis.*Motor neuron disease*- This disorder causes progressive weakness due to **upper and lower motor neuron degeneration**, often leading to **fasciculations** and atrophy.- Although weakness occurs, the CK elevation is usually mild or normal, and EMG characteristically shows **neurogenic** (not myopathic) changes.*Hypothyroidism*- Hypothyroidism can cause a mild form of chronic myopathy with proximal weakness, pain, and stiffness, often associated with generalized symptoms.- The associated CK elevation is typically **mild to moderate** (usually well below 2000 U/L), making the extreme elevation seen here less likely due to isolated hypothyroidism.

Question 47: A 36-year-old woman presents with fatigue, joint pain, and photosensitive rash. Blood tests show pancytopenia, positive ANA, and low complement levels. Urinalysis shows proteinuria and RBC casts. What is the most appropriate initial treatment?

A. NSAIDs
B. Hydroxychloroquine
C. Prednisolone (Correct Answer)
D. Methotrexate
E. Rituximab

Explanation: ***Prednisolone*** - The patient presents with features suggestive of **severe Systemic Lupus Erythematosus (SLE)**, including **lupus nephritis** (proteinuria, RBC casts) and **pancytopenia**, which constitute organ-threatening manifestations.- **High-dose systemic corticosteroids** like prednisolone are the initial treatment of choice for acute flares of severe SLE to rapidly suppress inflammation and prevent further organ damage.*NSAIDs* - **NSAIDs** are typically used for mild musculoskeletal symptoms in SLE, such as arthralgias, but are insufficient for systemic, organ-threatening disease like **lupus nephritis** or **pancytopenia**.- They carry risks, especially in patients with renal involvement, and would not address the severe inflammatory process requiring rapid immunosuppression.*Hydroxychloroquine* - **Hydroxychloroquine** is a cornerstone of SLE treatment for mild-to-moderate disease and for long-term maintenance, helping to reduce flares and improve survival.- However, it has a **slow onset of action** and is **insufficient** as monotherapy for acute, severe organ-threatening manifestations like active lupus nephritis or severe cytopenias.*Methotrexate* - **Methotrexate** is an immunosuppressant used in SLE, primarily for arthritis and skin manifestations, often as a **steroid-sparing agent**.- It is **not indicated** as an initial monotherapy for acute, severe, life-threatening SLE flares, especially those involving the kidneys and bone marrow, where rapid immunosuppression is critical.*Rituximab* - **Rituximab** is a B-cell depleting agent used in refractory or severe SLE, particularly for certain hematologic manifestations or lupus nephritis that is **unresponsive to conventional therapy**.- It is generally considered a **second-line or salvage therapy**, not the initial treatment for acute, severe presentations, unless specific contraindications to corticosteroids exist.

Question 48: A 49-year-old woman presents with fatigue, muscle weakness, and purple discoloration around her eyes (heliotrope rash). She has difficulty swallowing and a rash over her knuckles. CK is 3500 U/L. What is the most likely diagnosis?

A. Polymyositis
B. Dermatomyositis (Correct Answer)
C. Inclusion body myositis
D. Polymyalgia rheumatica
E. Hypothyroidism

Explanation: ***Dermatomyositis***- The combination of severe proximal **muscle weakness**, markedly elevated **CK** (3500 U/L), and characteristic skin findings such as **heliotrope rash** and **Gottron papules** is highly indicative of dermatomyositis.- **Dysphagia** is also a common feature in dermatomyositis due to the involvement of striated muscles in the pharynx and upper esophagus.*Polymyositis*- While polymyositis also presents with **proximal muscle weakness** and elevated **CK**, it is characterized by the **absence of the distinctive skin rashes** seen in this patient.- The presence of **heliotrope rash** and **Gottron papules** effectively rules out polymyositis, which is a muscle-centric inflammatory disorder.*Inclusion body myositis*- IBM typically presents with a more insidious onset and often affects **distal muscles** and **quadriceps** preferentially, leading to different patterns of weakness.- **CK elevation** in IBM is usually mild, rarely reaching the severe levels (3500 U/L) observed in acute inflammatory myopathies like dermatomyositis.*Polymyalgia rheumatica*- PMR is characterized by **pain and stiffness** in the shoulder and hip girdles, especially prominent in the morning, rather than objective **muscle weakness**.- Crucially, **CK levels are almost always normal** in polymyalgia rheumatica, making the elevated CK (3500 U/L) incompatible with this diagnosis.*Hypothyroidism*- Hypothyroid myopathy can cause **fatigue** and **muscle weakness**, but it lacks the specific **inflammatory skin manifestations** such as the heliotrope rash and Gottron papules.- While CK can be elevated in hypothyroidism, it usually does not reach the **extreme levels** of 3500 U/L seen in severe inflammatory myositis.

Question 49: A 29-year-old man presents with acute severe abdominal pain and vomiting. He has a strong family history of similar episodes. Serum amylase is normal. Urinary porphobilinogen is elevated. What is the most likely diagnosis?

A. Acute pancreatitis
B. Acute intermittent porphyria (Correct Answer)
C. Familial Mediterranean fever
D. Hereditary angioedema
E. Inflammatory bowel disease

Explanation: ***Acute intermittent porphyria***- Acute intermittent porphyria (**AIP**) presents with acute, severe, often colicky abdominal pain and vomiting, frequently mistaken for an acute abdomen presentation, consistent with the patient's symptoms and strong family history.- The definitive diagnostic marker for an acute porphyria attack is the significant elevation of **urinary porphobilinogen (PBG)** and delta-aminolevulinic acid (ALA), confirming the diagnosis over other causes of acute abdominal pain.*Acute pancreatitis*- Although acute pancreatitis causes severe abdominal pain and vomiting, the diagnosis requires significantly elevated **serum amylase** and/or lipase (usually threefold the upper limit of normal).- The patient's **normal serum amylase** level makes uncomplicated acute pancreatitis highly unlikely as the underlying cause, especially alongside the specific finding of elevated PBG.*Familial Mediterranean fever*- FMF causes severe, self-limiting episodes of serositis (peritonitis), causing fever and abdominal pain, but it is typically diagnosed by clinical criteria and genetic testing for the **MEFV mutation**.- Unlike AIP, FMF does not involve defects in the heme synthesis pathway and thus does not cause elevation of **urinary porphobilinogen**.*Hereditary angioedema*- HAE can cause severe colicky abdominal pain due to **visceral angioedema** (swelling of the bowel wall), which may mimic an acute abdomen.- This disorder is linked to a deficiency or dysfunction of **C1-inhibitor** and is not associated with elevated urinary porphobilinogen.*Inflammatory bowel disease*- IBD, such as Crohn's disease, causes chronic or relapsing abdominal pain, often accompanied by diarrhea, weight loss, and hematochezia, and usually does not present with sudden, profound acute attacks mimicking this porphyric crisis.- IBD diagnosis relies on endoscopy and biopsy, and it does not result in a characteristic elevation of **urinary porphobilinogen**.

Question 50: A 34-year-old woman presents with severe fatigue, muscle pain, and morning stiffness lasting over 2 hours. She has multiple tender points but normal inflammatory markers. What is the most appropriate initial treatment?

A. NSAIDs
B. Corticosteroids
C. Pregabalin (Correct Answer)
D. Methotrexate
E. Physiotherapy

Explanation: ***Pregabalin***- It is a first-line medication for the treatment of **fibromyalgia**, acting by binding to the alpha-2-delta subunit of voltage-gated **calcium channels**, thereby reducing central pain transmission.- It is specifically indicated for chronic, widespread pain associated with fibromyalgia, confirmed by the presence of multiple **tender points** and normal inflammatory markers.*NSAIDs*- **NSAIDs** primarily target pain caused by **inflammation** (e.g., inflammatory arthritis), which is absent in this patient (normal inflammatory markers).- They provide minimal, if any, benefit for the centralized pain sensitization and **allodynia** characteristic of fibromyalgia.*Corticosteroids*- **Corticosteroids** are potent anti-inflammatory agents used to treat acute flares of underlying inflammatory rheumatic diseases.- They are ineffective and not recommended for the management of fibromyalgia, as this condition lacks characteristic **systemic inflammation**.*Methotrexate*- **Methotrexate** is a disease-modifying anti-rheumatic drug (DMARD) strictly reserved for managing severe **inflammatory arthropathies** (e.g., Rheumatoid Arthritis).- It has no established role in treating the central pain disorder of fibromyalgia and should be avoided due to potential **toxicity**.*Physiotherapy*- While supervised **physiotherapy** (including low-impact exercise) is an essential non-pharmacological component of fibromyalgia treatment, pharmacological agents are often needed for initial symptom control.- **Pregabalin** is the most appropriate first-line *drug* intervention listed to mitigate severe fatigue and widespread pain rapidly.

Question 51: A 45-year-old woman presents with progressive dysphagia and Raynaud's phenomenon. She has tight, thickened skin on her hands and face. ANA shows nucleolar pattern. What is the most likely diagnosis?

A. Systemic lupus erythematosus
B. Sjögren's syndrome
C. Systemic sclerosis (Correct Answer)
D. Dermatomyositis
E. Mixed connective tissue disease

Explanation: ***Systemic sclerosis*** - The combination of **progressive dysphagia**, **Raynaud's phenomenon**, and **tight, thickened skin** on hands and face are classic manifestations. - A **nucleolar ANA pattern** is highly characteristic, often associated with specific autoantibodies like **anti-topoisomerase I (Scl-70)** or **anti-RNA polymerase III** in systemic sclerosis. *Systemic lupus erythematosus* - Typically presents with diverse symptoms including **arthritis**, rash (e.g., malar), photosensitivity, and renal involvement, which are not highlighted here. - ANA in SLE commonly shows a **homogeneous** or **speckled pattern**, with specific antibodies like **anti-dsDNA** or **anti-Sm**, rather than a nucleolar pattern. *Sjögren's syndrome* - Primarily characterized by **sicca symptoms** like dry eyes and dry mouth due to exocrine gland dysfunction. - While Raynaud's can occur, significant widespread skin thickening and dysphagia from esophageal dysmotility are not its primary features. *Dermatomyositis* - Features include **proximal muscle weakness** and distinctive skin findings like **heliotrope rash** and **Gottron's papules**, which are absent in this presentation. - Skin thickening as described is not typical; dysphagia, if present, is usually due to pharyngeal muscle weakness, not esophageal dysmotility. *Mixed connective tissue disease* - Defined by overlapping features of SLE, systemic sclerosis, and polymyositis, but the predominant features here align with systemic sclerosis. - The serological hallmark is a high titer of **anti-U1-RNP antibodies**, which doesn't specifically correlate with a nucleolar ANA pattern.

Question 52: A 32-year-old woman presents with recurrent miscarriages and arterial thrombosis. Blood tests show positive lupus anticoagulant and anticardiolipin antibodies. What is the most appropriate long-term treatment?

A. Aspirin alone
B. Warfarin (Correct Answer)
C. Clopidogrel
D. LMWH
E. No treatment

Explanation: ***Warfarin***- Warfarin is the definitive long-term therapy for **secondary prevention** of thrombosis in non-pregnant patients with Antiphospholipid Syndrome (APS) following an arterial or venous thrombotic event.- The target intensity is typically an **International Normalized Ratio (INR) of 2.0 to 3.0**, which is necessary to prevent severe recurrent events, particularly **arterial thrombosis**.*Aspirin alone*- Aspirin is primarily used for **primary prophylaxis** in high-risk, asymptomatic APS carriers or often adjunctively, but it is insufficient as monotherapy following a documented **arterial thrombosis**.- The risk profile is too high for antiplatelet therapy alone; the patient requires full anticoagulation to mitigate the risk of severe **recurrent clotting**.*Clopidogrel*- Clopidogrel is an **antiplatelet agent** that targets platelet aggregation, similar to aspirin, and is not the preferred primary long-term treatment modality for systemic hypercoagulability syndromes like APS.- **Anticoagulation** (Warfarin) is superior to antiplatelet therapy for preventing the broad spectrum of **venous and arterial thromboembolism** seen in APS.*LMWH*- Low Molecular Weight Heparin (LMWH) is the treatment of choice for acute thrombosis and is specifically used during **pregnancy** (often combined with low-dose aspirin) to prevent obstetric complications.- It is administered via injection and is generally not preferred for convenient **long-term, non-pregnancy management** due to the burden of daily injections.*No treatment*- Failure to treat the patient with established APS and previous thrombosis puts her at an exceedingly high risk of severe and potentially fatal **recurrent thrombotic events** (e.g., recurrent stroke, catastrophic APS).- APS is a serious chronic condition requiring lifelong medical intervention, often **anticoagulation**, once a significant thrombosis has occurred.

Question 53: A 48-year-old woman presents with fatigue, muscle weakness, and purple discoloration around her eyes. She has difficulty swallowing and a rash over her knuckles. CK is 4000 U/L. What is the most important additional investigation?

A. EMG
B. Muscle biopsy
C. CT chest/abdomen/pelvis (Correct Answer)
D. ANA and myositis antibodies
E. Thyroid function tests

Explanation: ***CT chest/abdomen/pelvis***- The clinical presentation (fatigue, proximal muscle weakness, **heliotrope rash**, **Gottron's papules**, dysphagia, and markedly elevated CK) is highly characteristic of **Dermatomyositis**.- Patients with Dermatomyositis have a significantly increased risk of **occult malignancy**, necessitating thorough screening, typically with a **CT scan of the chest, abdomen, and pelvis** to identify potential underlying cancers (e.g., ovarian, lung, gastric, pancreatic).*EMG*- While an **EMG** would show characteristic myopathic changes (e.g., fibrillations, positive sharp waves, low-amplitude motor unit potentials), the clinical picture and elevated CK already strongly suggest inflammatory myopathy.- Given the high association of Dermatomyositis with malignancy, identifying potential cancer takes precedence over further electrodiagnostic confirmation of the myopathy itself as the *most important additional investigation*.*Muscle biopsy*- A **muscle biopsy** is considered the **gold standard** for confirming Dermatomyositis, revealing perifascicular atrophy and perivascular inflammation.- However, in a patient with a clear clinical diagnosis of Dermatomyositis, the immediate priority is to screen for associated malignancy, which can be life-threatening, before proceeding with invasive diagnostic procedures for the myopathy itself.*ANA and myositis antibodies*- **ANA and myositis-specific autoantibodies** (e.g., anti-Mi-2, anti-TIF1-gamma, anti-NXP2) are important for classifying the subtype of inflammatory myopathy, predicting disease course, and guiding treatment.- While crucial for a complete workup, the *most important additional investigation* in this specific context (newly diagnosed Dermatomyositis with malignancy risk) is to rule out associated cancer.*Thyroid function tests*- **Hypothyroidism** can cause myopathy with features like fatigue, weakness, and elevated CK (myxedema myopathy), making **thyroid function tests** a reasonable general screening tool for myopathy.- However, the classic cutaneous findings of **heliotrope rash** and **Gottron's papules** are highly specific for Dermatomyositis, distinguishing it from thyroid-related myopathy and making malignancy screening the priority.

Question 54: A 54-year-old man presents with progressive muscle weakness affecting his shoulders and hips. He has difficulty rising from chairs. CK is 2800 U/L. Muscle biopsy shows inflammatory infiltrates. What is the most likely diagnosis?

A. Polymyalgia rheumatica
B. Polymyositis (Correct Answer)
C. Dermatomyositis
D. Inclusion body myositis
E. Muscular dystrophy

Explanation: ***Polymyositis***- This diagnosis is characterized by **symmetric proximal muscle weakness** (shoulders and hips) leading to difficulty rising from chairs, often presenting after age 20.- Laboratory findings include marked elevation of **Creatine Kinase (CK)** (2800 U/L) and muscle biopsy demonstrating **endomyseal inflammatory infiltrates** destroying muscle fibers.*Polymyalgia rheumatica*- PMR causes muscle **pain** and **stiffness** predominantly in the shoulders and hips, rather than frank muscle weakness severe enough to impair function.- Serum CK levels are generally **normal** or only minimally elevated, unlike the extreme elevation seen in this patient.*Dermatomyositis*- While DM shares the proximal muscle weakness and high CK, it is primarily differentiated by the presence of characteristic **cutaneous findings** like the **Heliotrope rash** or **Gottron papules**.- The muscle biopsy often shows **perifascicular atrophy** and **perivascular/perimyseal inflammatory infiltrates**, which differ anatomically from the endomyseal infiltrate typical of PM.*Inclusion body myositis*- IBM often presents with **asymmetric** weakness and involves **distal muscles** (e.g., forearm flexors, quadriceps) early in the disease course, unlike the purely symmetric, proximal pattern described.- It typically has a slow, insidious course and often presents with only **mildly elevated CK** levels (rarely over 1000 U/L), much lower than the 2800 U/L recorded here.*Muscular dystrophy*- Muscular dystrophies are **genetic disorders** characterized by ongoing muscle degeneration and regeneration, not primarily due to an acquired autoimmune inflammatory process.- Although CK is elevated in MD, the muscle biopsy would show features like fibrosis, fatty replacement, and variations in fiber size, lacking the predominant **inflammatory cell infiltrate**.

Question 55: A 46-year-old woman presents with recurrent miscarriages and deep vein thrombosis. Blood tests show prolonged APTT not correcting with mixing studies and positive anticardiolipin antibodies. What is the most likely diagnosis?

A. Factor V Leiden mutation
B. Protein C deficiency
C. Antiphospholipid syndrome (Correct Answer)
D. Prothrombin gene mutation
E. Lupus anticoagulant

Explanation: ***Antiphospholipid syndrome*** - The presence of **recurrent miscarriages** and **deep vein thrombosis (DVT)** are classic **clinical manifestations** that, when combined with specific laboratory findings, define Antiphospholipid Syndrome. - A **prolonged APTT not correcting with mixing studies** indicates the presence of a **Lupus Anticoagulant (LA)**, and **positive anticardiolipin antibodies** are key **laboratory criteria** for diagnosing APS. *Factor V Leiden mutation* - This mutation leads to **activated protein C resistance**, primarily increasing the risk of **venous thrombosis**, but it does not cause recurrent miscarriages or lead to positive antiphospholipid antibodies. - It is identified by specific genetic testing or functional assays, not by a prolonged APTT that fails to correct with mixing studies. *Protein C deficiency* - This condition results in an increased risk of **venous thrombosis** due to impaired natural anticoagulant pathways, but it is not associated with recurrent miscarriages or the presence of antiphospholipid antibodies. - Diagnosis involves measuring protein C activity or antigen levels, not through prolonged APTT or anticardiolipin antibody tests. *Prothrombin gene mutation* - The **prothrombin gene mutation (G20210A)** causes elevated plasma levels of **prothrombin (Factor II)**, significantly increasing the risk of **venous thromboembolism**. - It does not account for recurrent miscarriages or the presence of specific autoantibodies like anticardiolipin antibodies or Lupus Anticoagulant. *Lupus anticoagulant* - **Lupus anticoagulant (LA)** is a *laboratory finding* (a type of antiphospholipid antibody) demonstrated by a prolonged APTT that does not correct with mixing studies. - While LA is a *component* of the diagnostic criteria, **Antiphospholipid syndrome** is the comprehensive *clinical diagnosis* that encompasses both the clinical events (thrombosis, miscarriages) and the laboratory findings (LA, anticardiolipin antibodies).

Question 56: A 34-year-old woman presents with severe fatigue, muscle pain, and morning stiffness lasting over 2 hours. She has multiple tender points but normal inflammatory markers. What is the most appropriate initial treatment?

A. NSAIDs
B. Corticosteroids
C. Pregabalin (Correct Answer)
D. Methotrexate
E. Physiotherapy

Explanation: ***Pregabalin***- The patient's symptoms of severe fatigue, widespread muscle pain, morning stiffness lasting over 2 hours, and multiple tender points, coupled with normal inflammatory markers, are classic for **fibromyalgia**.- Pregabalin is a **first-line pharmacological treatment** for fibromyalgia, effective in reducing widespread pain and improving sleep by modulating neurotransmitter release. *NSAIDs*- NSAIDs primarily target **inflammatory pain**, but fibromyalgia is a **non-inflammatory chronic pain syndrome**.- They are generally **ineffective** for the widespread, neuropathic-like pain experienced in fibromyalgia. *Corticosteroids*- Corticosteroids are powerful **anti-inflammatory drugs**, and like NSAIDs, are not indicated for fibromyalgia as it is not an inflammatory condition.- Their long-term use carries significant side effects, making them unsuitable for chronic non-inflammatory pain. *Methotrexate*- Methotrexate is a **disease-modifying anti-rheumatic drug (DMARD)** used for autoimmune inflammatory conditions, such as rheumatoid arthritis.- It has **no role** in the treatment of fibromyalgia, which lacks an underlying autoimmune or inflammatory pathology. *Physiotherapy*- While **physical therapy and exercise** are critical components of a comprehensive fibromyalgia management plan, they are often initiated alongside or after pharmacological intervention.- For severe symptoms, a **pharmacological agent** is typically considered part of the initial treatment strategy to help manage pain and improve functional capacity before other therapies can be fully effective.

Question 57: A 44-year-old woman presents with recurrent miscarriages and arterial thrombosis. Blood tests show positive lupus anticoagulant and anticardiolipin antibodies on two occasions 12 weeks apart. What is the most appropriate long-term treatment?

A. Aspirin alone
B. Warfarin (Correct Answer)
C. Clopidogrel
D. LMWH
E. No treatment

Explanation: ***Warfarin***- **Warfarin**, a Vitamin K antagonist, is the standard long-term treatment for secondary prophylaxis against recurrent **arterial and venous thrombosis** in non-pregnant individuals with Antiphospholipid Syndrome (APS).- The goal is to maintain an International Normalized Ratio (**INR**) typically between 2.0 and 3.0, though higher targets (e.g., 2.5–3.5) may be used if thrombosis recurs.*Aspirin alone*- Aspirin is usually recommended for **primary prophylaxis** in asymptomatic carriers or in conjunction with **LMWH** during pregnancy to prevent obstetric complications.- It is considered insufficient as monotherapy for secondary prevention after a significant thrombotic event, especially arterial thrombosis, in non-pregnant patients.*Clopidogrel*- Clopidogrel is an oral **antiplatelet agent** (P2Y12 inhibitor) commonly used to reduce risks in specific arterial diseases, not as a blanket systemic anticoagulant.- It does not provide the necessary level of deep **anticoagulation** required to manage the high risk of recurrent systemic thrombosis seen in established APS.*LMWH*- Low Molecular Weight Heparin (**LMWH**) is the therapy of choice for APS patients during **pregnancy** (often combined with low-dose aspirin), as it does not cross the placenta.- Outside of pregnancy, it is not suitable for routine chronic maintenance therapy due to the need for daily subcutaneous injections and the availability of effective oral agents.*No treatment*- Treatment is absolutely required for this patient given the history of **recurrent miscarriages** and confirmed **arterial thrombosis**, which establishes a high-risk history.- Withholding anticoagulation in a patient with established APS and prior thrombotic events would result in a very high risk of potentially devastating thrombotic recurrence.

Question 58: A 48-year-old man presents with progressive muscle weakness affecting his shoulders and hips. He has difficulty rising from chairs and climbing stairs. CK is 2800 U/L. Muscle biopsy shows inflammatory infiltrates. What is the most appropriate treatment?

A. Physiotherapy alone
B. Prednisolone (Correct Answer)
C. Methotrexate
D. Azathioprine
E. Immunoglobulin

Explanation: ***Prednisolone***- **First-line therapy** for idiopathic inflammatory myopathies (IIMs) such as **polymyositis** or **dermatomyositis**, targeting the underlying autoimmune inflammation.- High-dose oral **glucocorticoids** are crucial for rapid suppression of the immune response, aiming to reduce inflammation shown by the muscle biopsy and lower the highly elevated **CK levels**.*Physiotherapy alone*- While essential for maintaining muscle function and preventing contractures, **physiotherapy** is only supportive and does not address the underlying severe autoimmune inflammation.- Given the highly elevated **CK** and active inflammation on biopsy, the patient requires immediate and potent **immunosuppressive medication** to halt muscle destruction.*Methotrexate*- This is an immunosuppressive agent typically used as a **second-line** or **steroid-sparing agent** in chronic or refractory inflammatory myopathy, not usually the initial monotherapy.- It has a slower onset of action compared to high-dose corticosteroids, making it unsuitable for initiating treatment in active, severe myositis.*Azathioprine*- Similar to methotrexate, **azathioprine** is primarily employed as a steroid-sparing agent or for maintenance therapy in patients with chronic or relapsing inflammatory myopathies.- It is not the initial drug of choice because **glucocorticoids** provide a faster and stronger initial immunosuppressive effect critical for halting acute muscle damage.*Immunoglobulin*- **Intravenous Immunoglobulin (IVIG)** is reserved for patients with severe, refractory disease, or those with contraindications to high-dose steroids (e.g., in some cases of dermatomyositis).- It is typically administered after the failure of primary therapy with **corticosteroids** and conventional immunosuppressants.

Question 59: A 47-year-old woman presents with fatigue, muscle weakness, and difficulty swallowing. She has a heliotrope rash around her eyes and Gottron's papules over her knuckles. CK is 3500 U/L. What is the most important investigation?

A. Muscle biopsy
B. EMG
C. CT chest/abdomen/pelvis (Correct Answer)
D. Myositis antibodies
E. Pulmonary function tests

Explanation: ***CT chest/abdomen/pelvis***- **Dermatomyositis (DM)** in adults, particularly those over age 40, has a high association (15-30%) with underlying **occult malignancy** (paraneoplastic syndrome).- This whole-body imaging is critical for a comprehensive and urgent search for cancer, which is the most important factor affecting management and prognosis.*Muscle biopsy*- This is the gold standard for definitive diagnosis, revealing perifascicular atrophy and inflammation, but it is typically reserved for confirmation in ambiguous cases.- Given the classic pathognomonic skin signs (**Heliotrope rash**, **Gottron's papules**), the diagnosis is highly probable, making malignancy screening the immediate priority over histological confirmation.*EMG*- **Electromyography (EMG)** confirms a primary muscle disease (myopathy) by demonstrating increased irritability, fibrillation potentials, and complex repetitive discharges.- While helpful for documenting the extent of muscle damage, EMG does not prioritize the immediate search for **paraneoplastic malignancy** or screen for visceral complications.*Myositis antibodies*- These antibodies (e.g., anti-TIF1-γ, anti-Jo-1) are crucial for providing prognostic information and classifying the specific inflammatory myopathy.- Although anti-TIF1-γ is highly associated with **cancer-associated myositis**, initial structural imaging is required to locate the underlying tumor.*Pulmonary function tests*- These tests are essential for screening for **interstitial lung disease (ILD)**, a common and serious complication of inflammatory myopathies, especially those positive for anti-synthetase antibodies (e.g., anti-Jo-1).- Although important for assessing long-term morbidity, the immediate and greatest threat to life that must be ruled out upon diagnosis is **occult malignancy**.

Question 60: A 32-year-old man presents with acute severe abdominal pain and vomiting. He has a family history of similar episodes. Serum amylase is normal but urinary porphobilinogen is markedly elevated. What is the most appropriate acute treatment?

A. IV fluids and analgesia
B. High carbohydrate diet
C. Hemin therapy
D. Avoid precipitating drugs
E. All of the above (Correct Answer)

Explanation: ***All of the above***- The clinical presentation of acute severe abdominal pain, vomiting, family history, and markedly elevated **urinary porphobilinogen (PBG)** is highly indicative of an acute porphyria attack.- Effective management of a severe acute porphyria attack necessitates a comprehensive approach encompassing **specific therapy** (hemin), **metabolic suppression** (high carbohydrate intake), and **intensive supportive care** (IV fluids, analgesia, and strict avoidance of precipitating factors).*IV fluids and analgesia*- **Intravenous fluids** are crucial to correct dehydration and address electrolyte imbalances, especially **hyponatremia**, which can aggravate the neurological symptoms frequently seen in porphyria.- **Opioid analgesics** are indispensable for managing the intense, often debilitating, visceral abdominal pain characteristic of an acute porphyria attack, as NSAIDs are typically inadequate and some may even be contraindicated.*High carbohydrate diet*- **High carbohydrate loading**, usually administered as an intravenous dextrose infusion, is a fundamental component of acute porphyria treatment.- Carbohydrates effectively **repress the activity of hepatic delta-aminolevulinic acid (ALA) synthase**, the rate-limiting enzyme in heme biosynthesis, thereby diminishing the production of neurotoxic porphyrin precursors like **ALA** and **PBG**.*Hemin therapy*- **Hemin (hematin) infusion** represents the most specific and definitive treatment for severe acute porphyria attacks.- Administered intravenously, **hemin directly supplies exogenous heme**, which subsequently downregulates **hepatic ALA synthase** activity, leading to a rapid reduction in the levels of toxic precursors **ALA** and **PBG**.*Avoid precipitating drugs*- Many medications, including various **barbiturates**, sulfonamides, and certain anticonvulsants, are known to induce **hepatic cytochrome P450 enzymes**.- This enzyme induction escalates the demand for heme, which in turn upregulates **ALA synthase**, thereby triggering or exacerbating an acute porphyria attack; thus, their strict avoidance is critical.

Question 61: A 49-year-old woman presents with fatigue, muscle weakness, and purple discoloration around her eyes. She has difficulty swallowing and a skin rash over her knuckles. CK is 4000 U/L. What is the most important additional investigation?

A. EMG
B. Muscle biopsy
C. CT chest/abdomen/pelvis (Correct Answer)
D. ANA and myositis antibodies
E. Thyroid function tests

Explanation: ***CT chest/abdomen/pelvis***- The constellation of symptoms, including **Heliotrope rash**, **Gottron papules**, proximal **muscle weakness**, **dysphagia**, and elevated **CK**, strongly indicates **Dermatomyositis**.- **Dermatomyositis** has a significant association with underlying **occult malignancy** (paraneoplastic syndrome), making comprehensive screening with CT imaging a critical *additional* investigation for staging and prognosis.*EMG*- An **EMG** can help confirm a **myopathic process** and differentiate it from neuropathies by showing specific findings like irritable myopathy.- While useful for diagnostic confirmation, the clinical picture is highly suggestive of dermatomyositis, and the immediate priority for an *additional* investigation is to screen for associated malignancy due to its prognostic implications.*Muscle biopsy*- **Muscle biopsy** is considered the **gold standard** for definitive diagnosis of dermatomyositis, revealing characteristic perivascular and perimysial inflammation.- However, in a patient with a classic presentation, ruling out life-threatening **occult malignancy** takes precedence as the most important *additional* investigation before proceeding with a potentially invasive procedure.*ANA and myositis antibodies*- These serological tests (e.g., **ANA**, **anti-Jo-1**, **anti-Mi-2**) are essential for confirming the diagnosis of inflammatory myopathy and subtyping **Dermatomyositis**.- While important for specific diagnosis and prognosis, the strong clinical suspicion means that screening for **paraneoplastic malignancy** is a more urgent *additional* step to impact patient outcomes.*Thyroid function tests*- **Thyroid function tests** are performed to rule out **hypothyroid myopathy**, which can present with muscle weakness and elevated **CK**.- Hypothyroid myopathy typically lacks the highly specific cutaneous manifestations, such as **Heliotrope rash** and **Gottron papules**, which are classic features of dermatomyositis, making cancer screening the higher priority.

Question 62: A 36-year-old woman presents with fatigue, joint pain, and a butterfly rash. Blood tests show pancytopenia, positive ANA, and low complement levels. Urinalysis shows proteinuria and RBC casts. What is the most appropriate initial treatment?

A. NSAIDs
B. Hydroxychloroquine
C. Prednisolone (Correct Answer)
D. Methotrexate
E. Rituximab

Explanation: ***Prednisolone***- The patient presents with features suggestive of severe, active Systemic Lupus Erythematosus (SLE), including active **Lupus Nephritis** (indicated by proteinuria and **RBC casts**) and **pancytopenia**.- **High-dose systemic glucocorticoids** (like oral prednisolone or IV methylprednisolone pulse therapy) are the most appropriate initial treatment for rapidly inducing remission in major organ-threatening SLE flares.*NSAIDs*- These agents are indicated only for mild symptoms like **arthralgia** or non-severe serositis (pericarditis/pleuritis).- They are insufficient to treat severe organ involvement like active **nephritis** and may worsen renal function in this setting.*Hydroxychloroquine*- While it is the standard maintenance medication for almost all SLE patients to manage mild symptoms and reduce long-term flares, it is inadequate for treating acute, life-threatening organ involvement.- It acts too slowly to be effective as the sole, immediate intervention for severe disease like active **Lupus Nephritis**.*Methotrexate*- This immunosuppressant is used as a **steroid-sparing agent** primarily for moderate manifestations, such as refractory arthritis or extensive skin disease.- It is not suitable for the initial **induction therapy** required to stabilize a patient with immediate severe organ damage.*Rituximab*- This B-cell depleting agent is generally reserved for cases of severe SLE that are **refractory** to conventional induction therapy (high-dose steroids, cyclophosphamide, or mycophenolate).- It is typically considered a third-line biologic agent, not the initial treatment strategy for an acute flare.

Question 63: A 28-year-old woman presents with recurrent episodes of severe abdominal pain, nausea, and confusion. During episodes, her urine turns dark red. Family history reveals similar episodes in her father. What is the most likely diagnosis?

A. Acute intermittent porphyria (Correct Answer)
B. Hereditary coproporphyria
C. Variegate porphyria
D. Erythropoietic protoporphyria
E. Congenital erythropoietic porphyria

Explanation: ***Acute intermittent porphyria*** - This condition is characterized by acute **neurovisceral attacks** involving severe **abdominal pain**, nausea, and **confusion** (neuropsychiatric symptoms). - The dark red urine observed during episodes is due to the non-enzymatic oxidation of accumulated **porphobilinogen (PBG)** and **delta-aminolevulinic acid (ALA)**. The positive family history also supports its genetic basis. *Hereditary coproporphyria* - While it causes acute **neurovisceral attacks** similar to AIP, hereditary coproporphyria often presents with additional **cutaneous photosensitivity** (blistering skin lesions), which is not described in the patient. - The biochemical hallmark is the elevation of **coproporphyrin** in urine and feces, distinguishing it from AIP where ALA and PBG are predominantly elevated. *Variegate porphyria* - This condition also presents with acute **neurovisceral attacks** (abdominal pain, neurological deficits), but a key differentiating feature is the common presence of prominent **cutaneous photosensitivity** (blistering and skin fragility). - The absence of skin lesions in this case makes Variegate Porphyria less likely compared to AIP. *Erythropoietic protoporphyria* - Erythropoietic protoporphyria primarily causes **non-blistering photosensitivity**, leading to pain, burning, and itching upon sun exposure, typically starting in childhood. - Crucially, it does **not** cause acute neurovisceral attacks or lead to elevated urine PBG/ALA, which are central to the patient's symptoms. *Congenital erythropoietic porphyria* - This is a rare and severe disorder that usually presents in **infancy** with extreme **photosensitivity**, resulting in severe scarring, hemolytic anemia, and **erythrodontia** (reddish-brown teeth). - The patient's presentation as a 28-year-old with neurovisceral symptoms and dark urine, but without these severe infantile features, rules out congenital erythropoietic porphyria.

Question 64: A 54-year-old man presents with progressive muscle weakness, particularly affecting proximal muscles. He has difficulty rising from chairs. CK is 3500 U/L. Muscle biopsy shows inflammatory infiltrates. What is the most likely diagnosis?

A. Polymyalgia rheumatica
B. Polymyositis (Correct Answer)
C. Dermatomyositis
D. Inclusion body myositis
E. Muscular dystrophy

Explanation: ***Polymyositis***- This is an **inflammatory myopathy** characterized by **progressive, symmetric proximal muscle weakness**, which manifests as difficulty rising from chairs.- The significantly elevated **CK (3500 U/L)** and the finding of **inflammatory infiltrates** on muscle biopsy are classic indicators of polymyositis, in the absence of distinguishing skin features.*Polymyalgia rheumatica*- The primary symptoms of PMR are **muscle pain and stiffness**, particularly in the shoulder and hip girdles, rather than profound muscle weakness.- **Creatine Kinase (CK) levels are typically normal** or only minimally elevated, which contradicts the very high CK value in the patient.*Dermatomyositis*- While sharing proximal muscle weakness and elevated CK, dermatomyositis is differentiated by characteristic **cutaneous manifestations**, such as **Gottron’s papules** or a **Heliotrope rash**, which are not described in this case.- Pathologically, dermatomyositis is often associated with **perifascicular atrophy** and humorally mediated damage, distinct from the predominantly cell-mediated inflammation of polymyositis.*Inclusion body myositis*- IBM often affects **distal muscles** (e.g., wrist flexors, ankle dorsiflexors) in addition to the quadriceps, often presenting with an asymmetric pattern, unlike the symmetric proximal weakness presented.- This diagnosis is histologically confirmed by the presence of **rimmed vacuoles** and protein aggregates within muscle fibers, specific findings not generally implied by a generic

Question 65: A 26-year-old woman presents with fatigue, joint pain, and a malar rash. Blood tests show ANA 1:640 (homogeneous pattern), anti-dsDNA positive, low C3 and C4. Urinalysis shows proteinuria and hematuria. What is the most likely diagnosis?

A. Drug-induced lupus
B. Systemic lupus erythematosus (Correct Answer)
C. Mixed connective tissue disease
D. Sjögren's syndrome
E. Dermatomyositis

Explanation: ***Systemic lupus erythematosus*** - The patient's presentation with **fatigue**, **joint pain**, **malar rash**, positive **ANA** (high titer, homogeneous pattern), **positive anti-dsDNA**, and **low C3 and C4** (indicating complement consumption) are all classic hallmarks of **Systemic Lupus Erythematosus (SLE)**. - The presence of **proteinuria** and **hematuria** on urinalysis strongly suggests **lupus nephritis**, a severe manifestation of SLE, further supporting this diagnosis.*Drug-induced lupus* - Drug-induced lupus typically presents with milder symptoms and usually lacks severe visceral involvement, such as the **lupus nephritis** seen in this patient. - It is primarily associated with **anti-histone antibodies**, and the presence of **anti-dsDNA antibodies** and significant complement consumption (low C3/C4) makes this diagnosis less likely.*Mixed connective tissue disease* - This syndrome is primarily defined by very high titers of **anti-U1-RNP antibodies**, which are not mentioned in the clinical presentation. - While MCTD can cause arthritis and fatigue, it rarely presents with the severe **lupus nephritis** and strong **anti-dsDNA** positivity seen in this case.*Sjögren's syndrome* - Sjögren's syndrome is characterized by **sicca symptoms** (dry eyes and mouth) due to exocrine gland dysfunction, and is associated with **anti-Ro/SSA** and **anti-La/SSB antibodies**. - The prominent **malar rash**, **anti-dsDNA positivity**, and significant **renal involvement** are not typical features of Sjögren's syndrome.*Dermatomyositis* - Dermatomyositis is characterized by **proximal muscle weakness** and specific skin findings like **Gottron's papules** or a **heliotrope rash**. - It is typically associated with myositis-specific antibodies (e.g., anti-Jo-1, anti-Mi-2), and the presence of **anti-dsDNA** with **lupus nephritis** makes dermatomyositis an unlikely diagnosis.

Question 66: A 31-year-old man presents with fever, night sweats, and weight loss over 2 months. Chest X-ray shows mediastinal lymphadenopathy. Lymph node biopsy shows Reed-Sternberg cells in a background of inflammatory cells. What is the most likely diagnosis?

A. Non-Hodgkin's lymphoma
B. Hodgkin's lymphoma (Correct Answer)
C. Sarcoidosis
D. Tuberculosis
E. Lung cancer

Explanation: ***Hodgkin's lymphoma*** - The presence of large, often binucleated **Reed-Sternberg (RS) cells** within a mixed background of inflammatory cells is the definitive histological hallmark. - The combination of **B symptoms** (fever, night sweats, weight loss) and **mediastinal lymphadenopathy** in a young adult is the classic clinical presentation. *Non-Hodgkin's lymphoma* - While NHL can present with B symptoms and lymphadenopathy, the biopsy would show effacement of the node architecture by monoclonal lymphoid cells and **lacks Reed-Sternberg cells**. - Histologically, NHL is characterized by the predominance of malignant lymphocytes themselves, rather than the mixed reactive inflammatory background seen in HL. *Sarcoidosis* - Sarcoidosis can cause bilateral hilar and mediastinal adenopathy, but the lymph node biopsy is characterized by finding non-caseating **granulomas**. - The biopsy would specifically **lack** the malignant Reed-Sternberg cells that were identified in this patient. *Tuberculosis* - Tuberculosis (TB) can result in constitutional symptoms and lymphadenopathy, but the biopsy typically reveals caseating **granulomas** containing **acid-fast bacilli (AFB)**. - Although TB is a differential for B symptoms and lymphadenopathy, the presence of **Reed-Sternberg cells** excludes TB as the primary diagnosis. *Lung cancer* - Lung cancer is primarily a disease of older individuals, and if presenting with adenopathy, the biopsy would show malignant epithelial cells (e.g., squamous or adeno-carcinoma). - Lung cancer does not produce **Reed-Sternberg cells** or the complex inflammatory background characteristic of HL.

Question 67: A 45-year-old woman presents with progressive dysphagia and Raynaud's phenomenon. She has tight, thickened skin on her hands and face. ANA shows nucleolar pattern. What is the most likely diagnosis?

A. Systemic lupus erythematosus
B. Sjögren's syndrome
C. Systemic sclerosis (Correct Answer)
D. Dermatomyositis
E. Mixed connective tissue disease

Explanation: ***Systemic sclerosis***- The triad of **Raynaud's phenomenon**, **progressive skin thickening (scleroderma)**, and **dysphagia** due to esophageal involvement is highly characteristic of Systemic Sclerosis (SSc).- The **ANA nucleolar pattern** is typically associated with antibodies like anti-topoisomerase I (**Scl-70**) or anti-RNA polymerase III, which confirm the diagnosis of SSc.*Systemic lupus erythematosus*- SLE typically presents with **malar rash**, arthritis, serositis, and kidney involvement, rather than dominant, tight, progressive skin thickening.- The characteristic ANA patterns in SLE are usually **homogeneous** or **speckled** (e.g., anti-dsDNA), not the nucleolar pattern seen here.*Sjögren's syndrome*- This syndrome is primarily defined by **sicca symptoms** (dry eyes and mouth) due to exocrine gland destruction.- While Raynaud's can occur, severe **scleroderma** involving the face and hands and significant visceral involvement (dysphagia from esophageal fibrosis) are uncommon.*Dermatomyositis*- The cardinal features include **proximal muscle weakness** and pathognomonic rashes like the **heliotrope rash** or **Gottron papules**.- Although dysphagia can occur due to muscle involvement, the profound **skin tightening** progressing without mention of severe muscle weakness makes SSc a substantially better fit.*Mixed connective tissue disease*- This diagnosis requires very high titers of **anti-U1-RNP antibodies** and overlapping features of SLE, SSc, and polymyositis.- While it can include Raynaud's and mild sclerodactyly, the extensive, tight skin thickening described here is more specific to pure **Systemic Sclerosis**.

Question 68: A 74-year-old woman is investigated for lethargy. Blood tests show: Hb 102 g/L, MCV 88 fL, WCC 5.2 × 10⁹/L, platelets 192 × 10⁹/L, ferritin 420 mcg/L, CRP 48 mg/L, ESR 78 mm/hr, creatinine 142 micromol/L (eGFR 38 mL/min/1.73m²). Blood film shows normochromic normocytic red cells with rouleaux formation. Serum protein electrophoresis demonstrates a monoclonal IgG kappa band of 28 g/L. What is the most important next investigation?

A. Bone marrow aspiration and trephine to quantify plasma cell percentage
B. Serum free light chains (kappa and lambda) and ratio calculation (Correct Answer)
C. Skeletal survey to assess for lytic bone lesions
D. 24-hour urine collection for Bence Jones protein quantification
E. Repeat blood tests in 3 months to assess for progression of paraprotein

Explanation: ***Serum free light chains (kappa and lambda) and ratio calculation*** - Determining the **serum free light chain (sFLC) ratio** is essential as an involved:uninvolved ratio **≥100** is now a formal **myeloma-defining biomarker**, even in the absence of CRAB symptoms. - This test is highly sensitive for detecting light chain involvement which may contribute to the patient's **renal impairment** (light chain cast nephropathy). *Bone marrow aspiration and trephine to quantify plasma cell percentage* - While necessary to confirm the diagnosis and quantify **clonal plasma cells** (≥ 10%), it is typically preceded by non-invasive biochemical screening like sFLC. - This procedure is invasive and is usually performed once a high clinical suspicion of **Multiple Myeloma** or high-risk disease is established by blood/urine tests. *Skeletal survey to assess for lytic bone lesions* - A **skeletal survey** (or nowadays, whole-body low-dose CT) is vital for identifying **bone destruction**, but it does not clarify the biochemical activity of the monoclonal protein as sFLC does. - The absence of lytic lesions would not exclude a diagnosis of myeloma if other **biomarkers** or CRAB features (like the patient's existing anaemia/renal failure) are present. *24-hour urine collection for Bence Jones protein quantification* - This test has largely been replaced in many protocols by the **Serum Free Light Chain assay**, which is more sensitive and convenient for the patient. - **24-hour collection** is cumbersome and notoriously prone to **collection errors**, making it a less ideal next step than serum-based assays. *Repeat blood tests in 3 months to assess for progression of paraprotein* - Delaying investigation is inappropriate here because the patient already demonstrates potential **end-organ damage** (anaemia and renal impairment). - The presence of a significant **monoclonal IgG kappa band** (28 g/L) requires urgent completion of the diagnostic workup to rule out **active myeloma**.

Question 69: A 58-year-old man with established seropositive rheumatoid arthritis has been treated with methotrexate, then combination methotrexate-sulfasalazine-hydroxychloroquine, with inadequate response. He was commenced on adalimumab (anti-TNF) with methotrexate 6 months ago. His DAS28 score has improved from 6.1 to 4.8, but he continues to have morning stiffness lasting 2 hours and synovitis in multiple joints. CRP remains elevated at 28 mg/L. What is the most appropriate management strategy according to UK guidelines?

A. Continue adalimumab for at least 12 months before assessing treatment failure, as 6 months is insufficient
B. Switch to an alternative anti-TNF agent (e.g., etanercept) as he may respond better to a different TNF inhibitor
C. Add prednisolone to the current regimen to provide additional disease control
D. Switch to a biologic with a different mechanism of action (e.g., rituximab, tocilizumab, or abatacept) (Correct Answer)
E. Increase methotrexate dose to maximum tolerated before changing biologic therapy

Explanation: ***Switch to a biologic with a different mechanism of action (e.g., rituximab, tocilizumab, or abatacept)*** - According to **NICE guidelines**, if a patient has an inadequate response to their first **TNF inhibitor** (adalimumab) after 6 months, the preferred next step is switching to a drug with a **different mechanism of action**. - This patient remains in the **moderate disease activity** category (DAS28 4.8 >3.2) with persistent **morning stiffness**, **synovitis**, and elevated **CRP**, indicating a need for a more effective therapy like a **B-cell depletor** (rituximab) or **IL-6 inhibitor** (tocilizumab). *Continue adalimumab for at least 12 months before assessing treatment failure, as 6 months is insufficient* - The standard timeframe for assessing the efficacy of biologic therapy in rheumatoid arthritis, particularly **TNF inhibitors**, is typically **3-6 months**. - Continuing an ineffective treatment beyond this timeframe would delay appropriate management, potentially leading to further **joint damage** and functional impairment given the persistent signs of active disease. *Switch to an alternative anti-TNF agent (e.g., etanercept) as he may respond better to a different TNF inhibitor* - While switching to a second **TNF inhibitor** is an option, UK **NICE guidelines** often prioritize switching to a biologic with a **different mechanism of action** after failure of a first anti-TNF, especially in seropositive patients where **rituximab** is a strong consideration. - The patient's lack of adequate response to adalimumab suggests that the **TNF pathway** may not be the optimal therapeutic target for this individual, making a switch to a different class more effective. *Add prednisolone to the current regimen to provide additional disease control* - **Corticosteroids** like prednisolone are primarily used for managing **flares** or as a bridging therapy, not as a long-term solution for inadequate response to a biologic DMARD. - Adding prednisolone would provide symptomatic relief but would not address the underlying failure of the **biologic DMARD** to achieve satisfactory disease control, potentially leading to **steroid-related side effects**. *Increase methotrexate dose to maximum tolerated before changing biologic therapy* - The patient has already failed **methotrexate monotherapy** and **triple therapy** (methotrexate-sulfasalazine-hydroxychloroquine), indicating that methotrexate alone is insufficient to control his disease. - While optimizing concomitant conventional DMARDs is important, the primary issue here is the **inadequate response** to the **anti-TNF biologic**; therefore, focusing on a change in biologic strategy is more appropriate at this stage.

Question 70: A 33-year-old woman at 34 weeks gestation presents to the emergency department with sudden onset dyspnoea and pleuritic chest pain. She is haemodynamically stable. CTPA confirms a left lower lobe pulmonary embolism. She has no previous VTE history and pregnancy has been uncomplicated. What is the most appropriate anticoagulation management for the remainder of pregnancy and postpartum period?

A. Commence treatment-dose LMWH, continue for 6 weeks postpartum, total minimum duration 3 months (Correct Answer)
B. Commence treatment-dose LMWH, continue throughout pregnancy, switch to warfarin after delivery for 6 weeks
C. Commence treatment-dose LMWH, continue for 3 months from diagnosis regardless of delivery timing
D. Commence treatment-dose LMWH, switch to DOAC after delivery, continue for 6 weeks postpartum
E. Commence treatment-dose LMWH, continue for remainder of pregnancy only, cease postpartum if asymptomatic

Explanation: ***Commence treatment-dose LMWH, continue for 6 weeks postpartum, total minimum duration 3 months*** - For pregnancy-associated **venous thromboembolism (VTE)**, treatment with **low-molecular-weight heparin (LMWH)** is required for the remainder of the pregnancy and at least **6 weeks postpartum**. - Guidelines specify that the total duration of anticoagulation must be a **minimum of 3 months**, ensuring the high-risk postpartum period is fully covered. *Commence treatment-dose LMWH, continue throughout pregnancy, switch to warfarin after delivery for 6 weeks* - While **warfarin** is safe for use during breastfeeding, it requires frequent **INR monitoring** and is generally less convenient than continuing LMWH postpartum for the remaining treatment window. - **LMWH** remains the preferred first-line agent throughout the entire management period due to its predictable pharmacokinetics and safety profile. *Commence treatment-dose LMWH, continue for 3 months from diagnosis regardless of delivery timing* - This approach is incorrect because it may lead to cessation of therapy early in the **postpartum period**, which is the time of highest physiological VTE risk. - Clinical guidelines mandate that anticoagulation must continue for at least **6 weeks after delivery**, even if the 3-month total duration has already been met. *Commence treatment-dose LMWH, switch to DOAC after delivery, continue for 6 weeks postpartum* - **Direct Oral Anticoagulants (DOACs)** are currently not recommended for women who are **breastfeeding** due to a lack of safety data and potential excretion into breast milk. - **LMWH** or **Warfarin** are the validated options for postpartum anticoagulation in patients who wish to breastfeed. *Commence treatment-dose LMWH, continue for remainder of pregnancy only, cease postpartum if asymptomatic* - Ceasing anticoagulation immediately after delivery is dangerous as the **postpartum state** is significantly more **prothrombotic** than pregnancy itself. - Management must always include a minimum of **6 weeks postpartum prophylaxis/treatment** to prevent recurrent pulmonary embolism or deep vein thrombosis.

Question 71: A 41-year-old man presents with acute onset pain and swelling of his right ankle. He has a history of psoriasis affecting his scalp and elbows. Joint aspiration reveals weakly positively birefringent crystals. Plain radiographs show soft tissue swelling and a small erosion at the first metatarsophalangeal joint. Serum urate is 0.38 mmol/L (normal <0.42). What diagnosis best explains the crystal findings in the context of his presentation?

A. Acute gout with normal serum urate due to increased renal excretion during acute attack
B. Calcium pyrophosphate deposition disease (pseudogout) coinciding with underlying psoriatic arthropathy (Correct Answer)
C. Psoriatic arthritis with secondary calcium pyrophosphate crystal deposition
D. Basic calcium phosphate crystal arthropathy associated with psoriatic joint damage
E. Laboratory error in crystal identification; negatively birefringent crystals more likely given clinical context

Explanation: ***Calcium pyrophosphate deposition disease (pseudogout) coinciding with underlying psoriatic arthropathy*** - The presence of **weakly positively birefringent crystals** in joint fluid is the hallmark diagnostic feature of **calcium pyrophosphate deposition disease (CPPD)**, also known as pseudogout. - This diagnosis directly explains the acute inflammatory episode, and its coexistence with the patient's **psoriasis** highlights that multiple arthropathies can occur in the same individual. *Acute gout with normal serum urate due to increased renal excretion during acute attack* - Gout is definitively diagnosed by the presence of **strongly negatively birefringent** needle-shaped monosodium urate crystals, which contradicts the

Question 72: A 52-year-old woman is admitted with bilateral leg swelling. She has a history of breast cancer treated with mastectomy and chemotherapy 18 months ago, now in remission. Doppler ultrasound confirms bilateral above-knee deep vein thromboses. CT chest-abdomen-pelvis shows no evidence of cancer recurrence but reveals extrinsic compression of the inferior vena cava by enlarged lymph nodes at the level of the renal veins. What is the most appropriate long-term anticoagulation strategy?

A. Low molecular weight heparin indefinitely as first-line due to cancer history
B. Warfarin with target INR 2-3 for 3 months, then reassess based on node resolution
C. Apixaban for 6 months as provoked VTE by mechanical obstruction
D. Inferior vena cava filter insertion followed by 3 months anticoagulation
E. Extended duration anticoagulation (indefinite or until IVC obstruction resolves) due to ongoing provoking factor (Correct Answer)

Explanation: ***Extended duration anticoagulation (indefinite or until IVC obstruction resolves) due to ongoing provoking factor*** - Anticoagulation must be maintained as long as a **persistent provoking factor** is present; mechanical compression of the **inferior vena cava (IVC)** by lymph nodes constitutes an ongoing high-risk state for recurrence. - Unlike transient risk factors (e.g., surgery), this **extrinsic obstruction** continues to promote venous stasis and thrombosis until the mechanical cause is surgically or medically resolved. *Low molecular weight heparin indefinitely as first-line due to cancer history* - While **LMWH** was historically preferred for **cancer-associated thrombosis (CAT)**, this patient is in remission, and the lymphadenopathy may not represent active malignancy. - **DOACs** are now generally preferred or equivalent to LMWH for CAT and would be more appropriate for long-term use in this patient if she has no gastrointestinal contraindications. *Warfarin with target INR 2-3 for 3 months, then reassess based on node resolution* - A **3-month duration** is typically reserved for VTE provoked by **transient** risk factors; it is insufficient while a major mechanical obstruction remains active. - Stopping treatment at 3 months while the **IVC is still compressed** would result in an unacceptably high risk of recurrent deep vein thrombosis. *Apixaban for 6 months as provoked VTE by mechanical obstruction* - Although **provoked VTE** is often treated for a fixed duration, the duration depends on the **reversibility** of the provoking factor. - A **6-month limit** is arbitrary in this context; anticoagulation should be "extended" or "indefinite" until the **mechanical stasis** is actually eliminated. *Inferior vena cava filter insertion followed by 3 months anticoagulation* - **IVC filters** are generally indicated only when anticoagulation is **contraindicated** or has failed despite therapeutic levels. - Filters do not treat the underlying thrombus and can actually **increase the risk** of long-term DVT; they are not a substitute for pharmacological anticoagulation in this hemodynamically stable patient.

Question 73: A 67-year-old man with established rheumatoid arthritis on methotrexate 20mg weekly and hydroxychloroquine 200mg twice daily has persistently active disease (DAS28 score 5.2) despite optimal conventional DMARD therapy for 8 months. He has no contraindications to biologics. His rheumatologist is considering adding a biologic agent. Which of the following statements regarding biologic DMARD selection is most accurate?

A. Anti-TNF agents are more effective than other biologic classes and should always be first-line
B. Patients with positive rheumatoid factor and anti-CCP antibodies have better response rates to rituximab compared to seronegative patients (Correct Answer)
C. Tocilizumab is contraindicated as monotherapy and must be combined with methotrexate
D. Abatacept is only licensed for use after failure of anti-TNF therapy
E. All biologic DMARDs have equal efficacy in clinical trials, so selection is based primarily on safety profile and patient preference

Explanation: ***Patients with positive rheumatoid factor and anti-CCP antibodies have better response rates to rituximab compared to seronegative patients*** - **Rituximab**, an anti-CD20 B-cell depleting therapy, demonstrates superior clinical response in patients who are **seropositive** for **rheumatoid factor (RF)** or **anti-CCP antibodies**. - This enhanced response is attributed to the central role of **B-cells** in producing these autoantibodies, which drive the inflammatory process in seropositive rheumatoid arthritis. *Anti-TNF agents are more effective than other biologic classes and should always be first-line* - Current guidelines suggest that **Anti-TNF**, **IL-6 inhibitors**, and **T-cell costimulation blockers** have comparable efficacy as first-line biologics after conventional DMARD failure. - The choice of agent is individualized based on **comorbidities**, patient preferences, and specific disease characteristics, rather than a universal hierarchy of efficacy for anti-TNF agents. *Tocilizumab is contraindicated as monotherapy and must be combined with methotrexate* - **Tocilizumab**, an **IL-6 receptor antagonist**, is unique among biologics for having demonstrated significant efficacy and approval as **monotherapy** in clinical trials for rheumatoid arthritis. - It is often utilized as monotherapy in patients who are **intolerant** of or have contraindications to methotrexate or other conventional synthetic DMARDs. *Abatacept is only licensed for use after failure of anti-TNF therapy* - **Abatacept**, a selective T-cell costimulation modulator, is licensed for use in RA patients who have had an inadequate response to **conventional DMARDs**. - It is **not restricted** to use only after failure of anti-TNF therapy and can be considered as a **first-line biologic** after cDMARDs. *All biologic DMARDs have equal efficacy in clinical trials, so selection is based primarily on safety profile and patient preference* - While many biologic classes achieve similar primary endpoints in broad clinical trials, **individual patient characteristics** such as serostatus, disease phenotype, and comorbidities can influence specific drug success rates. - Selection is a complex process considering **efficacy in specific patient subsets**, **safety profile**, administration route, **comorbidities** (e.g., risk of infection or heart failure), and patient preference.

Question 74: A 43-year-old woman presents with a 3-week history of fatigue and dyspnoea on exertion. She follows a strict vegan diet and takes no supplements. Blood tests reveal: Hb 79 g/L, MCV 103 fL, WCC 4.8 × 10⁹/L, platelets 168 × 10⁹/L, reticulocytes 38 × 10⁹/L, serum B12 145 ng/L (normal 200-900), serum folate 2.8 mcg/L (normal >3), LDH 580 U/L. What is the most appropriate next investigation to guide management?

A. Bone marrow aspiration and trephine to assess for megaloblastic changes
B. Intrinsic factor antibodies and gastric parietal cell antibodies to diagnose pernicious anaemia
C. Red cell folate level as this is more sensitive than serum folate for tissue deficiency
D. Methylmalonic acid and homocysteine levels to distinguish B12 from folate deficiency (Correct Answer)
E. Anti-tissue transglutaminase antibodies to screen for coeliac disease

Explanation: ***Methylmalonic acid and homocysteine levels to distinguish B12 from folate deficiency*** - The patient presents with **macrocytic anemia**, low **serum B12**, and low **serum folate**, along with elevated **LDH**, strongly suggesting a megaloblastic process. - Measuring **methylmalonic acid (MMA)** and **homocysteine** is essential: MMA is specifically elevated in **B12 deficiency**, while homocysteine is elevated in both **B12 and folate deficiencies**, allowing for definitive differentiation of the primary deficiency. *Bone marrow aspiration and trephine to assess for megaloblastic changes* - While a bone marrow biopsy would show characteristic **megaloblastic changes** such as hypersegmented neutrophils and megaloblasts, it is an invasive procedure. - Given the clear biochemical evidence of **vitamin B12** and **folate deficiency** and the patient's **vegan diet**, a bone marrow biopsy is generally not required for initial diagnosis. *Intrinsic factor antibodies and gastric parietal cell antibodies to diagnose pernicious anaemia* - These antibodies are specific for **pernicious anemia**, an autoimmune condition causing **B12 malabsorption**. - The patient's **strict vegan diet** without supplementation provides a direct and highly probable explanation for B12 deficiency (dietary), making autoimmune causes less likely as the immediate primary concern. *Red cell folate level as this is more sensitive than serum folate for tissue deficiency* - **Red cell folate** reflects long-term folate status and is less affected by recent dietary intake than serum folate. - However, its diagnostic utility is limited as it can be falsely low in **B12 deficiency** and is generally not preferred over **serum folate** and **homocysteine** levels for assessing folate status. *Anti-tissue transglutaminase antibodies to screen for coeliac disease* - **Coeliac disease** can cause malabsorption of various nutrients, including **folate** and **vitamin B12**, leading to anemia. - However, the most direct and evident cause for the patient's deficiencies, given her history, is her **strict vegan diet**, making other malabsorption syndromes a secondary consideration without other gastrointestinal symptoms.

Question 75: A 56-year-old man presents with sudden onset severe breathlessness 6 days following a right total knee replacement. CT pulmonary angiogram confirms bilateral pulmonary emboli. He has no previous history of venous thromboembolism. He weighs 82kg with normal renal function (eGFR 78 mL/min/1.73m²). He was receiving prophylactic low molecular weight heparin postoperatively. What is the most appropriate initial anticoagulation management?

A. Commence rivaroxaban 15mg twice daily for 3 weeks, then 20mg once daily
B. Commence apixaban 10mg twice daily for 7 days, then 5mg twice daily (Correct Answer)
C. Commence treatment-dose low molecular weight heparin with warfarin overlap, target INR 2-3
D. Commence dabigatran 150mg twice daily immediately
E. Commence unfractionated heparin infusion with monitoring of APTT ratio

Explanation: ***Commence apixaban 10mg twice daily for 7 days, then 5mg twice daily***- **Apixaban** is a recommended first-line direct oral anticoagulant (DOAC) for acute pulmonary embolism (PE), particularly for **provoked PE** like post-surgical cases, allowing for oral monotherapy from the outset.- The correct loading dose for acute PE in patients with normal renal function is **10mg twice daily for 7 days**, followed by the maintenance dose of **5mg twice daily**.*Commence rivaroxaban 15mg twice daily for 3 weeks, then 20mg once daily*- While **rivaroxaban** is also a first-line DOAC for PE, its recommended loading regimen involves **15mg twice daily for 21 days**, which differs from apixaban's shorter 7-day loading period.- This patient's clinical situation and current guidelines favor the rapid initiation and established efficacy of apixaban's 7-day loading phase in many protocols.*Commence treatment-dose low molecular weight heparin with warfarin overlap, target INR 2-3*- The combination of **low molecular weight heparin (LMWH)** and **warfarin** is an older standard of care that requires an initial parenteral agent and then careful INR monitoring to achieve therapeutic levels.- Current guidelines typically favor **DOACs** over Vitamin K antagonists (like warfarin) for most VTE patients due to their better safety profile (e.g., lower bleeding risk) and greater convenience.*Commence dabigatran 150mg twice daily immediately*- **Dabigatran** is a DOAC, but it is not approved for immediate initiation in acute VTE; it requires a **5-10 day lead-in period of parenteral anticoagulation** (e.g., LMWH) before oral administration.- Starting dabigatran immediately would leave the patient inadequately anticoagulated during the critical acute phase of the pulmonary embolism.*Commence unfractionated heparin infusion with monitoring of APTT ratio*- **Unfractionated heparin (UFH) infusion** is typically reserved for specific high-risk scenarios, such as patients with **severe renal impairment** (eGFR <15-30 mL/min), hemodynamically unstable PE, or when a rapid reversal might be necessary for intervention.- This patient has normal renal function (eGFR 78 mL/min) and is not described as hemodynamically unstable, making the complexity of UFH with **APTT monitoring** unnecessary.

Question 76: A 29-year-old woman presents with fatigue and pallor. She has menorrhagia and no other medical history. Blood tests reveal: Hb 87 g/L, MCV 71 fL, ferritin 8 mcg/L, serum iron 6 micromol/L (normal 10-30), transferrin saturation 12% (normal 20-50%), total iron-binding capacity (TIBC) 82 micromol/L (normal 45-70). She is commenced on oral ferrous sulfate 200mg three times daily. When should her full blood count be rechecked to assess treatment response?

A. After 1 week to assess for reticulocytosis
B. After 2-4 weeks to assess for rise in haemoglobin (Correct Answer)
C. After 3 months when haemoglobin normalisation is expected
D. After 6 months to assess for repletion of iron stores
E. After 1 month, but only if symptoms persist

Explanation: ***After 2-4 weeks to assess for rise in haemoglobin*** - In the management of **iron deficiency anaemia**, a follow-up **full blood count (FBC)** is typically performed within **2-4 weeks** to confirm an adequate response, defined as a rise in **haemoglobin (Hb)** of approximately **20 g/L**. - This early check is crucial to verify **treatment compliance**, confirm adequate **gastrointestinal absorption**, and ensure the initial diagnosis was correct. *After 1 week to assess for reticulocytosis* - While **reticulocytosis** peaks around **7-10 days** after starting iron therapy, it is not the standard clinical parameter used to monitor response in primary care. - A **Full Blood Count** at this stage is too early to see a significant, clinical change in the **haemoglobin concentration**. *After 3 months when haemoglobin normalisation is expected* - Waiting **3 months** for the first check is inappropriate because it delays the detection of **treatment failure** or ongoing **occult blood loss**. - Although iron stores may take this long to replenish, the **initial response** must be verified much sooner to ensure the patient is on the right track. *After 6 months to assess for repletion of iron stores* - **Iron stores** (measured by **ferritin**) are typically assessed **3-6 months** after the Hb has normalized, not as the primary timing for the first FBC follow-up. - Monitoring at this late stage would miss the opportunity to address **non-compliance** or **malabsorption** issues early in the treatment course. *After 1 month, but only if symptoms persist* - Follow-up testing is mandatory for **all patients** treated for iron deficiency to ensure the **haemoglobin** reaches the target range, regardless of symptom resolution. - Many patients may feel better before their **iron stores** are adequate, making clinical symptoms an unreliable guide for treatment monitoring.

Question 77: A 38-year-old woman with no significant past medical history presents with bilateral hand and wrist pain for 5 months. Examination reveals synovitis of the metacarpophalangeal joints bilaterally and both wrists. Blood tests show: CRP 34 mg/L, ESR 42 mm/hr, rheumatoid factor negative, anti-CCP antibodies negative. Hand X-rays show soft tissue swelling only with no erosions. What is the most appropriate classification of her condition?

A. Seronegative rheumatoid arthritis requiring disease-modifying therapy (Correct Answer)
B. Undifferentiated inflammatory arthritis requiring monitoring and symptomatic management
C. Psoriatic arthritis requiring assessment for psoriasis
D. Early rheumatoid arthritis not meeting ACR/EULAR criteria, continue observation
E. Probable viral arthritis likely to resolve spontaneously

Explanation: ***Seronegative rheumatoid arthritis requiring disease-modifying therapy*** - The patient meets the **ACR/EULAR 2010 classification criteria** for RA (score of 7 points: 10 joints = 5, duration >6 weeks = 1, and elevated CRP/ESR = 1). - Approximately **20-30% of RA cases** are seronegative for RF and anti-CCP; prompt treatment with **DMARDs** like methotrexate is essential to prevent erosions. *Undifferentiated inflammatory arthritis requiring monitoring and symptomatic management* - This diagnosis is reserved for patients who do not meet the full **classification criteria** for a specific inflammatory disease. - Since this patient scores over 6 points on the **RA criteria**, she is formalised as having RA rather than an undifferentiated condition. *Psoriatic arthritis requiring assessment for psoriasis* - While **psoriatic arthritis** can present as a polyarthritis, the symmetric involvement of **MCP joints** and wrists is more classic for rheumatoid arthritis. - There is no mention of **dactylitis**, nail changes, or relevant family history to tilt the diagnosis toward the **CASPAR criteria** for PsA. *Early rheumatoid arthritis not meeting ACR/EULAR criteria, continue observation* - This patient already meets the **ACR/EULAR criteria** (score ≥6), so observation alone would delay necessary **DMARD therapy**. - Delaying treatment in early RA increases the risk of irreversible **joint destruction** and functional impairment. *Probable viral arthritis likely to resolve spontaneously* - **Viral arthritis** (e.g., Parvovirus B19) typically resolves within **6 weeks**, whereas this patient has persistent symptoms for 5 months. - The presence of significantly elevated **CRP and ESR** over a long duration is highly suggestive of a chronic inflammatory process rather than a transient viral infection.

Question 78: A 64-year-old woman presents to the emergency department with severe pain and swelling of her right first metatarsophalangeal joint. She has a history of chronic kidney disease stage 3b (eGFR 42 mL/min/1.73m²) and hypertension treated with ramipril and bendroflumethiazide. Joint aspiration reveals negatively birefringent crystals. Her serum urate is 0.52 mmol/L. What is the most appropriate immediate management?

A. Commence allopurinol 100mg daily with NSAIDs for acute inflammation
B. Commence colchicine 500 micrograms four times daily until symptoms resolve
C. Commence prednisolone 30mg daily for 5-7 days with proton pump inhibitor cover (Correct Answer)
D. Commence febuxostat 80mg daily with colchicine prophylaxis
E. Commence naproxen 500mg twice daily for 7-10 days with proton pump inhibitor

Explanation: ***Commence prednisolone 30mg daily for 5-7 days with proton pump inhibitor cover*** - Oral **corticosteroids** are the first-line treatment for acute gout when both **NSAIDs** and **colchicine** are contraindicated or poorly tolerated. - This patient has **CKD stage 3b**, making steroids the safest choice to avoid **renal toxicity** or colchicine accumulation. *Commence allopurinol 100mg daily with NSAIDs for acute inflammation* - **Urate-lowering therapy (ULT)** like allopurinol should not be initiated during an **acute attack** as rapid changes in urate levels can exacerbate symptoms. - **NSAIDs** are contraindicated in patients with significant **chronic kidney disease** due to the risk of acute-on-chronic renal failure. *Commence colchicine 500 micrograms four times daily until symptoms resolve* - A dose of 500mcg four times daily is considered **excessive** and exceeds modern safety recommendations for acute gout management. - In **renal impairment**, colchicine must be dose-reduced (typically to BD) to prevent **toxicity** affecting the gastrointestinal and neuromuscular systems. *Commence febuxostat 80mg daily with colchicine prophylaxis* - Similar to allopurinol, **febuxostat** is a ULT and must be delayed until 2-4 weeks after the **acute inflammation** has fully resolved. - Starting ULT during a flare can **prolong the attack** by causing further mobilization of urate crystals from tissue stores. *Commence naproxen 500mg twice daily for 7-10 days with proton pump inhibitor* - **NSAIDs** are generally avoided in patients with an **eGFR <60** and are strictly contraindicated when the eGFR is below 30-45. - Naproxen can cause **prostaglandin inhibition**, leading to afferent arteriolar vasoconstriction and a further decline in **renal function**.

Question 79: A 51-year-old woman with early rheumatoid arthritis has been on methotrexate 20mg weekly for 8 months with good disease control (DAS28 score 2.4). She now presents with progressive painless swelling of her left elbow over 3 weeks, with no history of trauma. The joint is non-tender with a large effusion but no warmth or erythema. Her inflammatory markers are normal. What pathological process best explains this presentation?

A. Septic arthritis with low-grade infection requiring urgent aspiration and antibiotics
B. Acute flare of rheumatoid arthritis indicating treatment failure
C. Olecranon bursitis secondary to repetitive trauma
D. Rheumatoid nodulosis with extra-articular disease manifestation
E. Synovial hypertrophy and effusion despite systemic disease control, representing structural rather than inflammatory disease (Correct Answer)

Explanation: ***Synovial hypertrophy and effusion despite systemic disease control, representing structural rather than inflammatory disease***- The patient's **DAS28 score of 2.4** indicates **clinical remission** or low disease activity, and **normal inflammatory markers** (ESR/CRP) suggest a lack of systemic inflammation.- In **rheumatoid arthritis**, even with good systemic control, a single joint can develop **persistent synovial hypertrophy** and **effusion** due to chronic structural changes and past damage, which may not resolve despite a quiet inflammatory state.*Septic arthritis with low-grade infection requiring urgent aspiration and antibiotics*- While **immunosuppression** (methotrexate) increases infection risk, the absence of **pain, warmth, erythema**, and **normal inflammatory markers** makes septic arthritis highly unlikely.- Septic arthritis typically presents with a **hot, swollen, painful joint**, often with **systemic symptoms** and elevated inflammatory markers, even in low-grade cases.*Acute flare of rheumatoid arthritis indicating treatment failure*- An **acute rheumatoid arthritis flare** would typically involve a **worsening of systemic symptoms**, an increase in the **DAS28 score**, elevated **inflammatory markers**, and often involve multiple joints, not an isolated, painless swelling.- The patient's **good disease control** (DAS28 2.4) and **normal inflammatory markers** directly contradict an acute inflammatory flare.*Olecranon bursitis secondary to repetitive trauma*- **Olecranon bursitis** presents as swelling **posterior** to the elbow, directly over the olecranon process, and is often painful with direct pressure.- This patient describes a **large effusion** of the joint itself, implying intra-articular pathology, rather than a superficial bursal swelling, and denies **trauma**.*Rheumatoid nodulosis with extra-articular disease manifestation*- **Rheumatoid nodulosis** involves the development of **firm, non-tender subcutaneous nodules**, usually over pressure points (e.g., elbows, fingers), which are solid lesions.- The presentation of a **painless, progressive swelling** with a **large effusion** describes a fluid-filled joint rather than a solid nodule.

Question 80: A 47-year-old man presents with a 3-month history of progressive fatigue and exertional dyspnoea. He has a history of Crohn's disease managed with azathioprine. Blood tests reveal: Hb 94 g/L, MCV 108 fL, WCC 3.2 × 10⁹/L, platelets 145 × 10⁹/L, reticulocyte count 45 × 10⁹/L. Blood film shows hypersegmented neutrophils. What is the most likely underlying mechanism for his anaemia?

A. Chronic inflammation causing impaired iron utilisation and reduced erythropoietin response
B. Azathioprine-induced bone marrow suppression affecting all cell lineages
C. Folate deficiency secondary to impaired absorption in active Crohn's disease
D. Terminal ileal disease causing vitamin B12 malabsorption (Correct Answer)
E. Haemolysis secondary to azathioprine toxicity with inadequate bone marrow compensation

Explanation: ***Terminal ileal disease causing vitamin B12 malabsorption*** - This patient demonstrates **megaloblastic anaemia** characterized by a high **MCV (108 fL)** and the distinctive presence of **hypersegmented neutrophils** on the blood film. - **Crohn's disease** frequently affects the **terminal ileum**, which is the primary site for the absorption of the **Vitamin B12-intrinsic factor complex**, leading directly to this deficiency. *Chronic inflammation causing impaired iron utilisation and reduced erythropoietin response* - This describes **anaemia of chronic disease**, which typically presents as a **normocytic** or sometimes mildly microcytic anaemia, not macrocytic. - This mechanism would not explain the presence of **hypersegmented neutrophils**, which are a specific morphological hallmark of impaired DNA synthesis. *Azathioprine-induced bone marrow suppression affecting all cell lineages* - While **Azathioprine** can cause **pancytopenia** (low WBC, RBC, and platelets) and sometimes macrocytosis, it does not typically cause **hypersegmented neutrophils**. - The specific finding of **hypersegmented neutrophils** strongly points towards a **megaloblastic** process, which is primarily a nutritional deficiency, rather than direct cytotoxic bone marrow suppression. *Folate deficiency secondary to impaired absorption in active Crohn's disease* - **Folate** is primarily absorbed in the **jejunum**, and while deficiency can occur in Crohn's, it is less commonly associated with Crohn's than B12 deficiency due to terminal ileal involvement. - Both B12 and folate deficiency cause megaloblastic anaemia, but **terminal ileal disease** in Crohn's is classically linked to **B12 malabsorption**. *Haemolysis secondary to azathioprine toxicity with inadequate bone marrow compensation* - **Haemolysis** typically results in an **elevated reticulocyte count** as the bone marrow tries to compensate for increased red cell destruction. - This patient has a **low reticulocyte count (45 × 10⁹/L)** and **hypersegmented neutrophils**, which are inconsistent with a primary haemolytic process.

Question 81: A 34-year-old woman with newly diagnosed seropositive rheumatoid arthritis is started on methotrexate. She asks about the monitoring requirements for this medication. Which of the following represents the correct initial monitoring schedule for methotrexate therapy?

A. Full blood count and liver function tests weekly for 6 weeks, then monthly for 3 months, then every 3 months
B. Full blood count and liver function tests fortnightly for 6 weeks, then monthly for 3 months, then every 3 months (Correct Answer)
C. Full blood count and renal function tests weekly for 4 weeks, then monthly thereafter
D. Full blood count, liver function tests and renal function tests monthly for 6 months, then every 3 months
E. Full blood count and liver function tests monthly throughout treatment

Explanation: ***Full blood count and liver function tests fortnightly for 6 weeks, then monthly for 3 months, then every 3 months*** - According to **BSR and NICE guidelines**, initial monitoring for methotrexate involves **Full Blood Count (FBC)** and **Liver Function Tests (LFTs)** every 2 weeks (**fortnightly**) for the first 6 weeks. - This rigorous schedule is crucial for early detection of potentially serious side effects such as **bone marrow suppression** (e.g., leukopenia, thrombocytopenia) and **hepatotoxicity** (elevated transaminases). *Full blood count and liver function tests weekly for 6 weeks, then monthly for 3 months, then every 3 months* - **Weekly monitoring** is generally considered more frequent than necessary for standard initial methotrexate therapy in most patients, which can lead to increased patient burden without significantly enhanced safety. - Current guidelines, such as those from **NICE or BSR**, typically recommend a **fortnightly** monitoring schedule for the initial 6-week period rather than weekly. *Full blood count and renal function tests weekly for 4 weeks, then monthly thereafter* - This option critically **omits liver function tests (LFTs)**, which are an essential component of methotrexate monitoring due to the drug's well-known potential for causing **hepatotoxicity**. - While **renal function tests (RFTs)** are important as methotrexate is renally cleared, they are typically monitored as part of baseline assessment and then less frequently than FBC/LFTs unless specific risk factors exist. *Full blood count, liver function tests and renal function tests monthly for 6 months, then every 3 months* - **Monthly monitoring** from the very beginning of methotrexate therapy is insufficient for the initial, high-risk period when adverse effects are most likely to manifest. - Established guidelines require more frequent testing, specifically **fortnightly**, during the first 6 weeks to ensure patient safety during dose initiation and escalation. *Full blood count and liver function tests monthly throughout treatment* - This schedule fails to incorporate the critical **fortnightly monitoring** phase mandated during the initial 6 weeks of methotrexate therapy, which is essential to identify acute toxicities. - While monitoring intervals can be extended once a patient is stable on the medication, a fixed monthly schedule throughout treatment does not align with the standard safety protocols for initiation.

Question 82: A 66-year-old man is investigated for macrocytic anaemia. Blood tests show: Hb 89 g/L, MCV 118 fL, WCC 4.2 × 10⁹/L, platelets 156 × 10⁹/L, reticulocytes 18 × 10⁹/L, serum B12 95 ng/L (normal 200-900), serum folate 18 μg/L (normal 4-20), bilirubin 42 μmol/L (unconjugated), LDH 890 U/L. Blood film shows macrocytes, polychromasia, and spherocytes. What is the most likely diagnosis?

A. Pernicious anaemia with ineffective erythropoiesis
B. Autoimmune haemolytic anaemia with reticulocytosis causing macrocytosis (Correct Answer)
C. Myelodysplastic syndrome with associated haemolysis
D. Combined B12 deficiency and hereditary spherocytosis
E. Hypersplenism secondary to portal hypertension

Explanation: ***Autoimmune haemolytic anaemia with reticulocytosis causing macrocytosis*** - The presence of **spherocytes**, **unconjugated hyperbilirubinaemia**, and markedly elevated **LDH** are classic indicators of **extravascular haemolysis**. - Since **reticulocytes** are larger than mature red blood cells (high MCV), a robust regenerative response to haemolysis often manifests as **macrocytosis**. *Pernicious anaemia with ineffective erythropoiesis* - While B12 deficiency causes high LDH and bilirubin due to **intramedullary haemolysis**, it is typically associated with **hypersegmented neutrophils**, not **spherocytes**. - The low B12 here might be deceptive or secondary, as the **blood film morphology** (spherocytes) strongly points toward an immune-mediated destructive process. *Myelodysplastic syndrome with associated haemolysis* - **Myelodysplastic syndrome (MDS)** usually presents with **pancytopenia** and dysplastic features rather than isolated haemolytic markers and spherocytes. - While MDS can cause a high MCV, it does not explain the acute **unconjugated hyperbilirubinaemia** and high LDH seen in this patient's profile. *Combined B12 deficiency and hereditary spherocytosis* - **Hereditary spherocytosis** usually presents much earlier in life with a family history and **splenomegaly**, rather than a new-onset macrocytic anaemia in a 66-year-old. - A low B12 level in the presence of spherocytes is more likely a concurrent autoimmune finding (Evans syndrome or associated AIHA) rather than a genetic membrane defect. *Hypersplenism secondary to portal hypertension* - **Hypersplenism** typically leads to **pancytopenia** due to increased sequestration, not a targeted destruction that produces **spherocytes**. - This patient's biochemical markers (very high LDH and bilirubin) are more characteristic of **active haemolysis** than simple splenic sequestration.

Question 83: A 44-year-old woman with psoriatic arthritis affecting her hands and feet has had inadequate response to methotrexate and leflunomide. She develops new-onset blurred vision and eye pain. Ophthalmology diagnoses acute anterior uveitis. What is the most appropriate next step in managing her arthritis?

A. Add sulfasalazine to her current DMARD therapy
B. Switch to a TNF inhibitor, preferably a monoclonal antibody such as adalimumab (Correct Answer)
C. Add hydroxychloroquine with close ophthalmology monitoring
D. Start apremilast as first-line biologic for psoriatic arthritis
E. Switch to IL-17 inhibitor such as secukinumab

Explanation: ***Switch to a TNF inhibitor, preferably a monoclonal antibody such as adalimumab***- In patients with **psoriatic arthritis** failing conventional **DMARDs** who develop **acute anterior uveitis**, monoclonal TNF antibodies like **adalimumab** or **infliximab** are the preferred treatment.- These agents are significantly more effective than etanercept at treating and preventing recurrences of **extra-articular manifestations** like uveitis.*Add sulfasalazine to her current DMARD therapy*- **Sulfasalazine** has only modest efficacy in peripheral joint disease and is generally insufficient for patients who have already failed multiple **conventional DMARDs**.- It provides limited protection against **uveitis flare-ups** compared to biologics in the setting of refractory disease.*Add hydroxychloroquine with close ophthalmology monitoring*- **Hydroxychloroquine** is generally avoided or used with caution in psoriatic patients as it can potentially cause a **psoriasis flare** or exacerbate skin symptoms.- It does not have a therapeutic role in the management of **acute anterior uveitis**, which requires more potent systemic or topical immunosuppression.*Start apremilast as first-line biologic for psoriatic arthritis*- **Apremilast** is a **PDE4 inhibitor**, not a biologic, and typically demonstrates lower efficacy in joint disease compared to **TNF inhibitors**.- It has no established role or clinical evidence for the management or prevention of **uveitis**.*Switch to IL-17 inhibitor such as secukinumab*- While **IL-17 inhibitors** are highly effective for skin and joint symptoms, they have been associated with a lack of efficacy or potential worsening of **uveitis** episodes.- **TNF inhibitors** remain the gold standard when **uveitis** is a prominent clinical feature of the spondyloarthropathy.

Question 84: A 52-year-old woman diagnosed with immune thrombocytopenia (ITP) 18 months ago has been managed with intermittent corticosteroids. Her platelet count has gradually declined to 25 × 10⁹/L despite prednisolone 40mg daily for 3 weeks. She has easy bruising but no active bleeding. She has had her spleen previously removed following trauma 15 years ago. What is the most appropriate next treatment option?

A. Thrombopoietin receptor agonist such as eltrombopag or romiplostim (Correct Answer)
B. Rituximab infusion therapy
C. Intravenous immunoglobulin therapy
D. Azathioprine as steroid-sparing agent
E. Mycophenolate mofetil

Explanation: ***Thrombopoietin receptor agonist such as eltrombopag or romiplostim*** - This patient has **chronic ITP** (>12 months) that is **refractory to corticosteroids** and has already undergone a **splenectomy**, making **TPO-RAs** the preferred next-line treatment. - **Eltrombopag** and **romiplostim** stimulate the **bone marrow** to increase platelet production, with high response rates (~70-80%) in patients who have failed other therapies. *Rituximab infusion therapy* - **Rituximab** (anti-CD20) is a second-line option, but it has **lower sustained response rates** (approximately 40-60%) compared to **TPO-RAs**. - While it targets B-cell mediated destruction, the duration of response is often shorter than that provided by **thrombopoietin receptor agonists**. *Intravenous immunoglobulin therapy* - **IVIg** is primarily used for **rapid elevation** of platelet counts in emergency settings with **active bleeding** or prior to surgery. - Its effects are **temporary and short-lived**, typically lasting only a few weeks, which makes it unsuitable for the **long-term management** of chronic refractory ITP. *Azathioprine as steroid-sparing agent* - **Azathioprine** is a slow-acting immunosuppressant that can take **several months** to achieve a clinical effect. - It has a lower efficacy profile and a higher risk of **side effects** like bone marrow suppression compared to the targeted action of **TPO-RAs**. *Mycophenolate mofetil* - **Mycophenolate mofetil** (MMM) is an alternative second-line immunosuppressant that is sometimes used in chronic ITP management. - However, current guidelines generally favor **TPO-RAs** in post-splenectomy patients due to their superior **platelet-stimulating potency** and established efficacy data.

Question 85: What is the primary mechanism by which hepcidin regulates iron homeostasis in the body?

A. Direct inhibition of transferrin synthesis in the liver
B. Degradation of ferroportin, preventing iron export from cells (Correct Answer)
C. Enhanced absorption of dietary iron in the duodenum
D. Increased erythropoietin production by the kidneys
E. Promotion of iron release from ferritin stores

Explanation: ***Degradation of ferroportin, preventing iron export from cells***- **Hepcidin** acts as the master regulator of iron by binding to **ferroportin**, the primary iron exporter on the surface of enterocytes, macrophages, and hepatocytes.- This binding triggers the **internalization and lysosomal degradation** of ferroportin, sequestering iron within cells and lowering plasma iron levels.*Direct inhibition of transferrin synthesis in the liver*- Hepcidin is produced by the **liver**, but it does not directly control the synthesis of **transferrin**, which is the primary carrier protein for iron in the blood.- Transferrin levels are typically regulated by **body iron stores** and liver function rather than hepcidin-mediated degradation.*Enhanced absorption of dietary iron in the duodenum*- High levels of hepcidin actually **inhibit** iron absorption by degrading ferroportin on the basolateral membrane of **duodenal enterocytes**.- Suppression of hepcidin is what allows for enhanced absorption when iron stores are low or **erythropoietic demand** is high.*Increased erythropoietin production by the kidneys*- **Erythropoietin (EPO)** production is stimulated by **hypoxia** and is not a direct downstream effect of hepcidin activity.- In fact, high hepcidin levels can contribute to **anemia of chronic disease** by making iron unavailable for erythropoiesis, despite normal EPO levels.*Promotion of iron release from ferritin stores*- Hepcidin **prevents** the release of iron from **ferritin** stores by blocking the exporter (ferroportin) needed to move iron out of macrophages and hepatocytes.- This results in increased **intracellular ferritin** levels and low serum iron, a hallmark of inflammatory states.

Question 86: A 73-year-old woman with rheumatoid arthritis is admitted with suspected septic arthritis of the right knee. She takes methotrexate 20mg weekly, folic acid 5mg weekly, and etanercept 50mg subcutaneously weekly. Blood cultures are taken and empirical antibiotics started. What is the most appropriate management of her immunosuppressive medications?

A. Stop methotrexate and etanercept immediately; restart once infection resolved (Correct Answer)
B. Continue methotrexate but stop etanercept; restart biologic when infection controlled
C. Continue both medications to prevent arthritis flare during acute illness
D. Stop etanercept but continue methotrexate at reduced dose of 10mg weekly
E. Stop both medications and start prednisolone 20mg daily to control inflammation

Explanation: ***Stop methotrexate and etanercept immediately; restart once infection resolved*** - In the presence of a **serious infection** like **septic arthritis**, all immunosuppressive agents, including **methotrexate** (a conventional DMARD) and **biologic DMARDs (e.g., etanercept)**, must be immediately withheld. - This action allows the patient's immune system to effectively combat the pathogen, preventing the infection from worsening or leading to **sepsis** and permanent joint damage; medications are restarted only after full resolution. *Continue methotrexate but stop etanercept; restart biologic when infection controlled* - While **etanercept** (a biologic anti-TNF agent) carries a high risk for serious infections and should be stopped, **methotrexate** is also a significant immunosuppressant. - Continuing **methotrexate** during active **septic arthritis** can impair cellular immunity and delay the body's ability to clear the infection, potentially leading to prolonged or more severe disease. *Continue both medications to prevent arthritis flare during acute illness* - Prioritizing the prevention of a **rheumatoid arthritis flare** over managing a **life-threatening infection** like septic arthritis is clinically inappropriate. - Continuing potent **immunosuppressive medications** during active infection significantly increases the risk of **sepsis**, organ damage, and mortality. *Stop etanercept but continue methotrexate at reduced dose of 10mg weekly* - There is no clinical guideline supporting a **reduced dose** of methotrexate as a safe alternative to complete cessation during a severe acute infection. - Even at a lower dose, **methotrexate** can still compromise immune function, potentially hindering the body's ability to effectively fight the bacterial infection. *Stop both medications and start prednisolone 20mg daily to control inflammation* - Introducing high-dose **prednisolone** (a corticosteroid) during active **septic arthritis** is contraindicated as it further suppresses the immune system. - **Corticosteroids** can mask signs of infection, impair **leukocyte function**, and worsen the patient's ability to clear the bacterial pathogen, increasing the risk of complications.

Question 87: A 36-year-old man presents with a 2-week history of progressive dyspnoea and pleuritic chest pain. He is a long-distance lorry driver. He has no significant past medical history. CTPA confirms bilateral pulmonary emboli. His father had a 'clot in the lung' aged 44. Routine blood tests are normal. What is the most important additional investigation to guide long-term management?

A. Thrombophilia screen including protein C, protein S, antithrombin, and Factor V Leiden
B. Lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein-I antibodies (Correct Answer)
C. D-dimer levels to assess thrombotic burden
D. CT abdomen and pelvis to exclude underlying malignancy
E. Echocardiogram to assess right ventricular function

Explanation: ***Lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein-I antibodies*** - Testing for **Antiphospholipid Syndrome (APS)** is crucial because a diagnosis mandates **lifelong anticoagulation** to prevent recurrent events, regardless of initial provoking factors. - These tests (lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein-I antibodies) are part of the diagnostic criteria for APS and require repeat testing after 12 weeks for confirmation. *Thrombophilia screen including protein C, protein S, antithrombin, and Factor V Leiden* - While the family history is suggestive of an underlying clotting disorder, results for most **hereditary thrombophilias** rarely change the duration of anticoagulation for a first provoked VTE event. - Testing for **protein C, protein S, and antithrombin** is often inaccurate during the **acute phase** of thrombosis or while on anticoagulation, requiring deferral. *D-dimer levels to assess thrombotic burden* - **D-dimer** is primarily a screening tool with a high negative predictive value to *exclude* VTE, not to quantify the size or extent of a confirmed clot. - It has no role in guiding the **duration of long-term anticoagulation** once the diagnosis of pulmonary emboli is established. *CT abdomen and pelvis to exclude underlying malignancy* - Extensive screening for **occult malignancy** is generally reserved for patients with truly **unprovoked VTE** or those with other suggestive symptoms (e.g., weight loss, unexplained anemia). - This patient has a clear **provocative risk factor** (prolonged sitting as a lorry driver) and a family history suggesting a primary thrombophilia, making malignancy screening less of an immediate priority for long-term management guidance. *Echocardiogram to assess right ventricular function* - An **echocardiogram** is valuable for **acute risk stratification** in pulmonary embolism, assessing for right ventricular strain and guiding immediate management. - While it provides prognostic information, it does not determine the **required length or type of long-term anticoagulant therapy** for secondary prevention.

Question 88: A 61-year-old man presents with severe pain and swelling of his right knee. Joint aspiration reveals weakly positively birefringent rhomboid-shaped crystals. Serum calcium is 2.85 mmol/L (normal 2.20-2.60), phosphate 0.95 mmol/L (normal 0.80-1.40), and PTH 8.2 pmol/L (normal 1.6-6.9). What is the most likely underlying diagnosis?

A. Primary hyperparathyroidism (Correct Answer)
B. Hypervitaminosis D
C. Parathyroid carcinoma
D. Multiple myeloma
E. Tertiary hyperparathyroidism

Explanation: ***Primary hyperparathyroidism***- The patient's presentation of **pseudogout**, identified by **weakly positively birefringent rhomboid-shaped crystals** in the joint fluid, is frequently associated with metabolic disturbances, particularly conditions causing **hypercalcemia**.- The biochemical findings of **elevated serum calcium** (2.85 mmol/L) alongside an **elevated parathyroid hormone (PTH)** level (8.2 pmol/L) are the classic diagnostic markers for **primary hyperparathyroidism**.*Hypervitaminosis D*- While **hypervitaminosis D** causes **hypercalcemia**, it leads to feedback **suppression of PTH**, which contradicts the high PTH level observed in this patient.- This condition typically results from excessive vitamin D intake and would likely show significantly elevated **25-hydroxyvitamin D** levels.*Parathyroid carcinoma*- **Parathyroid carcinoma** is a rare malignancy that usually presents with much more **severe hypercalcemia** (often >3.5 mmol/L) and significantly higher PTH levels than seen here.- Clinical presentation may also include a **palpable neck mass** and more pronounced systemic symptoms of hypercalcemia.*Multiple myeloma*- **Multiple myeloma** causes **hypercalcemia** primarily through osteolytic bone destruction, which results in the **suppression of PTH**.- Diagnosis typically involves detecting a **monoclonal protein** (M-spike) and other features like anemia, renal impairment, or lytic bone lesions, none of which are characteristic of pseudogout crystals.*Tertiary hyperparathyroidism*- **Tertiary hyperparathyroidism** occurs after long-standing **chronic kidney disease (CKD)**, leading to autonomous PTH secretion and often hypercalcemia.- In this patient, the **phosphate level is normal**, and there is no clinical or biochemical evidence to suggest underlying advanced renal failure.

Question 89: A 47-year-old woman with established seropositive rheumatoid arthritis has progressive disease despite methotrexate 25mg weekly and sulfasalazine 2g daily. She has no history of tuberculosis or recurrent infections. Chest X-ray is normal. What is the most appropriate next step in management?

A. Add prednisolone 10mg daily for long-term disease control
B. Switch to hydroxychloroquine and leflunomide combination
C. Add a biologic DMARD such as a TNF inhibitor (Correct Answer)
D. Increase methotrexate to 30mg weekly with folic acid adjustment
E. Add low-dose oral methotrexate and increase to subcutaneous route

Explanation: ***Add a biologic DMARD such as a TNF inhibitor*** - Patients with **seropositive rheumatoid arthritis** who have failed to respond adequately to two **conventional synthetic DMARDs** (like methotrexate and sulfasalazine) with ongoing progressive disease should be escalated to a **biologic DMARD** or a targeted synthetic DMARD. - Given her optimal methotrexate dose (25mg weekly) and no contraindications (no history of **tuberculosis** or recurrent infections, normal **chest X-ray**), a **TNF inhibitor** is the most appropriate next step in management. *Add prednisolone 10mg daily for long-term disease control* - **Corticosteroids** like prednisolone are used for **short-term management** of flares or as **bridging therapy**, not for long-term disease control in progressive rheumatoid arthritis. - Long-term steroid use at this dose is associated with significant **adverse effects** such as osteoporosis, cataracts, and metabolic disturbances, and does not modify the underlying disease process to prevent joint damage. *Switch to hydroxychloroquine and leflunomide combination* - The patient has already failed a robust combination of two conventional DMARDs (**methotrexate and sulfasalazine**) for progressive disease. - Switching to another **conventional DMARD combination** is unlikely to be effective for severe, progressive disease and would delay the use of more potent biologic therapies. *Increase methotrexate to 30mg weekly with folic acid adjustment* - For **oral methotrexate**, doses above **20-25mg weekly** typically do not significantly increase efficacy due to **saturated absorption** in the gastrointestinal tract. - Increasing the oral dose beyond this level primarily increases the risk of **gastrointestinal side effects** and **hepatotoxicity** without providing substantial additional clinical benefit. *Add low-dose oral methotrexate and increase to subcutaneous route* - The patient is already on a high dose of **oral methotrexate** (25mg weekly), making the suggestion to "add low-dose oral methotrexate" illogical. - While switching to **subcutaneous methotrexate** can improve bioavailability, it is usually considered when oral absorption is suboptimal or to reduce gastrointestinal side effects, but it is insufficient as the sole escalation strategy for a patient who has failed combination csDMARDs with progressive disease.

Question 90: A 54-year-old man is diagnosed with an unprovoked deep vein thrombosis of the left leg. He has no past medical history and takes no regular medications. He has never smoked and drinks alcohol occasionally. Thrombophilia screening reveals heterozygous Factor V Leiden mutation. He completes 3 months of anticoagulation with apixaban. What is the most appropriate long-term management?

A. Continue anticoagulation indefinitely as he has unprovoked VTE with thrombophilia
B. Stop anticoagulation and restart only if further thrombotic events occur (Correct Answer)
C. Continue anticoagulation for a further 3 months then reassess bleeding risk
D. Reduce apixaban to prophylactic dose (2.5mg twice daily) for extended therapy
E. Switch to aspirin 75mg daily for long-term secondary prevention

Explanation: ***Stop anticoagulation and restart only if further thrombotic events occur***- **Heterozygous Factor V Leiden** is a common, low-risk thrombophilia that alone does not mandate lifelong anticoagulation after a single **unprovoked VTE**.- Standard guidelines recommend **3-6 months** of anticoagulation for a first unprovoked VTE; the presence of this specific mutation does not significantly change the risk-benefit ratio for indefinite therapy.*Continue anticoagulation indefinitely as he has unprovoked VTE with thrombophilia*- Indefinite therapy is usually reserved for **high-risk thrombophilias**, such as **Antiphospholipid Syndrome**, Antithrombin III deficiency, or **homozygous** Factor V Leiden.- For a heterozygous mutation, the **bleeding risk** of long-term anticoagulation often outweighs the benefit of preventing a recurrent event.*Continue anticoagulation for a further 3 months then reassess bleeding risk*- A **3-month course** is already the established standard for a first event; extending it to 6 months without a high-risk profile provides no proven additional long-term benefit.- Reassessing at 6 months is unnecessary since the patient has already completed the primary treatment phase for an **unprovoked event** with a low-risk mutation.*Reduce apixaban to prophylactic dose (2.5mg twice daily) for extended therapy*- While **dose reduction** is a strategy for extended VTE prophylaxis, it is typically indicated for patients deemed to require **lifelong anticoagulation** who have a high risk of bleeding.- This patient does not meet the criteria for **extended secondary prevention** based on a single VTE and a heterozygous Factor V Leiden status.*Switch to aspirin 75mg daily for long-term secondary prevention*- **Aspirin** is significantly less effective than anticoagulants for preventing recurrent VTE and is not first-line therapy for **secondary prevention**.- There is no clinical indication to transition to antiplatelet therapy after completing the treatment for **venous thromboembolism** in this scenario.

Question 91: A 28-year-old woman presents with fatigue and frequent infections. Blood tests show: Hb 82 g/L, MCV 102 fL, WCC 3.1 × 10⁹/L, neutrophils 1.2 × 10⁹/L, platelets 95 × 10⁹/L, reticulocytes 35 × 10⁹/L (normal 50-100). Blood film shows hypersegmented neutrophils. She follows a strict vegan diet and takes no supplements. What is the most appropriate initial investigation?

A. Serum vitamin B12 and red cell folate levels (Correct Answer)
B. Bone marrow aspiration and trephine
C. Anti-intrinsic factor antibodies and anti-parietal cell antibodies
D. Serum methylmalonic acid and homocysteine levels
E. HIV serology and viral screen

Explanation: ***Serum vitamin B12 and red cell folate levels*** - The patient presents with **macrocytic anemia** (MCV 102 fL), **pancytopenia** (low WCC, neutrophils, platelets), and **hypersegmented neutrophils**, which are classic features of **megaloblastic anemia** typically caused by B12 or folate deficiency. - Given her **strict vegan diet** without supplementation, measuring serum levels is the most appropriate first-line step to confirm a nutritional deficiency before more invasive tests or investigating other causes.*Bone marrow aspiration and trephine* - While marrow examination would show diagnostic **megaloblastic maturation**, this is an **invasive procedure** that is not indicated as an initial investigation for suspected nutritional deficiency. - It is generally reserved for cases where initial serology is inconclusive or if a primary **bone marrow disorder** (like MDS) is suspected after ruling out nutritional causes.*Anti-intrinsic factor antibodies and anti-parietal cell antibodies* - These tests are used to diagnose **pernicious anemia**, an autoimmune cause of vitamin B12 malabsorption. - Since the patient has a clear **dietary risk factor** (veganism), confirming the deficiency level precedes testing for specific autoimmune etiologies, making it a second-line investigation.*Serum methylmalonic acid and homocysteine levels* - These are highly sensitive **metabolic markers** used to confirm tissue-level deficiency when direct serum B12 and folate levels are **borderline** or inconclusive. - They are considered **second-line tests** used for diagnostic clarification if initial serum B12 and folate results are ambiguous, not the absolute initial investigation.*HIV serology and viral screen* - Although HIV can cause **pancytopenia**, the pathognomonic finding of **hypersegmented neutrophils** along with macrocytic anemia strongly points toward a megaloblastic process rather than a viral infection. - Nutritional deficiency is far more consistent with the specific hematological findings and the patient's diet than an acute or chronic viral syndrome.

Question 92: A 42-year-old woman with newly diagnosed rheumatoid arthritis is being considered for methotrexate therapy. She has a history of obesity (BMI 34 kg/m²), non-alcoholic fatty liver disease with ALT 78 U/L (normal <40), and type 2 diabetes. She drinks no alcohol. What is the most appropriate action regarding methotrexate initiation?

A. Start methotrexate with more frequent liver function monitoring due to pre-existing liver disease (Correct Answer)
B. Defer methotrexate and use hydroxychloroquine until liver function normalizes
C. Arrange liver biopsy or transient elastography before deciding on methotrexate
D. Contraindicate methotrexate permanently due to liver disease and use alternative DMARD
E. Start methotrexate at reduced dose of 5mg weekly and monitor closely

Explanation: ***Start methotrexate with more frequent liver function monitoring due to pre-existing liver disease***- **Methotrexate** is the first-line DMARD for **Rheumatoid Arthritis**; while it carries a risk of **hepatotoxicity**, it is not contraindicated unless ALT is >3x the upper limit of normal or **cirrhosis** is present.- This patient has risk factors for liver injury (**obesity**, **diabetes**, **NAFLD**), so the most appropriate strategy is initiation with **frequent liver enzyme monitoring** every 2–4 weeks initially.*Defer methotrexate and use hydroxychloroquine until liver function normalizes*- **Hydroxychloroquine** is generally reserved for mild disease or as an adjunct; delaying the gold-standard treatment, **methotrexate**, can lead to irreversible **joint destruction**.- In **NAFLD**, liver enzymes may not normalize without significant weight loss, making this an impractical clinical strategy for controlling active **RA**.*Arrange liver biopsy or transient elastography before deciding on methotrexate*- Routine **liver biopsy** or **FibroScan** is not required before starting methotrexate even in patients with **NAFLD**, provided enzymes are only mildly elevated (ALT 78 U/L is <2x normal).- Advanced imaging or histology is reserved for cases where there is clinical suspicion of **advanced fibrosis** or **cirrhosis**, which is not indicated by an ALT of 78 U/L.*Contraindicate methotrexate permanently due to liver disease and use alternative DMARD*- **NAFLD** is a relative, not an absolute, contraindication; current guidelines permit methotrexate use in these patients if they abstain from **alcohol** and undergo close surveillance.- Permanent avoidance unnecessarily limits therapeutic options for a patient with multiple **metabolic risk factors** who may benefit from aggressive RA control.*Start methotrexate at reduced dose of 5mg weekly and monitor closely*- A starting dose of 5mg is considered **sub-therapeutic** for managing **Rheumatoid Arthritis** effectively; the standard starting dose is typically 10–15mg weekly.- While caution is needed, **dose reduction** is less critical than **frequent monitoring** and supplemental **folic acid** to mitigate toxicity.

Question 93: A 68-year-old woman with chronic kidney disease stage 3b (eGFR 38 mL/min/1.73m²) presents with fatigue. Blood tests show: Hb 97 g/L, MCV 86 fL, WCC 6.2 × 10⁹/L, platelets 245 × 10⁹/L, ferritin 185 μg/L, transferrin saturation 18%, serum iron 8 μmol/L, CRP 4 mg/L. She has no history of bleeding. What is the most likely diagnosis?

A. Functional iron deficiency from chronic kidney disease (Correct Answer)
B. Anaemia of chronic disease
C. Early myelodysplastic syndrome
D. Absolute iron deficiency requiring investigation
E. Combined B12 and folate deficiency

Explanation: ***Functional iron deficiency from chronic kidney disease***- This patient demonstrates **functional iron deficiency (FID)**, where iron stores are present (ferritin >100 μg/L) but cannot be mobilized for erythropoiesis, evidenced by a **transferrin saturation (TSAT) <20%**.- In **CKD**, increased **hepcidin** levels sequester iron in macrophages, limiting its availability for the bone marrow despite adequate total body iron.*Anaemia of chronic disease*- While related, this specifically refers to a **normocytic anaemia** where high inflammatory states fully block iron usage; however, the term **Functional Iron Deficiency** more accurately describes the iron status in CKD management guidelines.- This patient's **low CRP** suggests that a generalized acute inflammatory response is not the primary driver compared to the underlying renal pathology.*Early myelodysplastic syndrome*- **Myelodysplastic syndrome (MDS)** typically presents with **macrocytosis** (high MCV) or other cytopenias like thrombocytopenia or leukopenia.- This patient has a **normocytic MCV (86 fL)** and normal white cell and platelet counts, making a primary bone marrow disorder less likely.*Absolute iron deficiency requiring investigation*- **Absolute iron deficiency** is characterized by a **low ferritin** level (typically <30 μg/L), whereas this patient has a ferritin of 185 μg/L.- The absence of a **bleeding history** and the high ferritin level indicate the issue is iron distribution rather than a total body deficit.*Combined B12 and folate deficiency*- Deficiency in **B12 or folate** typically leads to a **macrocytic anaemia** with an elevated MCV.- A combined deficiency might result in a normocytic picture, but there are no clinical or biochemical markers provided to suggest **megaloblastic** changes.

Question 94: A 35-year-old man presents with acute onset pain and swelling of his left wrist. He had a similar episode affecting his right ankle 3 months ago which resolved spontaneously. He has hypertension treated with bendroflumethiazide. Examination reveals an effusion of the left wrist with erythema. Joint aspiration shows negatively birefringent needle-shaped crystals. Serum urate is 0.52 mmol/L (normal <0.42). What is the most appropriate long-term management?

A. Start allopurinol 100mg daily and increase gradually to achieve target urate <0.30 mmol/L (Correct Answer)
B. Continue current management and only start urate-lowering therapy if he has further attacks
C. Switch bendroflumethiazide to an alternative antihypertensive and monitor serum urate
D. Start febuxostat 80mg daily as first-line urate-lowering therapy
E. Advise lifestyle modifications alone as serum urate is only marginally elevated

Explanation: ***Start allopurinol 100mg daily and increase gradually to achieve target urate <0.30 mmol/L*** - Long-term management with **urate-lowering therapy (ULT)** is indicated due to **recurrent gout attacks** (two episodes) and confirmed diagnosis by **negatively birefringent needle-shaped crystals**. - **Allopurinol** is the first-line ULT; it should be started at a low dose (e.g., **100mg daily**) and titrated upwards to achieve a target serum urate of **<0.30 mmol/L** to dissolve existing crystals and prevent new ones. *Continue current management and only start urate-lowering therapy if he has further attacks* - This approach is inappropriate because the patient has already experienced **recurrent gout attacks** and has confirmed hyperuricemia, which are clear indications for initiating **urate-lowering therapy**. - Delaying ULT increases the risk of further painful flares, **tophi formation**, and progressive **joint damage**. *Switch bendroflumethiazide to an alternative antihypertensive and monitor serum urate* - While **thiazide diuretics** like bendroflumethiazide can exacerbate hyperuricemia, simply switching the antihypertensive is insufficient as the sole long-term management for established and **recurrent gout**. - Although changing to agents like **losartan** or **calcium channel blockers** is beneficial, the patient's significantly elevated urate and history of attacks necessitate active **pharmacological urate lowering** beyond just drug modification. *Start febuxostat 80mg daily as first-line urate-lowering therapy* - **Febuxostat** is typically reserved as a **second-line** urate-lowering therapy for patients who cannot tolerate allopurinol or do not achieve target urate levels with allopurinol. - It is not the initial preferred therapy for most patients due to its higher cost and potential **cardiovascular risk concerns** in certain populations compared to allopurinol. *Advise lifestyle modifications alone as serum urate is only marginally elevated* - A serum urate level of **0.52 mmol/L** is not marginally elevated; it is significantly above the saturation point of urate (0.42 mmol/L) and is associated with crystal formation and gout attacks. - While **lifestyle modifications** are important adjuncts, they typically only reduce serum urate by a modest amount (**10-15%**) and are insufficient as monotherapy for patients with established, recurrent gout and such high urate levels.

Question 95: A 56-year-old woman with established rheumatoid arthritis presents with sudden onset severe headache, fever, and neck stiffness. She has been taking methotrexate 20mg weekly and adalimumab fortnightly. Her temperature is 38.7°C, heart rate 105 bpm, blood pressure 128/82 mmHg. She is photophobic and has no focal neurological signs. CT head shows no abnormality. What is the most appropriate immediate management?

A. Perform lumbar puncture and administer broad-spectrum antibiotics immediately (Correct Answer)
B. Perform lumbar puncture first, then start antibiotics if CSF analysis is abnormal
C. Administer IV corticosteroids for possible CNS vasculitis
D. Arrange urgent MRI brain to exclude abscess before lumbar puncture
E. Start oral aciclovir and await lumbar puncture results

Explanation: ***Perform lumbar puncture and administer broad-spectrum antibiotics immediately*** - The patient presents with the classic triad of **meningitis** (fever, headache, neck stiffness, photophobia), and her immunosuppressed state due to **methotrexate** and **adalimumab** significantly increases the risk of serious infection, including bacterial meningitis. - Immediate **lumbar puncture** (after a normal CT head, which rules out contraindications like mass effect) followed by prompt administration of **broad-spectrum antibiotics** is crucial to improve outcomes and reduce mortality in suspected bacterial meningitis. *Perform lumbar puncture first, then start antibiotics if CSF analysis is abnormal* - Delaying the initiation of **antibiotics** until after **CSF analysis** results are available is a critical error in suspected bacterial meningitis, as treatment delay significantly increases mortality. - **Empirical broad-spectrum antibiotics** should be started as soon as possible after obtaining cultures (blood and CSF), or even before LP if there is a delay in performing it. *Administer IV corticosteroids for possible CNS vasculitis* - While **CNS vasculitis** is a consideration in rheumatoid arthritis, the acute onset of high fever and meningeal signs points strongly towards an **infectious process** (meningitis), which requires immediate antibiotic intervention. - **Corticosteroids** (like dexamethasone) are used as **adjunctive therapy** in specific cases of bacterial meningitis to reduce inflammation and neurological sequelae, but they are not the primary treatment and do not replace antibiotics. *Arrange urgent MRI brain to exclude abscess before lumbar puncture* - An **urgent CT head** has already been performed and shown no abnormalities, which is sufficient to proceed safely with a **lumbar puncture** in the absence of focal neurological signs or signs of raised intracranial pressure (e.g., papilledema). - Waiting for an **MRI brain** would cause an unacceptable and potentially fatal delay in the diagnosis and treatment of acute bacterial meningitis, where every hour counts. *Start oral aciclovir and await lumbar puncture results* - Although **viral meningitis/encephalitis** is a possibility, the patient's severe symptoms, high fever, and immunosuppressed state make **bacterial meningitis** a more immediate and life-threatening concern, demanding prompt empirical antibiotic therapy. - If **viral encephalitis** were suspected (e.g., HSV), **intravenous aciclovir** would be indicated, not oral, and it should never delay or replace the empirical treatment for bacterial meningitis when bacterial infection is a strong possibility.

Question 96: A 66-year-old woman presents with fatigue. Blood tests show: Hb 78 g/L, MCV 72 fL, ferritin 285 mcg/L, CRP 68 mg/L, ESR 85 mm/hr. She has a 3-month history of pain and stiffness in her shoulders and hips, worse in the morning. Creatine kinase is normal. What is the underlying mechanism of her anaemia?

A. Chronic blood loss leading to iron depletion
B. Hepcidin-mediated reduction in iron availability for erythropoiesis (Correct Answer)
C. Autoimmune destruction of red blood cells
D. Folate deficiency due to increased cellular turnover
E. Direct bone marrow suppression by inflammatory cytokines

Explanation: ***Hepcidin-mediated reduction in iron availability for erythropoiesis*** - The patient's symptoms (pain and stiffness in shoulders and hips, worse in the morning) and high inflammatory markers (**CRP 68 mg/L**, **ESR 85 mm/hr**) are consistent with **polymyalgia rheumatica**, an inflammatory condition. - Inflammation leads to increased **hepcidin** production, which blocks **ferroportin**, thereby trapping iron within macrophages and hepatocytes and reducing its availability for erythropoiesis, causing **anaemia of chronic disease** (ACD) which can be microcytic. *Chronic blood loss leading to iron depletion* - **Iron deficiency anaemia** due to chronic blood loss would typically present with a **low ferritin** level, reflecting depleted iron stores. - This patient has a **high ferritin** (285 mcg/L), which is an acute-phase reactant and is elevated in inflammatory conditions, indicating iron sequestration rather than depletion. *Autoimmune destruction of red blood cells* - **Autoimmune haemolytic anaemia** usually presents with **normocytic** or **macrocytic anaemia** (due to reticulocytosis) and signs of haemolysis like elevated bilirubin or LDH. - The patient's anaemia is **microcytic** (MCV 72 fL) and there are no other indicators of haemolysis. *Folate deficiency due to increased cellular turnover* - **Folate deficiency** causes **macrocytic anaemia** (MCV > 100 fL) because of impaired DNA synthesis affecting erythroblast maturation. - The patient's anaemia is distinctly **microcytic** (MCV 72 fL), which contradicts a diagnosis of folate deficiency. *Direct bone marrow suppression by inflammatory cytokines* - While inflammatory cytokines can directly suppress erythropoiesis, this typically results in **normocytic anaemia**. - The **microcytic** nature of the anaemia in this context, combined with high ferritin and inflammatory markers, is primarily driven by restricted iron availability due to **hepcidin**.

Question 97: A 58-year-old man presents with sudden onset pain and swelling of his left knee. He is currently being treated for acute myeloid leukaemia with chemotherapy and his WCC is 1.2 × 10⁹/L. He is pyrexial at 38.4°C. Joint aspiration yields turbid fluid with WCC 45,000 cells/μL (90% neutrophils). Gram stain is pending. Polarised light microscopy shows no crystals. What is the most appropriate initial antibiotic therapy?

A. IV flucloxacillin
B. IV flucloxacillin and IV gentamicin
C. IV vancomycin and IV gentamicin
D. IV ceftriaxone
E. IV piperacillin-tazobactam (Correct Answer)

Explanation: ***IV piperacillin-tazobactam*** - This patient presents with **septic arthritis** in the context of **neutropenic sepsis** (WCC 1.2 × 10⁹/L), requiring **broad-spectrum empirical coverage** for both Gram-positive and **Gram-negative organisms**, especially **Pseudomonas aeruginosa**. - **Piperacillin-tazobactam** is a potent **antipseudomonal beta-lactam** that provides comprehensive coverage, making it a first-line choice for **febrile neutropenia** and suspected sepsis in immunocompromised patients pending culture results. *IV flucloxacillin* - While it provides excellent coverage for **methicillin-sensitive Staphylococcus aureus**, a common cause of septic arthritis, it offers **no coverage for Gram-negative bacteria**. - In a **neutropenic patient** with sepsis, empirical therapy must cover **Gram-negative pathogens**, including *Pseudomonas*, to prevent rapid clinical deterioration. *IV flucloxacillin and IV gentamicin* - This combination adds **Gram-negative coverage** via **gentamicin**, but it's generally not the preferred first-line for **febrile neutropenia** over a single antipseudomonal beta-lactam. - **Gentamicin** is an **aminoglycoside** associated with potential **nephrotoxicity** and requires therapeutic drug monitoring, which is less ideal for initial empirical therapy compared to a broad-spectrum beta-lactam. *IV vancomycin and IV gentamicin* - This regimen covers **MRSA** (via vancomycin) and Gram-negative bacteria (via gentamicin), but **vancomycin** is typically reserved for suspected MRSA infections, which is not strongly indicated here. - Empiric coverage for **febrile neutropenia** usually prioritizes broad-spectrum Gram-negative coverage, including **Pseudomonas**, with an antipseudomonal beta-lactam, before adding vancomycin without specific risk factors for MRSA. *IV ceftriaxone* - **Ceftriaxone** is a third-generation cephalosporin effective against many Gram-positive and Gram-negative bacteria, but it **lacks activity against *Pseudomonas aeruginosa***. - In **neutropenic sepsis**, **Pseudomonas coverage** is critical due to its high virulence and prevalence in this patient population, making ceftriaxone insufficient as monotherapy.

Question 98: A 33-year-old woman presents with fatigue and is found to have Hb 87 g/L, MCV 68 fL, ferritin 8 mcg/L (normal 15-300). She has no GI symptoms. Menstrual history reveals heavy periods with flooding for 5-7 days each month. She underwent bidirectional endoscopy 3 years ago for similar anaemia, which was normal. What is the most appropriate next management step?

A. Arrange repeat upper and lower GI endoscopy
B. Start oral iron supplementation and refer to gynaecology (Correct Answer)
C. Arrange CT abdomen and pelvis
D. Request video capsule endoscopy
E. Arrange small bowel MRI

Explanation: ***Start oral iron supplementation and refer to gynaecology*** - The patient presents with **iron deficiency anaemia** (low Hb, MCV, and ferritin) and a significant history of **menorrhagia**, which is the most likely cause of her iron loss. - Guidelines suggest addressing the obvious physiological source first; therefore, **oral iron** replaces stores while a **gynaecology referral** manages the underlying heavy menstrual bleeding. *Arrange repeat upper and lower GI endoscopy* - **Bidirectional endoscopy** was normal 3 years ago, and the patient has no new **gastrointestinal symptoms** to warrant immediate repeat invasive testing. - In premenopausal women, **menstrual blood loss** is statistically more likely than GI pathology if alarming red-flag symptoms are absent. *Arrange CT abdomen and pelvis* - A **CT scan** is not the first-line investigation for **iron deficiency anaemia** unless there is clinical suspicion of malignancy or a specific abdominal mass. - It would provide limited information regarding the **mucosal lesions** or heavy periods already explained by the clinical history. *Request video capsule endoscopy* - **Video capsule endoscopy** is reserved for investigating the **small bowel** after both upper and lower GI endoscopies have failed to find a source of occult bleeding. - It is not indicated here as the patient has an identified potential source (**menorrhagia**) and no symptoms suggesting small bowel Crohn's or angiodysplasia. *Arrange small bowel MRI* - **Small bowel MRI** is typically used to assess for **inflammatory bowel disease** or structural abnormalities, which do not align with this patient's presentation. - Correcting the **iron deficiency** and managing the gynaecological cause is prioritized over specialized imaging of the small intestine.

Question 99: What is the mechanism of action of tranexamic acid in the management of acute bleeding?

A. Activates Factor VII in the coagulation cascade
B. Inhibits fibrinolysis by blocking plasminogen activation (Correct Answer)
C. Promotes platelet aggregation at sites of vascular injury
D. Increases synthesis of vitamin K-dependent clotting factors
E. Enhances thrombin generation through Factor Xa activation

Explanation: ***Inhibits fibrinolysis by blocking plasminogen activation***- **Tranexamic acid** is a synthetic lysine analog that competitively inhibits the binding of **plasminogen** to fibrin.- By preventing plasminogen from converting into **plasmin**, it stabilizes the fibrin clot and reduces the breakdown of existing clots, thereby controlling **acute bleeding**.*Activates Factor VII in the coagulation cascade*- This describes the mechanism of action of **recombinant activated Factor VII (rFVIIa)**, which is used in specific bleeding disorders or massive hemorrhage.- Tranexamic acid primarily acts as an **antifibrinolytic** agent and does not directly activate coagulation factors like Factor VII.*Promotes platelet aggregation at sites of vascular injury*- **Platelet aggregation** is driven by factors such as ADP, thromboxane A2, and interaction with von Willebrand factor and collagen, facilitated by glycoprotein receptors.- Tranexamic acid has no direct effect on **platelet function** or their aggregation at injury sites; its role is purely in **fibrinolysis inhibition**.*Increases synthesis of vitamin K-dependent clotting factors*- The synthesis of **vitamin K-dependent clotting factors** (II, VII, IX, X, protein C, protein S) occurs in the liver and requires vitamin K.- Tranexamic acid is not involved in the **synthesis** of these factors; it affects the breakdown of fibrin, not its formation via factor production.*Enhances thrombin generation through Factor Xa activation*- **Thrombin generation** is a key step in the coagulation cascade, largely mediated by **Factor Xa** converting prothrombin to thrombin.- Tranexamic acid does not enhance **thrombin generation** or activate Factor Xa; instead, it prevents the enzymatic degradation of already formed fibrin clots.

Question 100: A 39-year-old woman with established rheumatoid arthritis on methotrexate 25mg weekly develops progressive shortness of breath over 6 weeks. Examination reveals fine inspiratory crackles at both lung bases. Oxygen saturation is 92% on room air. Chest X-ray shows bilateral reticular shadowing. High-resolution CT chest shows ground-glass opacification and interstitial changes. What is the most appropriate immediate management?

A. Stop methotrexate, start high-dose prednisolone, refer urgently to respiratory team (Correct Answer)
B. Continue methotrexate, add azathioprine as steroid-sparing agent
C. Stop methotrexate, switch to hydroxychloroquine
D. Continue methotrexate, add prophylactic co-trimoxazole for pneumocystis coverage
E. Refer for urgent lung biopsy before making treatment changes

Explanation: ***Stop methotrexate, start high-dose prednisolone, refer urgently to respiratory team*** - The patient's presentation with progressive shortness of breath, hypoxia, fine inspiratory crackles, and HRCT findings of **ground-glass opacification** and **interstitial changes** in the context of **methotrexate** use strongly indicate **methotrexate-induced pneumonitis**, a severe hypersensitivity reaction. - Immediate management requires **stopping the offending agent** (methotrexate) and initiating **high-dose corticosteroids** (e.g., prednisolone) to rapidly suppress inflammation. Urgent referral to a respiratory team is crucial for specialized management of this potentially life-threatening condition. *Continue methotrexate, add azathioprine as steroid-sparing agent* - Continuing **methotrexate** is contraindicated as it is the most likely cause of the acute pulmonary toxicity; further administration could lead to irreversible lung damage or death. - **Azathioprine** is a slow-acting immunosuppressant and not an appropriate immediate treatment for acute, severe drug-induced pneumonitis. *Stop methotrexate, switch to hydroxychloroquine* - While stopping methotrexate is correct, **hydroxychloroquine** is a mild disease-modifying antirheumatic drug (DMARD) and has no role in the acute management of **interstitial lung disease** or drug-induced pneumonitis. - This approach critically omits **corticosteroid therapy**, which is essential for rapidly resolving the active inflammatory process in the lungs. *Continue methotrexate, add prophylactic co-trimoxazole for pneumocystis coverage* - Continuing **methotrexate** is dangerous when drug-induced **pulmonary toxicity** is suspected; the immediate priority is to remove the causative agent. - While **Pneumocystis jirovecii pneumonia (PJP)** is a differential, the clinical picture, imaging findings (ground-glass opacities), and history of methotrexate use are more consistent with drug-induced pneumonitis, demanding cessation and active treatment over prophylaxis alone. *Refer for urgent lung biopsy before making treatment changes* - An **urgent lung biopsy** is an invasive procedure that should not delay immediate, life-saving therapeutic interventions such as stopping the suspected drug and initiating **high-dose corticosteroids**. - The clinical and radiological findings provide sufficient evidence for a presumptive diagnosis of **methotrexate-induced pneumonitis**, warranting prompt treatment without delaying for definitive histological confirmation.

Question 101: A 71-year-old man with a mechanical mitral valve replacement on warfarin (target INR 2.5-3.5) requires elective total knee replacement surgery. His INR has been stable. What is the most appropriate perioperative anticoagulation management?

A. Continue warfarin throughout, aiming for INR 2.0-2.5 on day of surgery
B. Stop warfarin 5 days before surgery, start therapeutic LMWH, stop LMWH 24 hours pre-operatively (Correct Answer)
C. Stop warfarin 5 days before surgery, start prophylactic LMWH, stop LMWH 12 hours pre-operatively
D. Stop warfarin 3 days before surgery, no bridging anticoagulation required
E. Stop warfarin 5 days before surgery, start IV unfractionated heparin infusion, stop 4 hours pre-operatively

Explanation: ***Stop warfarin 5 days before surgery, start therapeutic LMWH, stop LMWH 24 hours pre-operatively***- Patients with a **mechanical mitral valve** are at **high thromboembolic risk** and require **therapeutic bridging** anticoagulation when warfarin is interrupted.- Guidelines recommend stopping **warfarin 5 days prior** to allow the INR to normalize, with the last dose of **therapeutic LMWH** given **24 hours before** the procedure to balance clotting and bleeding risks.*Continue warfarin throughout, aiming for INR 2.0-2.5 on day of surgery*- For **high-bleeding risk** procedures like total knee replacement, an INR of 2.0-2.5 poses a significant risk of **major perioperative hemorrhage**.- Warfarin should typically be stopped to achieve an **INR <1.5** for major orthopedic surgery.*Stop warfarin 5 days before surgery, start prophylactic LMWH, stop LMWH 12 hours pre-operatively*- **Prophylactic dosing** of LMWH is insufficient to prevent **thrombosis** of a mechanical mitral valve, which requires full systemic anticoagulation.- A **12-hour gap** is generally too short for therapeutic-dose LMWH before major surgery, increasing the risk of **wound hematoma**.*Stop warfarin 3 days before surgery, no bridging anticoagulation required*- Stopping warfarin only **3 days before** is often inadequate for the INR to reach the safe target of **<1.5** for surgery.- Omitting bridging in a patient with a **mechanical mitral valve** is contraindicated due to the severe risk of **valve thrombosis and embolic stroke**.*Stop warfarin 5 days before surgery, start IV unfractionated heparin infusion, stop 4 hours pre-operatively*- While **IV unfractionated heparin (UFH)** is a valid bridging option, especially in **renal failure**, LMWH is generally preferred for elective cases due to ease of outpatient administration.- This option is less common than LMWH for elective surgery in stable patients and requires **hospital admission** several days prior to the procedure.

Question 102: A 44-year-old woman presents with a 4-week history of bilateral hand pain and morning stiffness lasting 90 minutes. Examination reveals synovitis of the MCP and PIP joints bilaterally. Blood tests show: CRP 35 mg/L, ESR 42 mm/hr, rheumatoid factor negative, anti-CCP antibody negative. X-rays of hands show soft tissue swelling only. What is the most appropriate classification of her condition?

A. Definite rheumatoid arthritis requiring immediate DMARD therapy (Correct Answer)
B. Seronegative inflammatory arthritis, monitor clinically
C. Probable rheumatoid arthritis, start hydroxychloroquine
D. Osteoarthritis with inflammatory component
E. Viral arthropathy, manage conservatively

Explanation: ***Definite rheumatoid arthritis requiring immediate DMARD therapy*** - Under the **ACR/EULAR 2010 criteria**, the patient scores sufficiently for a diagnosis based on **symmetrical small joint involvement** (multiple MCP/PIP joints), elevated inflammatory markers (**ESR/CRP**), and clinical synovitis. - Early initiation of **DMARD therapy** (e.g., Methotrexate) is critical to prevent permanent **joint erosion** and improve long-term functional outcomes, even in **seronegative** cases.*Seronegative inflammatory arthritis, monitor clinically* - This approach risks missing the "**window of opportunity**" where early intervention can induce remission and prevent the progression of **radiographic damage**. - Approximately 15–20% of rheumatoid arthritis cases are **seronegative** (RF and anti-CCP negative), but they still require aggressive management similar to seropositive cases.*Probable rheumatoid arthritis, start hydroxychloroquine* - The clinical presentation (symmetrical small joint synovitis, prolonged morning stiffness, elevated inflammatory markers) meets the **ACR/EULAR 2010 criteria** for **definite RA**, not just probable. - **Hydroxychloroquine** is generally a milder DMARD, often insufficient as monotherapy for active RA with high inflammatory markers; stronger agents like **methotrexate** are typically preferred first-line for definite RA.*Osteoarthritis with inflammatory component* - Osteoarthritis typically involves the **DIP joints** and the first CMC joint, usually manifesting as stiffness lasting less than **30 minutes**. - This patient's **morning stiffness of 90 minutes**, symmetrical MCP/PIP involvement, and significantly elevated inflammatory markers are distinctive features of an **inflammatory synovitis** characteristic of RA, not degenerative disease.*Viral arthropathy, manage conservatively* - **Viral arthropathy** (e.g., Parvovirus B19) usually has a more acute onset, often resolves within **2 to 3 weeks**, and may be associated with other systemic symptoms like a rash. - Symptoms persisting for **4 weeks** with significantly raised inflammatory markers and prominent, symmetrical synovitis are more indicative of a chronic **autoimmune process** like RA, rather than a self-limiting viral infection.

Question 103: A 52-year-old woman is diagnosed with iron deficiency anaemia. Upper GI endoscopy shows mild gastritis with no other abnormality. Colonoscopy is normal. She has regular menstrual periods. Coeliac serology (tissue transglutaminase antibody) is negative. She takes no regular medications. What is the most appropriate next investigation?

A. CT abdomen and pelvis
B. Video capsule endoscopy
C. Repeat upper GI endoscopy with duodenal biopsies (Correct Answer)
D. Haemoglobin electrophoresis
E. Reassure and treat with oral iron replacement only

Explanation: ***Repeat upper GI endoscopy with duodenal biopsies***- In a patient with **iron deficiency anaemia (IDA)** and negative coeliac serology, **duodenal biopsies** are crucial to exclude **seronegative coeliac disease** or other causes of malabsorption, which can be missed on visual inspection alone.- Current guidelines recommend obtaining duodenal biopsies during upper GI endoscopy for unexplained IDA, even if the mucosa appears normal, to detect subtle mucosal changes like **villous atrophy**.*CT abdomen and pelvis*- This imaging modality is primarily for evaluating **organ structures** and **masses**, and has a low sensitivity for detecting subtle mucosal abnormalities or inflammatory processes, which are key in IDA investigation.- It is generally not the initial investigation for **unexplained IDA** where mucosal pathology or bleeding from the GI tract is suspected after initial endoscopy.*Video capsule endoscopy*- This investigation is typically reserved for evaluating the **small bowel** for causes of obscure GI bleeding or malabsorption *after* both upper and lower endoscopies (including duodenal biopsies) have been unrevealing.- It should not precede a thorough endoscopic and histological assessment of the duodenum for conditions like **coeliac disease**, which can have focal or patchy involvement.*Haemoglobin electrophoresis*- This test is used to diagnose **haemoglobinopathies** (e.g., thalassemia, sickle cell disease) which cause microcytic anaemia due to abnormal haemoglobin production, not true **iron deficiency**.- Since the patient has a confirmed diagnosis of **iron deficiency anaemia**, investigating for structural haemoglobin variants is not indicated at this stage.*Reassure and treat with oral iron replacement only*- While the patient has regular menstrual periods, at 52 years old, **gastrointestinal blood loss** (even occult) or **malabsorption** must be thoroughly excluded as potential causes of IDA.- Failing to investigate the GI tract adequately in a patient with unexplained IDA can lead to missing significant underlying **pathology**, including malignancy.

Question 104: A 67-year-old man with psoriatic arthritis has failed treatment with methotrexate and leflunomide. He has extensive peripheral joint involvement affecting hands, wrists, and feet with significant functional impairment. He has a history of latent tuberculosis diagnosed 15 years ago for which he completed a full course of treatment. Chest X-ray is normal. What is the most appropriate next step before starting anti-TNF therapy?

A. Proceed directly to anti-TNF therapy without further TB screening
B. Perform interferon-gamma release assay (IGRA) only
C. Perform tuberculin skin test (Mantoux test) only
D. Perform IGRA and repeat chest X-ray, commence isoniazid prophylaxis if IGRA positive (Correct Answer)
E. CT chest to exclude active tuberculosis

Explanation: ***Perform IGRA and repeat chest X-ray, commence isoniazid prophylaxis if IGRA positive*** - Screening for **latent tuberculosis (LTBI)** is mandatory before starting **TNF inhibitors** because these drugs significantly increase the risk of **TB reactivation**. - Even with a history of treated LTBI, a current assessment using **IGRA** and imaging ensures no recent reinfection or active disease is present before suppressing the immune system.*Proceed directly to anti-TNF therapy without further TB screening* - This is unsafe as the risk of **disseminated tuberculosis** or **miliary TB** is high in patients on anti-TNF therapy with undetected latent infection. - Professional guidelines require a fresh clinical and laboratory assessment of **TB status** immediately prior to the initiation of biologic therapy.*Perform interferon-gamma release assay (IGRA) only* - While IGRA is a crucial part of the screening process, it should be paired with a **clinical evaluation** and **radiological assessment** to rule out active disease. - A single test is insufficient to fully evaluate the risk; a **chest X-ray** is required to look for signs of old or active pulmonary tuberculosis.*Perform tuberculin skin test (Mantoux test) only* - The **Tuberculin Skin Test (TST)** can yield **false-positive** results in patients who have had a prior **BCG vaccination**. - **IGRA** is generally preferred over TST in older patients or those previously vaccinated, as it is more specific and not affected by the BCG status.*CT chest to exclude active tuberculosis* - A **CT chest** is not a routine screening tool and is reserved for cases where the **chest X-ray** is abnormal or clinical suspicion of active TB remains high. - Subjecting a patient to higher doses of **radiation** via CT is unnecessary if the patient is asymptomatic and the screening chest X-ray is normal.

Question 105: A 29-year-old woman presents at 10 weeks gestation in her first pregnancy. She has a history of two previous unprovoked deep vein thromboses, the most recent being 18 months ago. She completed 6 months of anticoagulation with rivaroxaban after the last event. Thrombophilia screening performed 3 months after stopping anticoagulation showed heterozygous Factor V Leiden mutation. What is the most appropriate management?

A. Low-dose aspirin 75mg daily throughout pregnancy
B. Prophylactic dose low molecular weight heparin antenatally and for 6 weeks postpartum
C. Therapeutic dose low molecular weight heparin antenatally and for 6 weeks postpartum (Correct Answer)
D. Warfarin throughout pregnancy with target INR 2-3
E. Clinical surveillance only with compression stockings

Explanation: ***Therapeutic dose low molecular weight heparin antenatally and for 6 weeks postpartum*** - Patients with a history of **two or more previous unprovoked VTEs** are classified as high risk and require **therapeutic dose LMWH** throughout the pregnancy and the puerperium. - The addition of a **thrombophilia** (heterozygous Factor V Leiden) further increases the risk, necessitating full anticoagulation to prevent life-threatening recurrence. *Low-dose aspirin 75mg daily throughout pregnancy* - Aspirin is primarily used for the prevention of **pre-eclampsia** or in **antiphospholipid syndrome**; it is insufficient for preventing **venous thromboembolism**. - It does not provide the potent anticoagulant effect required for someone with a history of **recurrent unprovoked VTE**. *Prophylactic dose low molecular weight heparin antenatally and for 6 weeks postpartum* - While LMWH is the correct agent, a **prophylactic dose** is reserved for those with a single VTE or lower risk factors; it is insufficient for **recurrent unprovoked VTE** cases. - Guidelines specify that **recurrent unprovoked events** require higher intensity treatment (therapeutic or intermediate doses) due to the high risk of failure on standard prophylaxis. *Warfarin throughout pregnancy with target INR 2-3* - Warfarin is **teratogenic** and can cause **fetal warfarin syndrome** (including nasal hypoplasia and skeletal abnormalities) if used during the first trimester. - It also increases the risk of **fetal intracranial hemorrhage**; therefore, LMWH is the preferred anticoagulant as it does not cross the **placenta**. *Clinical surveillance only with compression stockings* - Surveillance alone is clinically dangerous for this patient given her history of **unprovoked VTE** and a confirmed **Factor V Leiden mutation**. - Compression stockings provide only mild risk reduction for **post-thrombotic syndrome** but are inadequate for the primary prevention of new clots in high-risk pregnancies.

Question 106: A 62-year-old man presents with a swollen, painful right first metatarsophalangeal joint. Joint aspiration reveals needle-shaped negatively birefringent crystals under polarised light microscopy. Serum urate is 0.38 mmol/L (normal 0.2-0.45). He has hypertension treated with bendroflumethiazide 2.5mg daily and amlodipine 5mg daily. What is the most appropriate management of his antihypertensive therapy?

A. Continue current antihypertensive therapy unchanged
B. Stop bendroflumethiazide and increase amlodipine to 10mg daily (Correct Answer)
C. Stop amlodipine and increase bendroflumethiazide to 5mg daily
D. Stop both medications and start ramipril
E. Add losartan to current therapy

Explanation: ***Stop bendroflumethiazide and increase amlodipine to 10mg daily*** - **Thiazide diuretics** like **bendroflumethiazide** increase serum urate levels by reducing renal excretion; they should be discontinued in patients presenting with **gout**. - Increasing the dose of **amlodipine** is a practical strategy to maintain blood pressure control while removing a known precipitant of the patient's **monosodium urate crystals**. *Continue current antihypertensive therapy unchanged* - Continuing **bendroflumethiazide** maintains a high risk for recurrent **gout flares** due to its inhibitory effect on urate excretion. - A **normal serum urate** during an acute attack is common due to urate deposition in the joint and does not justify continuing a causative medication. *Stop amlodipine and increase bendroflumethiazide to 5mg daily* - Increasing the dose of **bendroflumethiazide** would worsen **hyperuricaemia** and likely exacerbate the patient's joint inflammation. - **Amlodipine** is urate-neutral and does not need to be stopped; removing it while increasing a diuretic is contraindicated in this clinical scenario. *Stop both medications and start ramipril* - Stopping both medications unnecessarily risks a **hypertensive crisis** or poor long-term pressure control when only the thiazide is problematic. - While **ACE inhibitors** like **ramipril** are urate-neutral, there is no clinical indication to discontinue the tolerated **amlodipine**. *Add losartan to current therapy* - Although **losartan** has beneficial **uricosuric properties**, adding it without stopping the **bendroflumethiazide** fails to address the underlying drug-induced cause. - Polypharmacy should be avoided; the priority in **gout management** is the removal of offending agents before adding more antihypertensive medications.

Question 107: A 75-year-old woman is found to have the following blood results during investigation for fatigue: Hb 98 g/L, MCV 105 fL, WCC 4.5 × 10⁹/L, platelets 220 × 10⁹/L. Serum vitamin B12 is 185 ng/L (normal 200-900), serum folate is normal. She has no neurological symptoms. Blood film shows hypersegmented neutrophils. Intrinsic factor antibodies are negative. What is the most appropriate next investigation?

A. Schilling test
B. Anti-parietal cell antibodies
C. Upper gastrointestinal endoscopy
D. Serum methylmalonic acid and homocysteine levels (Correct Answer)
E. Bone marrow biopsy

Explanation: ***Serum methylmalonic acid and homocysteine levels*** - These metabolic markers are the most appropriate next step when **vitamin B12 levels** are in the **borderline range** (typically 150–400 pg/mL) to confirm a functional cellular deficiency. - An elevation in **methylmalonic acid (MMA)** is highly specific for Vitamin B12 deficiency, whereas **homocysteine** is elevated in both B12 and folate deficiencies. *Schilling test* - This was historically used to determine the cause of **vitamin B12 malabsorption**, but it is now largely obsolete and rarely available in clinical practice. - It involves the use of **radiolabeled B12** and does not help in the initial confirmation of a borderline deficiency state. *Anti-parietal cell antibodies* - While these have high **sensitivity** (approx. 90%) for **pernicious anemia**, they have very low specificity and are frequently positive in other autoimmune conditions or healthy elderly patients. - Confirming the deficiency itself with **metabolic markers** is prioritized over testing for these low-specificity antibodies, especially when **intrinsic factor antibodies** are negative. *Upper gastrointestinal endoscopy* - This may be indicated later to screen for **gastric adenocarcinoma** or **carcinoid tumors** if **pernicious anemia** is confirmed due to associated **atrophic gastritis**. - It is not a diagnostic tool for confirming the underlying **macrocytic anemia** or vitamin deficiency state itself. *Bone marrow biopsy* - While a biopsy would show **megaloblastic erythropoiesis**, it is an invasive procedure that is unnecessary when peripheral findings like **hypersegmented neutrophils** and **macrocytosis** are present. - Diagnostic confirmation should be achieved through less invasive **biochemical testing** of B12 metabolites before considering marrow examination.

Question 108: A 48-year-old man with chronic tophaceous gout on allopurinol 300mg daily presents with an acute flare affecting his right knee. He has stage 3 chronic kidney disease (eGFR 45 mL/min/1.73m²) and a history of peptic ulcer disease 5 years ago. He is not currently taking a proton pump inhibitor. What is the most appropriate treatment for this acute flare?

A. Increase allopurinol to 600mg daily
B. Colchicine 500 micrograms twice daily
C. Naproxen 500mg twice daily with omeprazole 20mg daily
D. Intra-articular corticosteroid injection to the affected knee (Correct Answer)
E. Stop allopurinol and start febuxostat

Explanation: ***Intra-articular corticosteroid injection to the affected knee*** - **Intra-articular steroids** are the treatment of choice for a **monoarticular gout flare** when systemic options like NSAIDs or colchicine are contraindicated due to **Stage 3 CKD** or GI risks. - This approach provides rapid, localized anti-inflammatory relief without increasing the risk of systemic side effects or worsening **renal function**. *Increase allopurinol to 600mg daily* - **Urate-lowering therapy (ULT)** should never be initiated or increased during an **acute flare**, as rapid changes in serum urate can prolong or worsen the attack. - Allopurinol dose adjustments should only be considered during **intercritical periods** once the acute inflammation has fully resolved. *Colchicine 500 micrograms twice daily* - Colchicine requires significant **dose reduction** or avoidance in patients with **chronic kidney disease (CKD)** due to the risk of accumulation and toxicity. - While still an option at very low doses in some CKD patients, it is less ideal than local steroids in this clinical scenario given the **eGFR of 45 mL/min**. *Naproxen 500mg twice daily with omeprazole 20mg daily* - **NSAIDs** are generally avoided in patients with **Stage 3 CKD** as they can cause further reduction in renal perfusion and acute kidney injury. - Additionally, despite the use of a PPI, a history of **peptic ulcer disease** makes NSAID therapy a higher-risk choice compared to local corticosteroids. *Stop allopurinol and start febuxostat* - **Stopping allopurinol** during a flare is unnecessary and may result in further fluctuations of urate levels, potentially extending the duration of the attack. - Switching to **febuxostat** is a strategy for long-term management of hyperuricaemia, not for the immediate treatment of **acute gouty inflammation**.

Question 109: A 55-year-old woman with rheumatoid arthritis treated with methotrexate 20mg weekly presents for routine monitoring. Her blood results show: Hb 115 g/L, WCC 3.2 × 10⁹/L, neutrophils 1.8 × 10⁹/L, platelets 180 × 10⁹/L, ALT 45 U/L (normal <40), AST 42 U/L (normal <40). She feels well with no symptoms. What is the most appropriate next step in management?

A. Continue methotrexate at current dose and repeat bloods in 2 weeks (Correct Answer)
B. Stop methotrexate immediately and repeat bloods in 1 week
C. Reduce methotrexate dose to 15mg weekly and repeat bloods in 2 weeks
D. Continue methotrexate and add folic acid 5mg three times weekly
E. Stop methotrexate and start sulfasalazine

Explanation: ***Continue methotrexate at current dose and repeat bloods in 2 weeks***- According to **British Society for Rheumatology (BSR)** guidelines, methotrexate should only be withheld if **neutrophils** are <1.5 × 10⁹/L or **transaminases** (ALT/AST) are >3x the upper limit of normal.- Since the patient’s neutrophils (1.8 × 10⁹/L) and liver enzymes are only **mildly elevated** (less than 2x normal), it is safe to continue treatment with closer **monitoring**.*Stop methotrexate immediately and repeat bloods in 1 week*- Stopping the medication is premature because the lab abnormalities do not meet the mandatory **toxicity thresholds** for cessation.- Abruptly stopping therapy without clinical indications like **severe leukopenia** or jaundice may lead to a flare of the patient's **rheumatoid arthritis**.*Reduce methotrexate dose to 15mg weekly and repeat bloods in 2 weeks*- Dose reduction is typically considered if there is a **persistent minor derangement** in blood results or if the patient is experiencing side effects.- For a first instance of borderline lab values in an asymptomatic patient, the standard approach is to repeat labs to confirm a trend before adjusting the **therapeutic dose**.*Continue methotrexate and add folic acid 5mg three times weekly*- **Folic acid** is already a standard co-prescription to reduce GI and mucosal side effects, but increasing its frequency does not replace the need for **repeat blood monitoring**.- While folic acid helps mitigate **methotrexate toxicity**, the immediate clinical priority is ensuring the **neutrophil count** remains stable.*Stop methotrexate and start sulfasalazine*- Switching to a different **DMARD** (Disease-Modifying Anti-Rheumatic Drug) like **sulfasalazine** is an escalation of management not warranted by these mild lab results.- Methotrexate is the **gold-standard** treatment, and switching is only indicated if the patient is intolerant or fails to respond after optimization.

Question 110: A 44-year-old woman with seropositive rheumatoid arthritis on methotrexate 25mg weekly and hydroxychloroquine 200mg twice daily continues to have active disease (DAS28 5.6). Before escalating to biologic therapy, her screening tests reveal: positive tuberculosis IGRA test, normal chest X-ray, HIV negative, hepatitis B surface antigen negative, hepatitis B core antibody positive, hepatitis B surface antibody positive. What is the most appropriate management plan?

A. Proceed with TNF inhibitor therapy as hepatitis B surface antibody is positive indicating immunity
B. Start antiviral prophylaxis with tenofovir before commencing biologic therapy
C. Check hepatitis B viral load and commence biologic only if undetectable (Correct Answer)
D. Commence TB prophylaxis, then start biologic therapy without hepatitis B intervention as core antibody indicates past cleared infection
E. Defer biologic therapy due to dual infection risk

Explanation: ***Check hepatitis B viral load and commence biologic only if undetectable*** - The patient has **resolved Hepatitis B** (HBsAg negative, anti-HBc positive, anti-HBs positive), but **HBV DNA** must be checked to rule out **occult infection** before starting biologics. - Monitoring **viral load** and transaminases is essential because immunosuppressive therapy, particularly **TNF inhibitors**, can trigger **HBV reactivation** in a core-antibody positive patient. *Proceed with TNF inhibitor therapy as hepatitis B surface antibody is positive indicating immunity* - While **anti-HBs** indicates immunity, the presence of **anti-HBc** means the virus persists in the liver as **covalently closed circular DNA (cccDNA)**. - Immunosuppression can lead to loss of immune control and **viral replication**, making simple observation without baseline viral load assessment risky. *Start antiviral prophylaxis with tenofovir before commencing biologic therapy* - **Routine prophylaxis** with **tenofovir** is generally mandatory for high-risk B-cell depleting agents like **Rituximab** in core-antibody positive patients. - For TNF inhibitors in patients with **resolved HBV**, a "monitor and preemptive treatment" strategy is often preferred over immediate **antiviral prophylaxis** unless HBV DNA is detectable. *Commence TB prophylaxis, then start biologic therapy without hepatitis B intervention as core antibody indicates past cleared infection* - While **TB prophylaxis** is necessary for the **latent TB** (positive IGRA), ignoring the HBV status is dangerous as "cleared" infection can still reactivate. - Guidelines mandate assessing the **HBV viral load** and performing periodic **liver function tests** to ensure safety during biologic therapy. *Defer biologic therapy due to dual infection risk* - **Active RA** (DAS28 5.6) warrants escalation of therapy, and both **latent TB** and **resolved HBV** can be managed concurrently with treatment. - Biologics are not contraindicated; they simply require **prophylactic TB treatment** and **HBV monitoring** or prophylaxis to prevent complications.

Question 111: A 54-year-old man with unprovoked pulmonary embolism diagnosed 2 years ago completed 6 months of anticoagulation and remained asymptomatic off treatment. He now presents with recurrent pulmonary embolism. Thrombophilia screening shows: protein C 68% (normal 70-140%), protein S 65% (normal 70-140%), antithrombin 92% (normal 80-120%), Factor V Leiden negative, prothrombin gene mutation negative, lupus anticoagulant negative. What is the most appropriate duration of anticoagulation following this recurrence?

A. 3 months, as this represents a provoked VTE (previous PE is the provoking factor)
B. 6 months, consistent with standard VTE treatment duration
C. 12 months, with reassessment of risk-benefit ratio before discontinuation
D. Lifelong anticoagulation (Correct Answer)
E. 3 months, followed by aspirin indefinitely

Explanation: ***Lifelong anticoagulation***- Patients with **recurrent unprovoked VTE** (venous thromboembolism) have a very high risk of further recurrence, estimated at approximately **15% per year** without treatment.- Current guidelines from **NICE** and **ESC** recommend **extended (indefinite) anticoagulation** for a second unprovoked event, provided the bleeding risk is not prohibitively high.*3 months, as this represents a provoked VTE (previous PE is the provoking factor)*- A previous VTE is not considered a "provoking factor" (like surgery or trauma); instead, it marks the patient as having a **high baseline risk** for future events.- Short-term treatment (3 months) is only appropriate for VTE provoked by a **major transient risk factor**, which is absent in this history.*6 months, consistent with standard VTE treatment duration*- While 6 months was once a common standard, it is now considered insufficient for **recurrent unprovoked** cases due to the high likelihood of relapse upon discontinuation.- The priority in this patient is **secondary prevention**, which necessitates a longer duration than the initial treatment of a first-time event.*12 months, with reassessment of risk-benefit ratio before discontinuation*- Fixed-term durations like 12 months are not recommended for **recurrent idiopathic** events because the underlying thrombotic tendency remains constant.- Although **annual reassessment** of bleeding risk is required, the default plan should be **permanent therapy** rather than planned discontinuation at one year.*3 months, followed by aspirin indefinitely*- **Aspirin** is significantly less effective than anticoagulants for preventing VTE recurrence and is not the standard of care for high-risk patients.- Anticoagulation (ideally with a **DOAC**) is preferred over aspirin as it offers superior protection against life-threatening **recurrent pulmonary embolism**.

Question 112: A 72-year-old woman is investigated for macrocytic anaemia. Blood tests show: Hb 89 g/L, MCV 112 fL, WCC 3.8 × 10⁹/L, platelets 142 × 10⁹/L, serum B12 102 ng/L (normal 200-900), red cell folate normal, serum folate normal. Blood film shows hypersegmented neutrophils. Intrinsic factor antibodies are positive. What is the most appropriate long-term management?

A. Oral cyanocobalamin 50 micrograms daily
B. Intramuscular hydroxocobalamin 1mg three times weekly for 2 weeks, then 1mg every 3 months
C. Intramuscular hydroxocobalamin 1mg on alternate days until no further improvement, then 1mg every 2 months (Correct Answer)
D. Oral B12 1000 micrograms daily indefinitely
E. Blood transfusion followed by oral B12 supplementation

Explanation: ***Intramuscular hydroxocobalamin 1mg on alternate days until no further improvement, then 1mg every 2 months*** - This patient has **pernicious anaemia** confirmed by macrocytic anaemia, low B12, and positive **intrinsic factor antibodies**, requiring parenteral therapy due to malabsorption. - The initial regimen rapidly replets B12 stores, and **1mg every 2 months** is a standard maintenance dose for pernicious anaemia, especially if severe or with neurological considerations. *Oral cyanocobalamin 50 micrograms daily* - This dose is too low to overcome the severe malabsorption due to the absence of **intrinsic factor** in pernicious anaemia. - **Oral supplementation** at this low dose is ineffective for initial or long-term management of B12 deficiency caused by malabsorption. *Intramuscular hydroxocobalamin 1mg three times weekly for 2 weeks, then 1mg every 3 months* - While the initial regimen is standard for B12 deficiency, the **1mg every 3 months** maintenance is typically for deficiency **without neurological features**. - For **pernicious anaemia**, especially with potential for severe symptoms, a more frequent maintenance (like every 2 months) is often preferred to ensure optimal B12 levels. *Oral B12 1000 micrograms daily indefinitely* - High-dose oral B12 can be absorbed via **passive diffusion**, but it is generally not the first-line or gold standard for confirmed autoimmune **pernicious anaemia**. - **Intramuscular injections** are preferred for pernicious anaemia to guarantee consistent therapeutic B12 levels and prevent long-term complications. *Blood transfusion followed by oral B12 supplementation* - **Blood transfusion** is usually reserved for **haemodynamic instability** or very severe anaemia (Hb < 70-80 g/L) and is not typically indicated for stable chronic anaemia at Hb 89 g/L. - **Oral B12 supplementation** is ineffective for long-term management of pernicious anaemia due to the persistent malabsorption caused by the lack of **intrinsic factor**.

Question 113: A 59-year-old man presents with severe pain and swelling of his right first metatarsophalangeal joint. He has a history of hypertension treated with bendroflumethiazide. Synovial fluid aspiration shows needle-shaped negatively birefringent crystals. His serum urate is 0.52 mmol/L (normal 0.2-0.45). What is the most important counselling point regarding long-term urate-lowering therapy?

A. Allopurinol should be started immediately at 300mg daily to prevent further attacks
B. Urate-lowering therapy is indicated because serum urate exceeds 0.45 mmol/L
C. Bendroflumethiazide should be stopped before considering urate-lowering therapy
D. Urate-lowering therapy should be started after acute attack resolves, with colchicine or NSAID prophylaxis for at least 1 month (Correct Answer)
E. Dietary modification alone is sufficient as serum urate is only marginally elevated

Explanation: ***Urate-lowering therapy should be started after acute attack resolves, with colchicine or NSAID prophylaxis for at least 1 month*** - Urate-lowering therapy (ULT) should typically be delayed until **2–4 weeks** after an acute gout attack has resolved to avoid exacerbating or prolonging the flare. - Co-prescribing **prophylactic colchicine** or a **low-dose NSAID** is essential for at least 3-6 months when starting ULT to prevent precipitation of further acute attacks due to rapid changes in serum urate levels. *Allopurinol should be started immediately at 300mg daily to prevent further attacks* - Starting allopurinol during an **acute gout attack** can worsen the inflammation and is generally contraindicated. - Allopurinol should be initiated at a **low dose** (e.g., 50-100mg daily), particularly in patients with renal impairment, and slowly titrated upwards to prevent hypersensitivity reactions and acute flares. *Urate-lowering therapy is indicated because serum urate exceeds 0.45 mmol/L* - While the patient's serum urate is elevated, the primary indication for ULT in this case is the **clinical diagnosis of gout** confirmed by synovial fluid crystals, not just a single high urate level. - Serum urate levels can paradoxically be **normal or even low** during an acute gout attack, making crystal analysis the definitive diagnostic test and guide for therapy. *Bendroflumethiazide should be stopped before considering urate-lowering therapy* - Thiazide diuretics, such as bendroflumethiazide, are known to **increase serum urate levels** and should ideally be switched to an alternative, like losartan or a calcium channel blocker. - However, stopping an essential antihypertensive is not a prerequisite for initiating ULT; ULT can be started while a thiazide is still being used, especially if the drug cannot be safely or easily switched. *Dietary modification alone is sufficient as serum urate is only marginally elevated* - Although beneficial, **dietary modifications** (e.g., reducing alcohol, purine-rich foods, sugary drinks) are rarely sufficient to achieve target urate levels (typically **<0.36 mmol/L**) to prevent recurrent attacks in patients with established gout. - This patient has a confirmed diagnosis of gout with crystalline evidence and a significantly elevated urate level, indicating the need for **pharmacological urate-lowering therapy**.

Question 114: A 41-year-old woman with antiphospholipid syndrome presents at 32 weeks gestation with left leg swelling and pain. Doppler ultrasound confirms proximal deep vein thrombosis. She has been on prophylactic enoxaparin 40mg daily throughout pregnancy. What is the most appropriate modification to her anticoagulation management?

A. Increase enoxaparin to treatment dose (1mg/kg twice daily) and continue until 6 weeks postpartum (Correct Answer)
B. Switch to warfarin with target INR 2-3
C. Continue prophylactic dose enoxaparin and add low-dose aspirin
D. Switch to fondaparinux
E. Increase enoxaparin to treatment dose and plan for epidural anaesthesia

Explanation: ***Increase enoxaparin to treatment dose (1mg/kg twice daily) and continue until 6 weeks postpartum*** - The confirmation of an **acute proximal deep vein thrombosis (DVT)** in a pregnant woman, especially with antiphospholipid syndrome and breakthrough despite prophylactic enoxaparin, mandates an immediate escalation to **therapeutic anticoagulation** with Low Molecular Weight Heparin (LMWH), typically **enoxaparin 1mg/kg twice daily**. - Anticoagulation for acute VTE in pregnancy must be maintained throughout the remainder of the pregnancy and continued for at least **6 weeks postpartum**, or for a minimum total duration of **3 months**, whichever is longer. *Switch to warfarin with target INR 2-3* - **Warfarin** is generally **contraindicated in pregnancy** as it readily **crosses the placenta**, leading to a risk of **fetal warfarin syndrome** (teratogenicity) during the first trimester and increased risk of **fetal hemorrhage** in later pregnancy. - **LMWH** is the preferred anticoagulant in pregnancy due to its non-placental transfer and superior safety profile for the fetus. *Continue prophylactic dose enoxaparin and add low-dose aspirin* - Continuing a **prophylactic dose** of enoxaparin is inadequate for managing an **established acute DVT**, especially when the clot occurred despite prophylaxis, indicating treatment failure. - While **low-dose aspirin** is often used in antiphospholipid syndrome for obstetric indications, it does not provide sufficient anticoagulation to treat an **acute proximal DVT**. *Switch to fondaparinux* - **Fondaparinux** is an indirect factor Xa inhibitor that may be used in VTE treatment, but it is typically reserved for patients with a documented **heparin allergy** or **heparin-induced thrombocytopenia (HIT)** due to more limited data regarding its safety and efficacy in pregnancy compared to LMWH. - **LMWH** remains the **gold standard** for treating VTE during pregnancy due to its extensive evidence base and favorable safety profile. *Increase enoxaparin to treatment dose and plan for epidural anaesthesia* - Increasing enoxaparin to a **treatment dose** is the correct immediate management for the DVT. However, planning for **epidural anaesthesia** concurrently with therapeutic anticoagulation is problematic. - Patients receiving **therapeutic doses of LMWH** require a mandatory waiting period (typically at least **24 hours**) after the last dose before neuraxial anesthesia can be safely performed to minimize the risk of **spinal hematoma**.

Question 115: A 63-year-old man presents with progressive fatigue over 6 months. Blood tests show: Hb 102 g/L, MCV 96 fL, WCC 5.8 × 10⁹/L, platelets 198 × 10⁹/L, reticulocyte count 0.8% (normal 0.5-2.5%), ferritin 180 mcg/L, B12 298 ng/L (normal 200-900), serum folate 6.8 mcg/L (normal 3-20). Blood film shows normochromic normocytic red cells with no abnormal cells. What is the most appropriate next investigation?

A. Bone marrow aspirate and trephine biopsy
B. Haemolysis screen including LDH, haptoglobin, and direct antiglobulin test
C. Comprehensive metabolic panel including renal function, liver function, and thyroid function (Correct Answer)
D. Serum erythropoietin level
E. Repeat full blood count in 2 weeks

Explanation: ***Comprehensive metabolic panel including renal function, liver function, and thyroid function***- This patient presents with a **normocytic normochromic anaemia** with a relatively low **reticulocyte count** (0.8% for Hb 102 g/L), which points towards a hypoproliferative cause rather than hemolysis or acute blood loss.- A comprehensive metabolic screen is the most appropriate next step to rule out common systemic causes such as **chronic kidney disease (CKD)**, **hypothyroidism**, or **liver disease**, which frequently present with this hematological profile.*Bone marrow aspirate and trephine biopsy*- This is an **invasive procedure** that should be reserved for cases where common systemic causes have been excluded or if there is stronger evidence of primary marrow failure or malignancy.- The absence of other **cytopenias** (normal WCC and platelets) and no abnormal cells on the blood film make marrow pathology less likely as the primary initial concern.*Haemolysis screen including LDH, haptoglobin, and direct antiglobulin test*- The **reticulocyte count of 0.8%** is within the normal range and not appropriately elevated for the degree of anaemia, which effectively rules out a vigorous compensatory response seen in **haemolytic anaemia**.- If hemolysis were occurring, one would expect a significantly elevated **reticulocyte count** and potentially abnormal red cell morphology on the blood film.*Serum erythropoietin level*- While **erythropoietin deficiency** (common in CKD) can cause normocytic anaemia, measuring the level is not a standard initial test.- Assessing **renal function (U&Es)** via a metabolic panel is a more practical first step to identify the underlying cause of potentially low erythropoietin production.*Repeat full blood count in 2 weeks*- Waiting for a repeat test is inappropriate in a patient with **progressive fatigue** over 6 months and established **anaemia** (Hb 102 g/L).- Clinical guidelines mandate that an explanation for anaemia in an older patient be sought through **systematic investigation** rather than observation.

Question 116: A 48-year-old woman presents 5 days post-total hip replacement with sudden onset pleuritic chest pain and dyspnoea. CT pulmonary angiogram confirms segmental pulmonary embolism. She weighs 68kg with normal renal function (eGFR 88 mL/min/1.73m²). She has no other significant medical history. What is the most appropriate anticoagulation regimen?

A. Apixaban 10mg twice daily for 7 days, then 5mg twice daily (Correct Answer)
B. Rivaroxaban 15mg twice daily for 21 days, then 20mg once daily
C. Dabigatran 150mg twice daily
D. Low molecular weight heparin for 5 days then warfarin (target INR 2-3)
E. Unfractionated heparin infusion followed by warfarin

Explanation: ***Apixaban 10mg twice daily for 7 days, then 5mg twice daily*** - This regimen is in line with **NICE guidelines** recommending **Direct Oral Anticoagulants (DOACs)** as first-line treatment for provoked pulmonary embolism in patients with normal renal function. - Apixaban is a **monotherapy** that does not require initial parenteral bridging, with a **loading dose** for 7 days followed by a maintenance dose. *Rivaroxaban 15mg twice daily for 21 days, then 20mg once daily* - While rivaroxaban is an appropriate first-line DOAC, its standard loading dose duration for acute **Venous Thromboembolism (VTE)** is **21 days**, which is a different regimen compared to the 7-day apixaban load. - Both are valid options, but the specific apixaban regimen is a commonly cited and guideline-supported choice for acute PE. *Dabigatran 150mg twice daily* - This option is incorrect because dabigatran requires an **initial lead-in therapy** with parenteral anticoagulation (e.g., **Low Molecular Weight Heparin (LMWH)**) for at least 5 days before the oral dose is started. - Initiating dabigatran immediately without **heparin bridging** in an acute PE deviates from established clinical protocols. *Low molecular weight heparin for 5 days then warfarin (target INR 2-3)* - The traditional **LMWH to warfarin bridging** regimen is now generally considered **second-line** treatment unless DOACs are contraindicated, such as in patients with **antiphospholipid syndrome**. - This regimen necessitates regular **INR monitoring** and carries a higher risk of dietary and drug interactions compared to DOACs. *Unfractionated heparin infusion followed by warfarin* - **Unfractionated heparin (UFH)** is typically reserved for patients with **haemodynamic instability** (massive PE), severe renal impairment (CrCl < 15), or those at high risk of bleeding who may require rapid reversal. - This patient is stable with **normal renal function**, making the continuous infusion and intensive monitoring of UFH unnecessary.

Question 117: A 26-year-old woman of West African descent presents with fatigue. Blood tests show: Hb 78 g/L, MCV 62 fL, ferritin 85 mcg/L, serum iron 18 mcmol/L (normal 10-30), TIBC 55 mcmol/L (normal 45-70). Haemoglobin electrophoresis shows HbA2 6.8% (normal 2.5-3.5%). What is the most likely diagnosis?

A. Iron deficiency anaemia with concurrent inflammation
B. Beta-thalassaemia trait (Correct Answer)
C. Alpha-thalassaemia trait
D. Sickle cell trait
E. Anaemia of chronic disease

Explanation: ***Beta-thalassaemia trait*** - The pathognomonic finding is an **elevated HbA2 (>3.5%)**, which in this patient is 6.8%, representing a compensatory increase in delta-chain production due to reduced beta-chain synthesis. - It presents as a **microcytic anaemia** with a strikingly low **MCV** relative to the mildness of the anaemia, while **ferritin** and iron studies remain within normal limits, ruling out iron deficiency. *Iron deficiency anaemia with concurrent inflammation* - While inflammation can elevate ferritin levels, **TIBC** is typically low or normal in inflammation. Here, TIBC is normal, but the key differentiator is the **elevated HbA2**, which is not seen in iron deficiency. - True iron deficiency would demonstrate **low ferritin** and often **elevated TIBC**, neither of which is present in this clinical picture. *Alpha-thalassaemia trait* - **Hb electrophoresis** is typically normal in alpha-thalassaemia trait because all hemoglobin types (HbA, HbA2, HbF) require alpha chains for their formation. - Diagnosis usually requires **DNA analysis** to identify gene deletions, as it does not present with the elevated **HbA2** seen in beta-thalassaemia trait. *Sickle cell trait* - Characterized by the presence of **HbS** on electrophoresis, usually making up about 25-45% of the total hemoglobin, which is not indicated by the elevated HbA2. - Patients with sickle cell trait typically have **normal red cell indices** (MCV and MCH) and do not present with microcytic anaemia. *Anaemia of chronic disease* - Characterized by **low serum iron**, low TIBC, and normal-to-high ferritin levels due to iron trapping in macrophages. - It typically presents as a normocytic or mildly microcytic anaemia, but it never causes an **elevation in HbA2**.

Question 118: A 56-year-old man with rheumatoid arthritis has failed methotrexate and sulfasalazine combination therapy. He continues to have active disease with DAS28 score of 5.8. His consultant is considering biologic therapy. He has a history of pulmonary tuberculosis treated 15 years ago. Chest X-ray shows apical scarring. What is the most appropriate next step before initiating TNF inhibitor therapy?

A. Proceed with TNF inhibitor as TB was adequately treated previously
B. Perform interferon-gamma release assay (IGRA) and treat if positive
C. Start prophylactic isoniazid for 3 months before TNF inhibitor (Correct Answer)
D. Consider alternative biologic therapy such as rituximab
E. Arrange CT thorax to assess for active TB

Explanation: ***Start prophylactic isoniazid for 3 months before TNF inhibitor*** - **TNF inhibitors** facilitate the breakdown of **granulomas**, significantly increasing the risk of **latent Mycobacterium tuberculosis reactivation** even in patients previously treated. - Current guidelines (BSR/NICE) mandate prophylactic anti-TB therapy (e.g., **isoniazid** for 3–6 months) for patients with **radiological evidence** of past TB (apical scarring) before starting therapy to ensure safety. *Proceed with TNF inhibitor as TB was adequately treated previously* - Adequate prior treatment does not eliminate the risk of **reactivation** of residual dormant bacilli when **TNF-alpha secondary defense mechanisms** are inhibited. - Proceeding without prophylaxis in a patient with **apical scarring** carries an unacceptably high risk of disseminated or extrapulmonary TB. *Perform interferon-gamma release assay (IGRA) and treat if positive* - **IGRA** and TST status are often irrelevant in patients with clear **radiographic evidence** of prior TB infection, as prophylaxis is indicated based on the chest X-ray findings alone. - A negative IGRA would not override the clinical and radiological history of **pulmonary tuberculosis** in the context of high-risk immunosuppression. *Consider alternative biologic therapy such as rituximab* - While **rituximab** (B-cell depletion) has a lower risk of TB reactivation than TNF inhibitors, it is typically reserved for patients who fail an initial TNF inhibitor or have specific contraindications. - The presence of treated TB is not a contraindication to TNF inhibitors, provided appropriate **chemoprophylaxis** is administered. *Arrange CT thorax to assess for active TB* - **CT thorax** is not routinely indicated if the clinical assessment and **chest X-ray** do not suggest current active infection (e.g., no new infiltrates, fever, or weight loss). - The primary concern here is **latent TB reactivation**, which is managed via prophylaxis rather than diagnostic imaging for active disease stage.

Question 119: A 34-year-old woman presents with fatigue and is found to have microcytic anaemia: Hb 95 g/L, MCV 68 fL, ferritin 8 mcg/L. She has no gastrointestinal symptoms and has regular but heavy menstrual periods (changing pads every 2 hours on heavy days, lasting 7 days). What is the most appropriate initial management approach?

A. Oral iron supplementation and gynaecology referral for menorrhagia management (Correct Answer)
B. Upper and lower GI endoscopy to exclude malignancy
C. Blood transfusion followed by oral iron therapy
D. Intravenous iron infusion
E. Coeliac serology and proceed to endoscopy regardless of result

Explanation: ***Oral iron supplementation and gynaecology referral for menorrhagia management*** - The patient has **microcytic anaemia** with severely **low ferritin** (8 mcg/L), highly suggestive of **iron deficiency anaemia**, which is clearly attributed to **menorrhagia** (heavy menstrual periods). - The initial management involves replenishing iron stores with **oral iron supplementation** and addressing the underlying cause of chronic blood loss by referral for **menorrhagia management**. *Upper and lower GI endoscopy to exclude malignancy* - **GI endoscopy** is typically indicated for iron deficiency anaemia in men, **postmenopausal women**, or individuals with **gastrointestinal symptoms** or a family history of GI malignancy. - In a **premenopausal woman** with a clear physiological cause of blood loss (menorrhagia) and no GI symptoms, extensive GI investigation is not the most appropriate initial step. *Blood transfusion followed by oral iron therapy* - **Blood transfusion** is reserved for patients with **severe symptomatic anaemia** (e.g., Hb < 70 g/L) or those with cardiovascular instability, which is not the case for this patient (Hb 95 g/L). - For stable patients, **oral iron therapy** is the standard first-line treatment to gradually correct iron deficiency. *Intravenous iron infusion* - **Intravenous iron** is indicated when **oral iron** is poorly tolerated, ineffective, or when rapid correction of iron deficiency is clinically necessary (e.g., severe malabsorption, ongoing significant blood loss, or pre-surgical requirements). - As an initial approach, **oral iron** is preferred given its safety and cost-effectiveness, and there is no contraindication or urgency warranting IV iron in this stable patient. *Coeliac serology and proceed to endoscopy regardless of result* - While **Coeliac serology** can be a screening tool for malabsorption in unexplained iron deficiency, proceeding directly to **endoscopy regardless of the result** is an overinvestigation without gastrointestinal symptoms. - The primary focus should remain on the identified cause of **menorrhagia** and initiating **oral iron** before considering invasive procedures for other potential causes.

Question 120: A 70-year-old man with chronic kidney disease stage 4 (eGFR 22 mL/min/1.73m²) presents with an acute flare of gout affecting his left ankle. His current medications include amlodipine, bisoprolol, and atorvastatin. He has a history of peptic ulcer disease. What is the most appropriate treatment for his acute gout attack?

A. Colchicine 500 micrograms four times daily
B. Naproxen 500mg twice daily with omeprazole
C. Oral prednisolone 30mg daily (Correct Answer)
D. Intra-articular corticosteroid injection
E. Allopurinol 100mg daily

Explanation: ***Oral prednisolone 30mg daily*** - **Oral corticosteroids** are the preferred first-line treatment for acute gout when **NSAIDs** and **colchicine** are contraindicated due to **chronic kidney disease (CKD)**. - This patient's **eGFR of 22 mL/min** and history of **peptic ulcer disease** make systemic steroids the safest and most effective systemic option without risking renal toxicity or GI bleeding. *Colchicine 500 micrograms four times daily* - In **CKD stage 4**, the clearance of colchicine is significantly reduced, leading to high risks of **neuromuscular toxicity** and bone marrow suppression. - The proposed dose of **four times daily** is dangerously high for someone with an **eGFR < 30 mL/min**; a much lower, infrequent dose would be required. *Naproxen 500mg twice daily with omeprazole* - **NSAIDs** are strictly contraindicated in **Stage 4 CKD** because they may further decrease renal blood flow and precipitate **acute-on-chronic kidney injury**. - Despite PPI coverage with **omeprazole**, his history of **peptic ulcer disease** increases the risk of a life-threatening gastrointestinal hemorrhage. *Intra-articular corticosteroid injection* - While effective for **monoarthritis**, oral prednisolone is often prioritized in clinical scenarios where immediate access to specialized **joint aspiration** or injection expertise is unavailable. - Although a valid consideration, **systemic corticosteroids** (oral) are generally the first practical systemic approach for acute flares in patients with multiple comorbidities. *Allopurinol 100mg daily* - **Allopurinol** is a urate-lowering therapy and should not be initiated during an **acute flare**, as rapid changes in serum urate can prolong or worsen the inflammation. - Starting this medication now does not address the **acute pain and swelling** currently experienced by the patient.

Question 121: A 38-year-old woman presents with a 4-month history of symmetrical hand pain and early morning stiffness lasting 90 minutes. Examination reveals swelling of the MCP and PIP joints bilaterally. Blood tests show: RF negative, anti-CCP antibody positive at high titre (>200 U/mL), CRP 42 mg/L, ESR 38 mm/hr. X-rays of hands show soft tissue swelling only. What is the most accurate prognostic implication of these findings?

A. The negative RF indicates a better prognosis than seropositive disease
B. High titre anti-CCP antibodies predict more aggressive erosive disease (Correct Answer)
C. Absence of erosions on initial X-ray indicates low risk of joint damage
D. Normal inflammatory markers exclude significant disease activity
E. The diagnosis cannot be confirmed without positive RF

Explanation: ***High titre anti-CCP antibodies predict more aggressive erosive disease***- **Anti-CCP antibodies** are highly specific for rheumatoid arthritis and are strong predictors of **future joint destruction** and radiological progression.- A **high titre** (>200 U/mL) of anti-CCP antibodies indicates a significantly increased risk for a more **aggressive clinical course**, often requiring early and intensive **DMARD therapy**.*The negative RF indicates a better prognosis than seropositive disease*- While **rheumatoid factor (RF)** is a prognostic marker, a negative RF does not negate the poor prognosis associated with **positive anti-CCP antibodies**.- Patients with **anti-CCP positive** but RF negative RA often experience a disease course similar to those who are double-positive for both markers.*Absence of erosions on initial X-ray indicates low risk of joint damage*- In early rheumatoid arthritis, initial X-rays typically show only **soft tissue swelling**, with **bony erosions** developing later in the disease course.- The presence of **high titre anti-CCP antibodies** and elevated **inflammatory markers** (CRP, ESR) predicts a high risk of future joint damage, regardless of initial X-ray findings.*Normal inflammatory markers exclude significant disease activity*- In this patient, both **CRP (42 mg/L)** and **ESR (38 mm/hr)** are significantly elevated, indicating active systemic **inflammation**.- Elevated inflammatory markers are associated with higher disease activity and a greater likelihood of **radiographic progression** and worse prognosis in RA.*The diagnosis cannot be confirmed without positive RF*- Rheumatoid arthritis can be diagnosed based on **ACR/EULAR criteria**, where **anti-CCP antibody positivity** (especially high titre) contributes significantly to the diagnostic score.- Approximately 20% of RA cases are **seronegative for RF** (seronegative RA), and **anti-CCP antibodies** are often present and diagnostic in these cases.

Question 122: A 67-year-old woman with established rheumatoid arthritis has been taking methotrexate 20mg weekly for 18 months with good disease control. Her recent blood tests show: Hb 88 g/L, MCV 108 fL, WCC 3.2 × 10⁹/L, platelets 145 × 10⁹/L. She takes folic acid 5mg once weekly, 48 hours after her methotrexate dose. What is the most appropriate next step in management?

A. Stop methotrexate and commence sulfasalazine
B. Continue current dose and recheck bloods in 2 weeks
C. Reduce methotrexate dose to 15mg weekly
D. Stop methotrexate temporarily and increase folic acid to daily dosing (Correct Answer)
E. Arrange urgent bone marrow biopsy

Explanation: ***Stop methotrexate temporarily and increase folic acid to daily dosing***- The patient's blood tests show **macrocytic anemia** (Hb 88 g/L, MCV 108 fL) and **leukopenia** (WCC 3.2 × 10⁹/L), indicative of **bone marrow suppression** likely due to **methotrexate toxicity**.- The most appropriate immediate action is to temporarily cease **methotrexate** and increase the dose of **folic acid** to daily to counteract the folate antagonism and promote hematopoietic recovery.*Stop methotrexate and commence sulfasalazine*- While **sulfasalazine** is an alternative DMARD for rheumatoid arthritis, the immediate and critical concern is the acute **methotrexate toxicity** and **bone marrow suppression**.- Commencing a new medication without first resolving the underlying toxicity is inappropriate and could potentially complicate the clinical picture or delay recovery.*Continue current dose and recheck bloods in 2 weeks*- Continuing **methotrexate** in the presence of significant **leukopenia** and **anemia** is dangerous and substantially increases the risk of severe infections and other life-threatening complications.- Waiting two weeks to recheck bloods is an unacceptable delay for managing drug-induced **myelosuppression** that requires urgent intervention.*Reduce methotrexate dose to 15mg weekly*- Simply reducing the dose is insufficient when there is clear evidence of active and significant **bone marrow suppression** and **toxicity**.- The drug must be completely withheld to allow for hematological recovery before any consideration of reintroduction or dose adjustment.*Arrange urgent bone marrow biopsy*- A **bone marrow biopsy** is generally not the initial step for suspected drug-induced myelosuppression when the offending agent is known and can be immediately discontinued.- The priority is to remove the causative drug and provide supportive care, reserving invasive diagnostics for cases where the etiology is unclear or there is no response to withdrawal.

Question 123: A 45-year-old man presents with acute onset severe pain and swelling of his right knee. Joint aspiration reveals positively birefringent rhomboid-shaped crystals under polarised light microscopy. Which biochemical abnormality is most directly associated with this condition?

A. Hyperuricaemia
B. Hypercalcaemia (Correct Answer)
C. Hyperparathyroidism
D. Hypomagnesaemia
E. Hypophosphataemia

Explanation: ***Hypercalcaemia***- Joint aspiration showing **positively birefringent rhomboid-shaped crystals** is diagnostic of **Calcium Pyrophosphate Deposition (CPPD)**, also known as pseudogout.- Elevating serum **calcium levels** directly promotes the formation of these crystals, and its presence warrants screening for underlying metabolic disorders.*Hyperuricaemia*- This biochemical abnormality is the hallmark of **Gout**, not CPPD or pseudogout.- Gout presents with **negatively birefringent needle-shaped crystals** of monosodium urate, distinct from the rhomboid crystals described.*Hyperparathyroidism*- While **primary hyperparathyroidism** is a known risk factor for pseudogout, it is a clinical condition rather than the "direct biochemical abnormality."- It predisposes to CPPD primarily by causing **hypercalcaemia**, which is the more direct metabolic driver for crystal deposition.*Hypomagnesaemia*- Low levels of **magnesium** act as a risk factor because magnesium is a cofactor for **alkaline phosphatase**, which helps keep pyrophosphate soluble.- While associated with CPPD, **hypercalcaemia** remains a more frequent and classic biochemical screening target in initial presentations.*Hypophosphataemia*- This is incorrect as the actual association is with **hypophosphatasia**, a rare metabolic disorder affecting phosphate metabolism.- **Low phosphate** itself is not a primary driver of CPPD; instead, imbalances in **pyrophosphate** levels within the joint space are the critical factor.

Question 124: A 52-year-old woman with newly diagnosed rheumatoid arthritis is being considered for disease-modifying antirheumatic drug (DMARD) therapy. She has active disease with a DAS28 score of 5.2 and has no contraindications to treatment. According to current UK guidelines, what is the most appropriate first-line DMARD therapy?

A. Methotrexate monotherapy (Correct Answer)
B. Hydroxychloroquine monotherapy
C. Sulfasalazine monotherapy
D. Combination therapy with methotrexate, hydroxychloroquine, and sulfasalazine
E. Adalimumab (TNF inhibitor)

Explanation: ***Methotrexate monotherapy*** - Current **NICE/UK guidelines** (NG100) recommend starting with **conventional synthetic DMARD monotherapy**, with **methotrexate** being the preferred first-line choice due to its high efficacy and safety profile in active RA. - It should be initiated and titrated to an optimal dose (e.g., up to **25mg weekly**) to achieve the treatment target of remission or low disease activity, especially with a high **DAS28 score of 5.2**. *Hydroxychloroquine monotherapy* - While a DMARD, hydroxychloroquine is generally considered **less potent** than methotrexate and is typically reserved for **mild rheumatoid arthritis** or as part of combination therapy. - It has a slower onset of action and is less effective at preventing **joint erosion** compared to methotrexate, making it unsuitable for active disease with a high DAS28 score. *Sulfasalazine monotherapy* - Sulfasalazine is an alternative conventional DMARD, but it is often considered **less effective** than methotrexate for inducing rapid remission in patients with active, newly diagnosed RA. - It is a suitable first-line option if **methotrexate is contraindicated** or poorly tolerated, but the patient in the scenario has no contraindications. *Combination therapy with methotrexate, hydroxychloroquine, and sulfasalazine* - While combination DMARD therapy was once a common initial strategy, **current UK guidelines** (NICE NG100, 2018) recommend starting with **monotherapy** to reduce initial toxicity and simplify treatment. - Intensified treatment with combination DMARDs or biologics is reserved for patients who do not achieve treatment targets on **optimal monotherapy**. *Adalimumab (TNF inhibitor)* - **Biological DMARDs** like adalimumab are not first-line therapies for newly diagnosed rheumatoid arthritis according to UK guidelines. - Their use is restricted to patients who have had an **inadequate response** to at least two conventional synthetic DMARDs (including methotrexate) and who have persistently **high disease activity** (e.g., DAS28 > 5.1).

Question 125: A 72-year-old man with metastatic lung cancer develops acute shortness of breath. CT pulmonary angiogram confirms bilateral pulmonary emboli. His platelet count is 45 × 10⁹/L, haemoglobin 88 g/L, creatinine 145 µmol/L (eGFR 38 mL/min/1.73m²). He is haemodynamically stable. What is the most appropriate anticoagulation approach?

A. Treatment dose low molecular weight heparin (Correct Answer)
B. Reduced dose apixaban 2.5mg twice daily
C. Therapeutic dose unfractionated heparin infusion
D. Inferior vena cava filter insertion without anticoagulation
E. Treatment dose rivaroxaban 15mg twice daily for 3 weeks then 20mg daily

Explanation: ***Treatment dose low molecular weight heparin*** - **Low molecular weight heparin (LMWH)** is the preferred initial choice for **cancer-associated thrombosis (CAT)**, balancing efficacy and bleeding risk. - Although the patient has **thrombocytopenia** (platelet count 45 × 10⁹/L) and renal impairment (eGFR 38 mL/min/1.73m²), LMWH can be dose-adjusted based on weight and renal function, offering more control than fixed-dose DOACs in this setting. *Reduced dose apixaban 2.5mg twice daily* - This is an **inadequate dose** for the acute treatment of pulmonary embolism; the standard initial dose for PE is 10mg twice daily for 7 days. - Apixaban 2.5mg twice daily is primarily used for **secondary prevention** after the initial treatment phase or for stroke prevention in non-valvular atrial fibrillation. *Therapeutic dose unfractionated heparin infusion* - **Unfractionated heparin (UFH)** is typically reserved for patients who are **haemodynamically unstable** or have severe renal failure (eGFR <30 mL/min/1.73m²) due to its short half-life and reversibility. - It requires **frequent activated partial thromboplastin time (aPTT) monitoring** and carries a higher risk of **heparin-induced thrombocytopenia (HIT)** compared to LMWH. *Inferior vena cava filter insertion without anticoagulation* - **IVC filters** are generally indicated only when anticoagulation is **absolutely contraindicated**, such as in cases of active major bleeding. - The patient's platelet count of 45 × 10⁹/L and stable condition do not constitute an absolute contraindication to anticoagulation, and filters have potential complications without treating the underlying thrombotic state. *Treatment dose rivaroxaban 15mg twice daily for 3 weeks then 20mg daily* - While **DOACs** are an option for CAT, **rivaroxaban** is often associated with a higher risk of **gastrointestinal bleeding**, especially in patients with metastatic lung cancer or active GI malignancy. - The patient's **thrombocytopenia** (45 × 10⁹/L) and moderate renal impairment make the fixed-dose regimen of rivaroxaban less flexible and potentially riskier than the dose-adjustable LMWH.

Question 126: A 45-year-old woman presents with bilateral leg swelling 2 weeks after a long-haul flight. Doppler ultrasound confirms bilateral above-knee deep vein thrombosis. She has had two previous unprovoked DVTs. Thrombophilia screening reveals: antithrombin activity 45% (normal 80-120%), protein C 98%, protein S 105%, Factor V Leiden negative, prothrombin gene mutation negative, lupus anticoagulant negative. What is the most appropriate long-term management?

A. Lifelong anticoagulation with warfarin (target INR 2-3) (Correct Answer)
B. Six months anticoagulation followed by reassessment
C. Lifelong anticoagulation with a direct oral anticoagulant
D. Lifelong anticoagulation with warfarin (target INR 3-4)
E. Low molecular weight heparin for 6 months then stop

Explanation: ***Lifelong anticoagulation with warfarin (target INR 2-3)***- The patient has **Antithrombin deficiency** (activity 45%) and a history of **recurrent unprovoked VTE**, which represents a high risk for future thrombotic events, necessitating **lifelong anticoagulation**.- **Warfarin** is often preferred over DOACs in antithrombin deficiency due to more extensive evidence and direct inhibition of vitamin K-dependent clotting factors, which is considered more robust in severe thrombophilias.*Six months anticoagulation followed by reassessment*- A 6-month course is insufficient for a patient with **multiple unprovoked DVT episodes** and a confirmed **inherited high-risk thrombophilia** like antithrombin deficiency.- Stopping anticoagulation after such a short period would lead to a very high **recurrence risk**, far exceeding the acceptable threshold for this clinical scenario.*Lifelong anticoagulation with a direct oral anticoagulant*- While **DOACs** are first-line for most VTE cases, current guidelines and clinical practice often still favor **warfarin** for **antithrombin deficiency** due to a lack of extensive data on DOACs in this specific high-risk population.- The mechanisms by which DOACs act (e.g., direct Factor Xa or thrombin inhibition) might be less optimally effective in all cases of antithrombin deficiency compared to the broad action of warfarin.*Lifelong anticoagulation with warfarin (target INR 3-4)*- An **INR target of 3-4** is considered high intensity and is typically reserved for very specific indications, such as **mechanical heart valves** or recurrent events despite a standard INR.- Maintaining a higher INR significantly increases the risk of **major bleeding complications** without providing additional proven benefit for venous thromboembolism in most cases.*Low molecular weight heparin for 6 months then stop*- **LMWH** is used for acute treatment and specific situations like VTE in pregnancy or cancer, but it is not practical or generally recommended for **long-term indefinite oral anticoagulation**.- Stopping therapy after 6 months, even with LMWH, would leave the patient unprotected against the **high risk of recurrence** due to her underlying antithrombin deficiency and prior events.

Question 127: A 58-year-old woman is diagnosed with unprovoked pulmonary embolism. She has completed 6 months of anticoagulation with apixaban and has recovered well. She has no active cancer, normal renal function (eGFR >60), and no major bleeding risk factors. What is the most appropriate recommendation regarding duration of anticoagulation?

A. Stop anticoagulation after 6 months as treatment is complete
B. Continue full-dose apixaban indefinitely
C. Switch to aspirin 75mg daily indefinitely
D. Continue reduced-dose apixaban (2.5mg twice daily) indefinitely if annual bleeding risk <2% (Correct Answer)
E. Stop anticoagulation but restart if further thrombosis occurs

Explanation: ***Continue reduced-dose apixaban (2.5mg twice daily) indefinitely if annual bleeding risk <2%***- Patients with an **unprovoked pulmonary embolism** have a high annual risk of recurrence (approx. 10%), making **extended anticoagulation** the preferred strategy if bleeding risk is low.- Trials like **AMPLIFY-EXT** demonstrated that a **reduced-dose** (2.5 mg BID) is as effective as full-dose in preventing recurrence but carries a significantly lower risk of **major bleeding**.*Stop anticoagulation after 6 months as treatment is complete*- Stopping anticoagulation after 6 months for unprovoked VTE leads to unacceptably high **recurrence rates** compared to extended therapy.- Current guidelines recommend considering **indefinite treatment** for unprovoked events unless there is a high **bleeding risk**.*Continue full-dose apixaban indefinitely*- While effective, **full-dose apixaban** (5 mg BID) increases the risk of bleeding over the long term without providing superior protection against recurrence compared to the **reduced dose**.- The **2.5 mg BID** dose is specifically indicated for long-term prophylaxis after the initial 6-month treatment phase.*Switch to aspirin 75mg daily indefinitely*- **Aspirin** is significantly less effective than anticoagulants for the secondary prevention of **venous thromboembolism (VTE)**.- It should only be considered as a last resort for patients who refuse or cannot tolerate any form of **oral anticoagulation**.*Stop anticoagulation but restart if further thrombosis occurs*- This approach is reactive rather than preventative and exposes the patient to the potentially fatal risk of a **recurrent pulmonary embolism**.- **Unprovoked VTE** carries a long-term risk that necessitates a proactive, **preventative strategy** using low-dose anticoagulation.

Question 128: A 68-year-old man with atrial fibrillation on warfarin (target INR 2-3) presents to the emergency department following a fall with significant head trauma. CT head shows acute subdural haematoma requiring urgent surgical evacuation. His INR is 3.2. What is the most appropriate immediate management of his anticoagulation?

A. Administer vitamin K 5mg intravenously slowly
B. Administer prothrombin complex concentrate plus vitamin K 5mg intravenously (Correct Answer)
C. Stop warfarin and recheck INR in 6 hours
D. Administer fresh frozen plasma 4 units
E. Administer protamine sulfate intravenously

Explanation: ***Administer prothrombin complex concentrate plus vitamin K 5mg intravenously*** - This patient has a **life-threatening intracranial hemorrhage** (acute subdural haematoma) requiring immediate and complete reversal of warfarin's anticoagulant effect for urgent surgery. - **Prothrombin complex concentrate (PCC)** provides rapid reversal by supplying activated clotting factors (II, VII, IX, X), while **intravenous vitamin K** ensures sustained new factor synthesis, preventing rebound anticoagulation. *Administer vitamin K 5mg intravenously slowly* - **Vitamin K** alone has a delayed onset of action, typically taking **4-6 hours** to significantly lower the INR. - This delay is unacceptable in a situation of acute, **life-threatening bleeding** requiring immediate surgical intervention, as the hematoma could expand significantly. *Stop warfarin and recheck INR in 6 hours* - Simply stopping **warfarin** is insufficient for **major or life-threatening bleeding** because of warfarin's long half-life and the slow clearance of depleted clotting factors. - Rechecking INR in 6 hours would delay critical treatment, putting the patient at high risk of **neurological deterioration** due to ongoing bleeding. *Administer fresh frozen plasma 4 units* - **Fresh frozen plasma (FFP)** contains all clotting factors but requires **large volumes** for effective reversal, posing a risk of fluid overload. - FFP also requires **blood group compatibility** and takes longer to thaw and administer compared to PCC, making it less ideal for immediate, critical reversal. *Administer protamine sulfate intravenously* - **Protamine sulfate** is the specific antidote for **heparin** (unfractionated and low molecular weight heparin) by neutralizing its anticoagulant effects. - It has **no effect on warfarin's anticoagulant action**, which works by inhibiting vitamin K-dependent clotting factor synthesis.

Question 129: A 32-year-old woman who is 28 weeks pregnant presents with left leg swelling and pain. Ultrasound Doppler confirms left femoral deep vein thrombosis. She has no significant past medical history and no family history of thrombosis. What is the most appropriate anticoagulation management?

A. Low molecular weight heparin throughout pregnancy and 6 weeks postpartum (Correct Answer)
B. Warfarin for remainder of pregnancy then 6 weeks postpartum
C. Rivaroxaban throughout pregnancy and 6 weeks postpartum
D. Low molecular weight heparin until delivery, then switch to warfarin for 6 weeks
E. Low molecular weight heparin until delivery only, no postpartum anticoagulation needed

Explanation: ***Low molecular weight heparin throughout pregnancy and 6 weeks postpartum*** - **Low molecular weight heparin (LMWH)** is the preferred anticoagulant in pregnancy as it **does not cross the placenta** and carries no risk of fetal hemorrhage or teratogenicity. - Management of **Venous Thromboembolism (VTE)** in pregnancy requires treatment for the remainder of the pregnancy and at least **6 weeks postpartum**, ensuring a minimum total duration of 3 months. *Warfarin for remainder of pregnancy then 6 weeks postpartum* - **Warfarin** is generally **contraindicated** in pregnancy because it crosses the placenta and is **teratogenic**, especially during the first trimester (warfarin embryopathy). - It also increases the risk of **fetal intracranial hemorrhage**, particularly if used near the time of delivery. *Rivaroxaban throughout pregnancy and 6 weeks postpartum* - **Direct Oral Anticoagulants (DOACs)** like rivaroxaban are **contraindicated** in pregnancy due to a lack of safety data and potential for reproductive toxicity. - Animal studies have shown that DOACs cross the placenta and may lead to **fetal harm** and increased pregnancy loss. *Low molecular weight heparin until delivery, then switch to warfarin for 6 weeks* - While switching to **warfarin postpartum** is a valid clinical option because it is compatible with breastfeeding, continuing **LMWH** throughout is also an acceptable and often simpler management strategy. - This option is less ideal than the correct answer as it implies a mandatory switch, whereas LMWH alone is often preferred to avoid the complexities of **INR monitoring** in a new mother. *Low molecular weight heparin until delivery only, no postpartum anticoagulation needed* - The **postpartum period** (especially the first 6 weeks) is the time of highest weight-for-weight risk for VTE due to physiological changes and potential delivery trauma. - Stopping anticoagulation at delivery would be dangerous and is **incorrect management**, as guideline-directed therapy must continue for at least **6 weeks postpartum**.

Question 130: A 62-year-old man presents with fatigue. Blood tests show: Hb 92 g/L, MCV 88 fL, WCC 3.8 × 10⁹/L, platelets 145 × 10⁹/L, reticulocyte count 0.5% (normal 0.5-2.5%), ferritin 380 µg/L, ESR 78 mm/hr, CRP 45 mg/L. Renal and liver function are normal. Blood film shows normochromic normocytic red cells with rouleaux formation. What is the most appropriate next investigation?

A. Bone marrow biopsy
B. Serum protein electrophoresis and immunofixation (Correct Answer)
C. Direct antiglobulin test (Coombs test)
D. Flow cytometry for paroxysmal nocturnal haemoglobinuria
E. JAK2 mutation analysis

Explanation: ***Serum protein electrophoresis and immunofixation***- The combination of **normocytic anaemia**, a significantly elevated **ESR (78 mm/hr)**, and **rouleaux formation** on the blood film is highly suggestive of a **paraproteinaemia**, such as **multiple myeloma**.- This investigation is the essential first-line screening test to identify a **monoclonal (M) protein spike**, which is characteristic of plasma cell dyscrasias.*Bone marrow biopsy*- While a **bone marrow biopsy** is crucial for confirming the diagnosis of **multiple myeloma** by quantifying plasma cell infiltration, it is typically performed *after* a paraprotein has been identified.- It is a more invasive procedure and follows initial non-invasive screening steps like **serum protein electrophoresis**.*Direct antiglobulin test (Coombs test)**- This test is used to diagnose **autoimmune haemolytic anaemia**, which would typically present with a **high reticulocyte count** due to increased red blood cell destruction and compensatory marrow activity.- The patient's **low reticulocyte count (0.5%)** indicates **underproduction** of red blood cells, not increased destruction, making hemolytic anemia unlikely.*Flow cytometry for paroxysmal nocturnal haemoglobinuria*- **Paroxysmal nocturnal haemoglobinuria (PNH)** is characterized by **intravascular haemolysis** (e.g., elevated LDH, low haptoglobin, dark urine) and often presents with **pancytopenia**.- It does not cause the striking **rouleaux formation** or the extremely high **ESR** and **CRP** seen in this patient.*JAK2 mutation analysis*- This analysis is primarily used to diagnose **myeloproliferative neoplasms** (e.g., polycythemia vera, essential thrombocythemia).- These conditions typically manifest with **elevated blood counts** (e.g., erythrocytosis, thrombocytosis) or specific cytopenias with marrow fibrosis, not the **anaemia** and rouleaux seen here.

Question 131: A 45-year-old woman with rheumatoid arthritis on long-term methotrexate presents with fatigue. Blood tests show: Hb 102 g/L, MCV 104 fL, WCC 5.8 × 10⁹/L, platelets 165 × 10⁹/L. She is taking folic acid 5mg once weekly. What is the most appropriate management to address her anaemia?

A. Stop methotrexate and switch to alternative DMARD
B. Increase folic acid to 5mg daily (Correct Answer)
C. Check vitamin B12 level and commence supplementation
D. Prescribe folinic acid rescue therapy
E. Add oral iron supplementation

Explanation: ***Increase folic acid to 5mg daily*** - **Methotrexate** is a **folate antagonist** that inhibits **dihydrofolate reductase**, commonly leading to **macrocytic anaemia** as evidenced by the high **MCV (104 fL)**. - Increasing the frequency of **folic acid** supplementation (e.g., daily, avoiding the day of methotrexate administration) is the standard management to mitigate haematological side effects and improve tolerability, particularly when weekly dosing is insufficient. *Stop methotrexate and switch to alternative DMARD* - Stopping methotrexate is a premature step since the anaemia is **mild (Hb 102 g/L)** and can often be corrected with appropriate supportive care. - **Methotrexate** is a cornerstone treatment for **rheumatoid arthritis**, and switching should only be considered if dose adjustments or optimized supplementation fail to control toxicity or if there are more severe side effects. *Check vitamin B12 level and commence supplementation* - While **Vitamin B12 deficiency** can cause macrocytosis, the patient's current medication, **methotrexate**, is a direct cause of folate antagonism, making it the most probable cause of the macrocytic anaemia. - Although assessing B12 is part of a complete workup for macrocytic anaemia, given the clear precipitating factor, it is not the **most appropriate immediate** intervention compared to adjusting folate supplementation. *Prescribe folinic acid rescue therapy* - **Folinic acid (leucovorin)** is typically reserved for managing acute, severe **methotrexate toxicity** (e.g., myelosuppression, mucositis) or for high-dose methotrexate regimens. - It is not the standard approach for managing mild, chronic **macrocytosis** due to regular methotrexate use, where increased daily folic acid is preferred. *Add oral iron supplementation* - **Iron deficiency** typically results in **microcytic anaemia** (low MCV), whereas this patient clearly presents with **macrocytic anaemia** (MCV 104 fL). - Supplementing iron in a patient with a **macrocytic** profile would be inappropriate and would not address the underlying folate pathway interference caused by methotrexate.

Question 132: A 35-year-old woman presents with a 3-month history of fatigue and shortness of breath on exertion. She follows a strict vegan diet. Blood tests show: Hb 88 g/L, MCV 118 fL, WCC 4.2 × 10⁹/L, neutrophils 2.8 × 10⁹/L, platelets 112 × 10⁹/L. Blood film shows hypersegmented neutrophils. Which single test would most reliably confirm the specific deficiency causing her anaemia?

A. Serum vitamin B12 level
B. Serum folate level
C. Serum methylmalonic acid level (Correct Answer)
D. Bone marrow biopsy showing megaloblastic changes
E. Anti-intrinsic factor antibodies

Explanation: ***Serum methylmalonic acid level*** - **Methylmalonic acid (MMA)** is a highly specific marker for **vitamin B12 deficiency** as B12 is a cofactor for its metabolism, leading to MMA accumulation when deficient. - Elevated MMA levels are seen in B12 deficiency but remain normal in **folate deficiency**, making it the most reliable test to differentiate the two causes of **megaloblastic anaemia**. *Serum vitamin B12 level* - Serum B12 levels can sometimes fall into a **"grey zone"** or be falsely normal despite **tissue-level deficiency**, especially in early stages. - This test might not always reflect the true functional B12 status, and other factors can influence its concentration. *Serum folate level* - While folate deficiency also causes **macrocytic anaemia** with **hypersegmented neutrophils**, it is less likely in a vegan, as many plant foods are rich in folate. - Testing folate directly does not confirm **vitamin B12 deficiency** and could lead to misdiagnosis if only folate is supplemented, masking a critical B12 deficiency. *Bone marrow biopsy showing megaloblastic changes* - A bone marrow biopsy would confirm **megaloblastic anaemia** by showing characteristic morphological changes, but it cannot differentiate between **B12** and **folate deficiency**. - It is an **invasive procedure** and less specific for identifying the *exact* deficiency compared to biochemical blood tests. *Anti-intrinsic factor antibodies* - These antibodies are specific for **Pernicious Anaemia**, an autoimmune condition causing **B12 malabsorption**, not direct dietary deficiency. - Given the patient's **strict vegan diet**, a **dietary deficiency** is the most probable cause, making tests for malabsorption secondary to confirming the deficiency itself.

Question 133: A 28-year-old woman of Mediterranean origin presents with fatigue. Blood tests show: Hb 108 g/L, MCV 68 fL, ferritin 95 µg/L, serum iron 18 µmol/L (normal 10-30), transferrin saturation 28%, red cell count 5.8 × 10¹²/L. Blood film shows target cells and basophilic stippling. What is the most likely diagnosis?

A. Beta-thalassaemia trait (Correct Answer)
B. Iron deficiency anaemia
C. Anaemia of chronic disease
D. Sideroblastic anaemia
E. Alpha-thalassaemia trait

Explanation: ***Beta-thalassaemia trait*** - The patient's **Mediterranean origin**, combined with **microcytic anaemia** (low MCV 68 fL) and **normal iron studies** (ferritin 95 µg/L, serum iron, transferrin saturation), strongly points to thalassaemia. - The **elevated red cell count** (5.8 × 10¹²/L) despite anaemia and the presence of **target cells** and **basophilic stippling** on blood film are classic features of beta-thalassaemia trait. *Iron deficiency anaemia* - This is unlikely because **ferritin** and **iron studies** (serum iron, transferrin saturation) are within normal limits, directly contradicting iron deficiency. - In iron deficiency, the **red cell count** is typically decreased or normal, not elevated, and the MCV would usually be low but not always as low as 68 fL with these iron levels. *Anaemia of chronic disease* - While anaemia of chronic disease can be microcytic, the MCV is rarely as low as 68 fL, and although **ferritin** is usually normal or elevated, **serum iron** and **transferrin saturation** would typically be low. - The **red cell count** is usually normal or low, not elevated, differentiating it from thalassaemia. *Sideroblastic anaemia* - Sideroblastic anaemia often presents with **increased serum iron** and **ferritin** due to iron overload, which are not seen here. - The blood film might show **dimorphic red cell population**, and a definitive diagnosis requires a bone marrow biopsy for **ring sideroblasts**. *Alpha-thalassaemia trait* - While alpha-thalassaemia trait can also cause microcytic anaemia with a high red cell count and target cells, the patient's **Mediterranean origin** makes beta-thalassaemia more probable. - Differentiation typically relies on **haemoglobin electrophoresis**, which would show **increased HbA2** in beta-thalassaemia trait, while alpha-thalassaemia trait usually has normal HbA2.

Question 134: A 68-year-old man presents with fatigue and pallor. Blood tests reveal: Hb 82 g/L, MCV 68 fL, MCH 22 pg, ferritin 8 µg/L, transferrin saturation 12%. He denies any obvious blood loss. Upper GI endoscopy and colonoscopy are both normal. What is the most appropriate next investigation?

A. Capsule endoscopy of small bowel
B. Bone marrow biopsy
C. Haemoglobin electrophoresis
D. Coeliac serology including tissue transglutaminase antibodies (Correct Answer)
E. CT chest, abdomen and pelvis

Explanation: ***Coeliac serology including tissue transglutaminase antibodies*** - This patient has **iron deficiency anaemia** (low ferritin, low MCV) with no source found on standard GI endoscopy; **Coeliac disease** is a common cause of iron malabsorption due to **duodenal villous atrophy**. - International guidelines recommend screening for Coeliac disease in all cases of unexplained iron deficiency, even in the absence of GI symptoms. *Capsule endoscopy of small bowel* - This is typically reserved for cases where both endoscopy and **Coeliac serology** are negative, to look for **angiodysplasia** or small bowel tumors. - It is a more invasive and expensive investigation that should follow simpler screening tests. *Bone marrow biopsy* - This is unnecessary when the iron studies (low **ferritin** and **transferrin saturation**) clearly establish a diagnosis of iron deficiency. - Biopsy is generally used for evaluating **myelodysplastic syndromes** or unexplained pancytopenia, not simple microcytic anaemia. *Haemoglobin electrophoresis* - This test screens for **haemoglobinopathies** like **Thalassaemia**, which also present with low MCV. - However, the low **ferritin** level specifically confirms iron depletion, whereas ferritin is typically normal or high in thalassaemia. *CT chest, abdomen and pelvis* - While used to search for **occult malignancy**, it is not the standard next step for iron deficiency after negative direct visualization of the GI tract. - It lacks the sensitivity to detect the functional malabsorption typical of **Coeliac disease**.

Question 135: A 55-year-old woman with type 2 diabetes and hypertension presents with sudden onset severe pain and swelling of her left knee. She has been feeling unwell with fever. Examination reveals a hot, swollen, tender knee with restricted movement. Knee aspiration yields turbid fluid. Microscopy shows weakly positive birefringent rhomboid-shaped crystals. Gram stain is negative. White cell count in synovial fluid is 28 × 10⁹/L with 85% neutrophils. What is the most appropriate immediate management?

A. Start oral colchicine and arrange outpatient rheumatology review
B. Administer intra-articular corticosteroid injection
C. Start empirical intravenous antibiotics and await culture results (Correct Answer)
D. Start oral NSAIDs and arrange urgent MRI knee
E. Prescribe oral prednisolone and discharge with GP follow-up

Explanation: ***Start empirical intravenous antibiotics and await culture results*** - The patient presents with **fever**, a high synovial **WCC (28 x 10⁹/L)** with **85% neutrophils**, and turbid fluid, making **septic arthritis** the most critical diagnosis to rule out or treat immediately. - **Crystal arthropathy** (pseudogout) and infection frequently **coexist**; a negative Gram stain does not exclude sepsis, and delaying **empirical intravenous antibiotics** can lead to rapid **joint destruction**, osteomyelitis, or systemic sepsis. *Start oral colchicine and arrange outpatient rheumatology review* - While colchicine treats **calcium pyrophosphate deposition (CPPD)**, it is insufficient for a patient presenting with **systemic symptoms** like fever and severe joint pain, indicative of potential sepsis. - Outpatient review is inappropriate as the risk of **septic arthritis** requires immediate hospital admission for urgent diagnosis and IV therapy. *Administer intra-articular corticosteroid injection* - Injecting corticosteroids into a potentially **infected joint** is strictly **contraindicated** as it can worsen the infection by suppressing local immunity. - This intervention should only be considered after **septic arthritis** has been definitively ruled out by negative cultures. *Start oral NSAIDs and arrange urgent MRI knee* - **NSAIDs** may mask the pain and inflammation of infection but will not treat the underlying **bacterial source**, which is the primary concern given the fever and turbid fluid. - An **MRI** is not the primary diagnostic tool for septic arthritis; **synovial fluid culture** is the gold standard, and clinical urgency mandates treatment before imaging. *Prescribe oral prednisolone and discharge with GP follow-up* - **Systemic steroids** can facilitate the spread of **bacterial infection** and are not the first-line treatment for acute monoarthritis of unknown etiology with signs of sepsis. - Discharge is unsafe for a patient with **fever** and restricted movement, as they require immediate hospital admission, monitoring for clinical deterioration, and further management of the joint.

Question 136: A 72-year-old woman with recurrent episodes of gout is started on allopurinol for urate-lowering therapy. She has normal renal function. What is the target serum urate level that should be achieved to effectively prevent further acute attacks and reduce tophi formation?

A. Below 300 µmol/L (Correct Answer)
B. Below 360 µmol/L
C. Below 420 µmol/L
D. Below 480 µmol/L
E. Below 540 µmol/L

Explanation: ***Below 300 µmol/L***- Guidelines from the **British Society for Rheumatology (BSR)** recommend a target of **<300 µmol/L** (approx. 5 mg/dL) for patients with recurrent gout, especially those with **tophi** or chronic gouty arthritis.- Achieving this lower target is crucial to effectively **dissolve existing monosodium urate crystals** and prevent new crystal formation, thus reducing acute attacks and promoting **tophi resorption**.*Below 360 µmol/L*- While **360 µmol/L** (6 mg/dL) is the absolute upper limit of "normal" for some guidelines, it is considered a **sub-optimal target** for patients with established gout, particularly with tophi or frequent attacks.- Maintaining levels just below this threshold carries a higher risk of persistent **crystal deposition** compared to the more aggressive <300 µmol/L target.*Below 420 µmol/L*- This level (7 mg/dL) represents the approximate **saturation point** of urate in physiological conditions; exceeding it increases the risk of **precipitation** into joints.- Targeting this level does not provide the necessary **concentration gradient** required to dissolve existing crystals or prevent further acute episodes in patients with established gout.*Below 480 µmol/L*- This level (8 mg/dL) is considered **hyperuricaemic** and is associated with a significantly increased risk of developing **gout flares** and renal complications.- It is far above any recommended therapeutic target for **urate-lowering therapy (ULT)** in clinical practice for patients with recurrent gout.*Below 540 µmol/L*- This concentration (9 mg/dL) is significantly elevated and indicates **uncontrolled gout**, posing a high risk for the development of extensive **polyarticular tophi**.- At this level, **allopurinol** therapy would be considered ineffective or inadequately titrated to meet clinical objectives for gout management.

Question 137: A 65-year-old man presents to the emergency department with sudden onset severe pain, swelling and erythema of his right first metatarsophalangeal joint. He is unable to bear weight. He has a history of hypertension treated with bendroflumethiazide and stage 3 chronic kidney disease (eGFR 42 mL/min/1.73m²). Joint aspiration reveals needle-shaped negatively birefringent crystals under polarized light microscopy. Serum urate is 485 µmol/L. What is the most appropriate acute management?

A. Allopurinol 100mg daily with colchicine cover
B. Colchicine 500 micrograms four times daily
C. Oral prednisolone 30mg daily for 5 days (Correct Answer)
D. Indomethacin 50mg three times daily
E. Febuxostat 80mg daily

Explanation: ***Oral prednisolone 30mg daily for 5 days*** - In patients with **renal impairment** (CKD Stage 3), **corticosteroids** are the safest and most effective first-line treatment for an acute gout flare. - They provide rapid anti-inflammatory action while avoiding the gastrointestinal and renal risks associated with high-dose colchicine or **NSAIDs**. *Allopurinol 100mg daily with colchicine cover* - **Urate-lowering therapy (ULT)** should not be initiated during an **acute attack**, as fluctuations in serum urate levels can worsen or prolong the joint inflammation. - Allopurinol is used for long-term prophylaxis and is typically started at least 2–4 weeks after the acute episode has completely resolved. *Colchicine 500 micrograms four times daily* - This dose is excessively high and increases the risk of **toxicity**, especially in a patient with an **eGFR of 42 mL/min/1.73m²**. - Current guidelines recommend lower doses (e.g., 500mcg twice daily) in renal impairment to avoid side effects like **diarrhoea** and myelosuppression. *Indomethacin 50mg three times daily* - **NSAIDs** like indomethacin are generally **contraindicated** in patients with significant chronic kidney disease due to the risk of further **nephrotoxicity**. - They can worsen renal function by inhibiting prostaglandins that maintain renal blood flow, leading to acute-on-chronic kidney injury. *Febuxostat 80mg daily* - Similar to allopurinol, **febuxostat** is a urate-lowering agent intended for chronic management, not for treating **acute inflammation**. - Starting this during a flare can precipitate further **monosodium urate crystal** deposition and flare-up instability.

Question 138: A 42-year-old man with known rheumatoid arthritis presents for review. He has been taking methotrexate 20mg weekly for 3 months with good disease control. His recent blood tests show: Hb 118 g/L, WCC 3.2 × 10⁹/L, platelets 145 × 10⁹/L, ALT 95 U/L (normal <40), AST 88 U/L (normal <40). He is taking folic acid 5mg weekly. What is the most appropriate next step in management?

A. Stop methotrexate immediately and arrange urgent liver ultrasound
B. Continue methotrexate and increase folic acid to daily dosing
C. Withhold methotrexate temporarily and recheck liver function in 2 weeks (Correct Answer)
D. Switch to sulfasalazine as an alternative DMARD
E. Continue methotrexate at current dose and monitor monthly

Explanation: ***Withhold methotrexate temporarily and recheck liver function in 2 weeks***- The patient exhibits **hepatotoxicity** with **ALT/AST levels** more than twice the upper limit of normal (>2x ULN) and mild **leucopenia**, necessitating a temporary pause in treatment.- According to **BSR guidelines**, withholding the drug and monitoring allows the liver enzymes to normalize before deciding whether to restart at a **lower dose** or switch therapies.*Stop methotrexate immediately and arrange urgent liver ultrasound*- Immediate permanent cessation is premature as the **transaminitis** is moderate (<3x ULN) and may be transient.- An **urgent ultrasound** is not the first-line step for drug-induced liver injury unless there are signs of biliary obstruction or chronic liver disease.*Continue methotrexate and increase folic acid to daily dosing*- **Folic acid** can reduce gastrointestinal side effects, but it cannot reverse or safely manage active **drug-induced hepatotoxicity**.- Continuing the dose despite significant **enzyme elevation** (>2x ULN) and low **WCC** risks progressive bone marrow suppression and liver damage.*Switch to sulfasalazine as an alternative DMARD*- While **sulfasalazine** is an alternative, it is premature to switch before confirming if the toxicity resolves with a temporary break and **dose adjustment**.- The patient previously had **good disease control** on methotrexate, making it preferable to maintain the therapy if safety parameters allow.*Continue methotrexate at current dose and monitor monthly*- Continuing the current dose is unsafe when **ALT** is significantly elevated and **leucopenia** is present, as it leads to increased toxicity risk.- **Monthly monitoring** is insufficient; more frequent (biweekly) rebalancing is required until blood counts and liver enzymes stabilize.

Question 139: A 58-year-old woman presents with a 6-month history of symmetrical joint pain and stiffness affecting her hands and feet, particularly severe in the mornings and lasting over an hour. Examination reveals swelling of the metacarpophalangeal and proximal interphalangeal joints bilaterally. Blood tests show rheumatoid factor positive and anti-CCP antibody positive. What is the most appropriate first-line pharmacological treatment to initiate?

A. Methotrexate with folic acid supplementation (Correct Answer)
B. Prednisolone 60mg daily as monotherapy
C. Hydroxychloroquine monotherapy
D. Etanercept subcutaneous injection
E. Oral NSAIDs with proton pump inhibitor

Explanation: ***Methotrexate with folic acid supplementation***- **Methotrexate** is the gold-standard, first-line **Conventional Synthetic Disease-Modifying Antirheumatic Drug (csDMARD)** recommended for patients with rheumatoid arthritis (RA) to reduce disease activity and prevent joint destruction.- **Folic acid supplementation** is essential to reduce the risk of side effects such as **hepatotoxicity**, gastrointestinal distress, and **stomatitis** and must be taken on a different day than the methotrexate dose.*Prednisolone 60mg daily as monotherapy*- While **glucocorticoids** are used as **bridging therapy** to provide rapid symptomatic relief while DMARDs take effect, they should not be used as monotherapy.- Long-term high-dose steroid use is avoided due to significant risks of **osteoporosis**, infection, and **metabolic disturbances**.*Hydroxychloroquine monotherapy*- This is generally reserved for **mild, seronegative disease** or as part of a combination therapy; it is typically insufficiently potent for **seropositive RA** with severe symptoms.- It has a slower onset of action and lacks the robust evidence for **prevention of erosive joint damage** compared to methotrexate.*Etanercept subcutaneous injection*- **Etanercept**, a TNF-inhibitor (Biologic DMARD), is reserved for patients who have an inadequate response to at least two **conventional DMARDs**, including methotrexate.- Initiating biologics as the very first pharmacological step is not cost-effective and does not follow the standard **step-up management** guidelines.*Oral NSAIDs with proton pump inhibitor*- **NSAIDs** provide only **symptomatic relief** for pain and inflammation and do not alter the course of the disease or prevent joint damage.- They are used as adjuncts for pain management but must never replace **DMARDs** in the treatment of active rheumatoid arthritis.

Practice by Chapter

Anaemia investigation

Practice Questions

Crystal arthropathies

Practice Questions

Rheumatoid arthritis

Practice Questions

Venous thromboembolism

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free